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ABSTRACT
LINDSEY ALLEN HO: NOVEL STATISTICAL METHODS FOR THE
STUDY DESIGN AND ANALYSIS OF GENOME-WIDE ASSOCIATION
STUDIES.
(Under the direction of Dr. Ethan M. Lange.)
In Chapter 2, we compare the power of association studies using cases and screened
controls to studies that incorporate free public control genotype data. We describe a
two-stage replication-based design, which uses free public control genome-wide genotype
data in the first stage, and follow-up genotype data on study controls in the second
stage. We assess the impact of systematic ancestry differences and batch genotype
effects. We show that the proposed two-stage replication-based design can dramatically
increase statistical power and decrease cost of large-scale genetic association studies.
In Chapter 3, we describe and compare conventional haplotype analysis approaches
to a number of haplotype sharing measures. We evaluate the impact of the inclusion of
markers in linkage disequilibrium (LD) on power and assess the utility of recoding scores
using thresholds. Finally, we develop a quick and novel approach based on categorizing
similar haplotypes into contingency tables. These alternative methods are compared
via simulation assuming a rare-recessive disorder caused by a small number of high-
penetrant mutations within a single disease locus. We found that incorporating allele
frequencies and dichotomizing scores increased power. Conversely, using fixed windows
and excluding single nucleotide polymorphisms (SNPs) in low LD or with low minor
allele frequencies decreased power. Finally we show that our novel clustering algorithm
had competitive power than permutation testing.
In Chapter 4, we describe an alternative method to single SNP analyses of single
or multiple candidate genes that is designed to increase power when multiple SNPs are
associated with the trait. Our method is based on forward selection in regression that
iii
provides a joint test of the statistical significance of a gene. Within the framework of a
simulated candidate gene study as well as a study of related candidate genes, we assess
the power of this method by simulating a quantitative trait and compare our proposed
method to single SNP and other multiple SNP models. Our results suggest that our
method is competitive to conventional methods and may be more powerful when SNP
x SNP interactions exist.
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CHAPTER 1
INTRODUCTION AND
LITERATURE REVIEW
1.1 Introduction
A brief and directed review of seminal analytical techniques that have aided researchers
in revealing genetic determinants of disease is contained herein, as well as study design
and statistical issues surrounding these approaches. Linkage analysis is discussed in
Section 1.2, association studies are reviewed in Section 1.3, and a concise and pertinent
list of terms and definitions used in the field of genetics is presented in Section 1.4.
1.2 Linkage analysis
Linkage analysis has traditionally been used in determining disease genes, which in-
volves proposing a genetic model a priori that explains disease inheritance and sub-
sequently observe disease status and marker genotype patterns in pedigrees (Lander
and Schork, 1994; Ellsworth and Manolio, 1999c). Linkage analysis has particularly
been successful with monogenic Mendelian diseases (Jimenez-Sanchez et al., 2001;
Hirschhorn and Daly, 2005). Pritchard (2001) and Reich and Lander (2001) have
observed that these monogenic diseases are often due to rare variants (Hirschhorn and
Daly, 2005). The mapping resolution of linkage analyses has been reported to be no
more than about 1 centiMorgan, on average 1,000 kilobases (Boehnke, 1994).
In contrast to simple Mendelian disorders, common diseases may be the result of the
total effect of and/or interactions among multiple genetic and environmental factors
(Hirschhorn and Daly, 2005; Wang et al., 2005). As a result, any particular causal
gene could have an overall modest effect on disease risk. Furthermore, there have
been several reports that linkage analysis is not well powered to uncover these common
genetic variants (Risch and Merikangas, 1996; Risch, 2000; Cardon and Bell, 2001;
Tabor et al., 2002).
1.3 Association studies
Association studies are a strategic complement to linkage studies and, unlike linkage
studies, are powered to identify common genetic variants underlying complex diseases
(Risch and Merikangas, 1996; Cardon and Bell, 2001; Tabor et al., 2002; Carlson et al.,
2004; Hirschhorn and Daly, 2005). One way to analyze data from an association study
is to compare unrelated diseased cases and controls with respect to their frequencies of
alleles or genotypes at a given marker. It is also possible to use family-based controls
as a way to control for population stratification (Hirschhorn and Daly, 2005).
1.3.1 Population stratification
Population stratification is the existence of multiple subgroups within a population
such that the disease prevalence within each subgroup is different (Hirschhorn and
Daly, 2005). In association studies, population stratification can result in the overrep-
resentation of one or more subgroups in the sampled disease cases. This can result
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in a false-positive test at a given genetic marker if the allele frequencies differ in the
different subgroups. However, there has been a considerable amount of debate as to the
extent to which population stratification results in false-positives (Cardon and Palmer,
2003; Marchini et al., 2004; Clayton et al., 2005; Berger et al., 2006).
1.3.2 Family-based sampling designs
To address the possible complications arising from population stratification, family-
based sampling designs have been developed to choose the optimal control population.
In the parent-parent-affected offspring trio design, genotype data is collected on af-
fected individuals and their parents, and information is used on the alleles transmitted
and not transmitted from the parents to the affected offspring. The non-transmitted
alleles constitute the control sample, whereas in the unrelated case-control study de-
sign, individuals form the control sample. Several methods have been developed to
analyze such data (Falk and Rubinstein, 1987; Terwilliger and Ott, 1992; Spielman
et al., 1993; Spielman and Ewens, 1996), though it has been noted that Spielman and
Ewens’ (1996) transmission disequilibrium test (TDT), which has been widely used and
is essentially McNemar’s test of symmetry for paired data (McNemar, 1947), is subject
to technical artifacts due to laboratory difficulties (Mitchell et al., 2003; Hirschhorn
and Daly, 2005). In addition, the parent-parent-affected offspring trio design may be
biased toward ascertaining younger patients for late onset diseases (Hirschhorn and
Daly, 2005).
To circumvent this ascertainment bias for late onset diseases, the discordant sib
design was developed, which is a family-based association approach that matches an
affected individual with one or more unaffected siblings (Boehnke and Langefeld, 1998;
Horvath and Laird, 1998; Spielman and Ewens, 1998). In addition to being immune to
population stratification, the discordant sib design allows the control of shared envi-
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ronmental effects, assuming that siblings within a family shared the same environment.
However, despite the advantages, Horvath and Laird (1998), Morton and Collins (1998),
and Spielman and Ewens (1998) have reported that family-based association designs
only involving siblings are not as powerful as case-control studies.
1.3.3 Population-based sampling design: unrelated cases and
controls
The unrelated case-control study design, a traditional epidemiological tool, has been
easy and convenient for studying the relationship between putative genetic risk factors
and disease outcome (Schork et al., 2001), though the ease and convenience must be
considered in light of its caveats. Population based samples of a large number of affected
individuals (i.e. individuals with the disease or trait, cases) and a large number of
presumably well-matched unaffected individuals (i.e. individuals without the disease
or trait, controls) are collected and one way of evaluating statistical significance is to
examine the difference in observed frequencies of the cases’ and controls’ exposure to
the genetic risk factor. If significantly more cases than controls are exposed to the
genetic risk factor, then one may deduce that the genetic risk factor is involved in
disease pathogenesis, or protective to disease pathogenesis if significantly more controls
than cases are exposed.
The main assumption of genetic case-control studies is that the alleles at the locus
in question have a causal relationship with disease status (Schork and Chakravarti,
1996). It is further assumed that the genotyped alleles are either at the disease locus
or in linkage disequilibrium (LD) with the causal genetic variant. If the alleles are in
linkage equilibrium with the disease locus, then the causality assumption is questionable
(Schork and Chakravarti, 1996).
Unlike linkage studies that follow inheritance patterns of disease status and geno-
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typed markers within pedigrees, the unrelated case-control study design is population
based and relationships are unknown, i.e. in the case of haplotypes, information is not
captured on the evolution of haplotypes throughout time from the most recent common
ancestor. Furthermore, affection status is not followed over generations and analysis
rests upon correlations of current disease status with current genotypes (Balding, 2006).
1.3.4 Types of population association studies
Balding (2006) described four main types of population association studies, though
a particular study may exhibit characteristics from more than one type. Candidate
polymorphism studies investigate a particular polymorphism which is believed to be
involved in disease onset. In candidate gene studies, 5 to 50 single nucleotide polymor-
phisms (SNPs) within a gene are genotyped, the candidate gene being determined from
the results of a previous linkage or association study or from prior biological knowledge
about the gene’s function. Fine mapping studies often probe a candidate region of
1 to 10 megabases with hundreds of SNPs genotyped and possibly spanning 5 to 50
genes. Similar to candidate gene studies, an earlier linkage or association study may
have located the candidate region, though unlike candidate gene studies, fine mapping
covers a much wider region.
Genome-wide association (GWA) studies are the fourth type of population associa-
tion study. This approach searches the majority of the genome for genetic variants that
give rise to disease. Whereas candidate gene studies can be thought of as a hypothesis-
testing approach since positional or functional knowledge motivates these studies, GWA
studies represent a hypothesis-generating approach since the genomic location of disease
susceptibility variants is not assumed, but rather the aim is to uncover these variants
(Borecki and Suarez, 2001; Hirschhorn and Daly, 2005).
Previously, GWA studies were not reasonable to conduct because of the required
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extensive labor and high cost (Hirschhorn and Daly, 2005). However, the decreasing
cost per genotype coupled with the improving technical ability to genotype at high-
throughput are making GWA studies a realistic alternative. As an example of high-
throughput, in Phase I of the International HapMap Project over one million SNPs
were genotyped in each of 269 DNA samples and in Phase II an additional 4.6 mil-
lion genotyped SNPs per DNA sample is the goal (International HapMap Consortium,
2005).
Commercially available high-throughput genotype platforms with genome-wide cov-
erage have been made available by companies such as Third Wave, Sequenom, ABI,
Illumina, Parallele, Affymetrix, and Perlegen. Each company utilizes a unique genotyp-
ing assay. These platforms allow the interrogation of a large number of genetic markers
on a sample of subjects with the use of robotic automation, though the cost to do so may
be restrictive. An example of such genotyping technologies is Illumina’s HumanHap300-
Duo and -Duo+ Genotyping BeadChips (www.illumina.com). The HumanHap300-Duo
accomodates two DNA samples simultaneously on more than 318,000 tag SNPs selected
from Phase I and II of the International HapMap Project. The two sample format os-
tensibly decreases experimental variability. In regions near a gene or in evolutionarily
conserved regions there is an increased density of tag SNPs.
1.3.5 Utility of the International HapMap Project in associa-
tion studies
When planning a GWA study, determining how many and which markers to genotype
is crucial to potential success, which can be aided by utilizing the haplotype map of
the International HapMap Project. This haplotype map reveals patterns of LD across
the entire human genome (International HapMap Consortium, 2005).
In particular, the aim of the International HapMap Project was to provide tools
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for genetic studies (e.g. candidate gene, linkage, and GWA studies) based on the ‘indi-
rect’ association approach. Collins et al. (1997) proposed this ‘indirect’ approach, in
which a set of genetic markers could be used to test for disease association in genomic
regions, and these markers would not necesarily be required to have a functional effect
on disease status. Subsequently, causal sequence variants could then be explored in
genomic regions where associations with disease have been previously found. On the
other hand, the ‘direct’ approach assesses disease association for each putative causal
variant across the entire genome (Risch, 2000). To locate candidate variants would
require sequencing the whole genome of many patient samples for a considerable cost
(Botstein and Risch, 2003).
The members of the International HapMap Consortium (2003) believe that the
indirect approach has the potential of outperforming the direct approach with respect
to capturing most human sequence variation, based upon ideas from human population
genetics. Kruglyak and Nickerson (2001) claim that about 90% of human sequence
variation consists of common variants. Furthermore, these common variants are the
result of a single mutation which ocurred at some point in time, so variants in close
proximity on the same chromosome are associated with the mutation. The indirect
approach capitalizes on these associations by using a small set of variants that represent
the LD patterns of common variation in the genome. Thus, it is not necessary to obtain
previous knowledge about functional variants in order to scan the regions of interest
(International HapMap Consortium, 2003). The hope is that a region or gene associated
with disease would be discovered even if the particular genetic marker tested is not
the causal variant. Additionally, the amount of genotyping (and hence the overall
study cost) would be significantly reduced since a subset of representative common
variants rather than the entire set would be genotyped. In terms of GWA studies,
Balding (2006) approximates that around 300,000 SNPs would capture a majority of
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the common genetic variation in Caucasians and more SNPs for African poplations due
to increased genetic diversity.
1.3.6 Qualitative vs. quantitative phenotype
Phenotypes can be measured qualitatively or quantitatively. Qualitative phenotypes
are dichotomous, for example, presence or absence of a disease. A quantitative trait
is measurable and could contain discrete values (e.g. number of tumors) or could be
continuous (e.g. blood pressure). It is thought that the variation in quantitative traits
could be explained by genetic and/or environmental factors (Complex Trait Consor-
tium, 2003). Schork and Chakravarti (1996) describe qualitative traits as possibly
having multiple genetic and perhaps nongenetic determinants. It could be argued that
all traits could be considered quantitative since quantitative variables such as hormones
and protein amounts may be involved in disease pathogenesis. On the contrary, alleles
and mutations, which may underly disease onset or phenotypic expression, are discrete
in nature and thus it is not possible that all traits are quantitative.
The Complex Trait Consortium (2003) state that the same mapping strategies can
be used to search for causal loci in monogenic Mendelian disorders as well as for QTLs.
They view the classification of genetic effects as a continuum where on one end lies the
single gene effect of Mendelian diseases with a dichotomous outcome (i.e. affected or
unaffected). On the other end are quantitative traits that are influenced by multiple
genes, each with a small effect. In between these two poles are traits that are con-
trolled by multiple loci and possibly environmental determinants resulting in several
intermediate phenotypes.
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1.3.7 Common vs. rare causal genetic variants
As mentioned in sections 1.2 and 1.3, linkage analysis has been successful in mapping
rare genetic variants in monogenic Mendelian disorders whereas association studies are
more suited for detecting common alleles in complex diseases. However, two studies
have identified common variants using linkage analysis. Human leukocyte antigen was
suggested to be involved in type 1 diabetes (Concannon et al., 1998) and apolipoprotein
E was shown to play a role in late-onset Alzheimer’s disease, though an abundant
amount of references such as these may not exist.
A rough guide to variants considered common is having a minor allele frequency
above 5% (Balding, 2006). The Common Disease/Common Variant (CD/CV) idea,
proposed in the late 1990’s (Lander, 1996; Cargill et al., 1999; Chakravarti, 1999),
hypothesizes that common genetic variants are responsible for risk of common diseases.
Although several reports such as Corder et al. (1993), Bertina et al. (1994), and
Altshuler et al. (2000) support the CD/CV hypothesis, the extent to which it holds
remains unclear (Balding, 2006). Alternatively, multiple rare genetic variants may
contribute to complex diseases.
Rare variants may be more likely discovered in population isolates and founder
populations (e.g. Saami of Scandinavia, Laan and Pbo (1997)) due to their extensive
LD patterns. For example, it has been shown that there is considerable LD around
rare disease mutations in population isolates such as the Finns, Ashkenazi Jews, and
Mennonites (Risch, 2000). Moreover, for association tests power improves significantly
as LD increases. However, for these populations it may be unlikely to detect common
alleles (Wright et al., 1999).
Rare variants may be the result of a recent mutation and therefore restricted to
a single founder population or they may be the result of a historical mutation and
typically found in one major ethnic group (Risch, 2000). Thus, the same gene in other
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populations could be investigated for other functional variants associated with a similar
trait. If multiple functional variants are found, then this would strongly suggest a causal
relationship between the gene and trait.
On the other hand, common variants are probably present in many different pop-
ulations consisting of varying ethnicities (Risch, 2000). Positive associations between
a candidate variant and trait across multiple populations would imply causality. How-
ever, non-reproducibility would not necesarily refute a causal relationship since among
populations, gene expression may result in differing degrees of association.
1.3.8 Single SNP tests of association: unrelated cases and con-
trols
When SNPs are genotyped, there are several analytic approaches that can be employed.
In the genotype association test of 2 degrees of freedom, cases and controls can be clas-
sified in the rows and genotypes in the columns (Balding, 2006). For a diallelic SNP
with alleles ‘D’ and ‘d’, the possible genotypes are dd (homozygotes), Dd (heterozy-
gotes), and DD (homozygotes). Thus, the resulting contingency table is of dimension
2 × 3 and contains the respective cross classified counts. To assess the null hypothesis
of no association between disease status and genotype, either the Pearson’s 2 degree of
freedom χ2 test or Fisher’s exact test may be used. The latter is recommended if the
contingency table contains small expected cell counts. It is based on enumerating all
possible realizations of cell counts given the marginal totals, and so is computationally
burdensome. Both tests are readily available in standard statistical software programs.
There is widespread belief (Balding, 2006) that any particular causal SNP will often
approximately influence disease risk in an additive fashion. In other words, assuming ‘D’
is the causal disease allele, the risk of disease for a heterozygote Dd will be intermediate
between the homozygous risks of dd and DD, where the risk for homozygotes dd (i.e.
10
those without any copy of the disease allele) is less than that of homozygotes DD (i.e.
those with two copies of the disease allele). The genotype association test described
above performs reasonably well in terms of power despite the underlying risks involved.
However, the allelic association test of 1 degree of freedom is more powerful than the
genotype association test if the genotype risks are additive. The construction of the 2
× 2 contingency table is as follows. Disease status constitutes the rows and alleles are
classified in the columns instead of genotypes, such that each subject contributes two
counts to any given cell. In particular, a homozygote dd will be counted twice in the d
allele column, similarly for a homozygote DD in the D allele column, and a heterozygote
Dd contributes one count to the d column and another to the D column. Pearson’s
1 degree of freedom χ2 statistic or Fisher’s exact test may be computed to test the
null hypothesis of no association. The main drawback of this approach is that alleles
within any given individual must be independent, or in genetics terms, Hardy-Weinberg
equilibrium (HWE) must hold in both cases and controls. Due to the assumption of
HWE and the observation that risk estimates are not interpretable, Sasieni (1997) does
not recommend the 1 degree of freedom allelic association test.
Using the 2 × 3 contingency table construction as described above, the Cochran-
Armitage test (Armitage, 1955) is yet another analytic option. This method tests for a
linear trend in the proportion of cases relative to the ‘ordered’ genotypes dd, Dd, and
DD. In the case of the additive genetic disease model, one would expect subjects with
two copies of the disease allele (i.e. genotype DD) to exhibit a higher proportion of cases
compared to individuals with zero copies (i.e. genotype dd), and those with one copy
(i.e. genotype Dd) to have an intermediate proportion of cases. The Cochran-Armitage
test is conservative and similar to the genotype association test, does not require the
assumption of HWE. It has good power for the additive model, though the farther from
the additive model, the more the power diminishes (Balding, 2006).
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1.3.9 Haplotype based approaches: motivations and difficul-
ties
Haplotypes have proven to be important in the fine-mapping of Mendelian disorders
(Schaid, 2004b). It is now the hope that haplotypes will facilitate the genetic discovery
and mapping of common diseases that are polygenic, unlike single-gene Mendelian
disorders. Haplotypes have been used in GWA studies, motivated by empirical results
suggesting that haplotype ‘blocks’ define the sequence variation throughout the genome,
in which the blocks are more conserved than in other regions (Daly et al., 2001; Jeffreys
et al., 2001; Patil et al., 2001; Gabriel et al., 2002).
Furthermore, McVean et al. (2004) offer strong evidence that recombination rates
are not uniformly distributed across the genome and that certain regions of the genome
are more likely to recombine (i.e. ‘hot’ spots) whereas other regions are less likely (i.e.
‘cold’ spots), resulting in areas of weak and strong LD, respectively.
Aside from the observation of haplotype blocks, there are several additional reasons
that suggest the utility of haplotypes. There are biological aspects of haplotypes.
Previously, genetic markers were widely spaced (Schaid, 2004a), and thus not capturing
the DNA sequence regions pertaining to biological function. Presently, the genotyping
of SNPs has been at a higher density, such that these genetic markers comprising
haplotypes are more representative of regions of biological function. Additionally, in
light of the central dogma, DNA sequence variation on a haplotype gives rise to the
linear arrangement of amino acids via transcription and translation, which subsequently
determines protein folding (Clayton et al., 2004). Furthermore, there are several reports
of a ‘super-allele’ (Schaid, 2004a), which is the result of multiple mutations on the same
haplotype that interact with each other to largely influence the observed phenotype
(Clark et al., 1998; Drysdale et al., 2000; Hollox et al., 2001).
The use of haplotypes to test for a trait of interest offers some statistical advan-
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tages. Schaid (2004a) has reviewed the literature on the statistical power of analyzing
haplotypes compared to single markers. It is difficult to directly compare the results
from various reports on the statistical power of analyzing haplotypes in contrast to
single markers, since investigations differ in their assumptions, though Schaid (2004a)
concludes the following. For quantitative traits, if there are more haplotypes than
causative SNPs (i.e. SNPs that influence the trait), among all the measured SNPs,
than single SNP tests are more powerful than haplotype based tests (Bader, 2001).
In addition, Long and Langley (1999) found that despite testing SNPs that were not
causal but rather in LD with a QTL, the single SNP tests were still more powerful.
On the other hand, for the dichotomous outcome of affecteds and unaffecteds in the
case-control setting, haplotype based tests are more powerful when the SNPs are in
LD with a causal variant (Akey et al., 2001). As described previously about common
complex diseases, several genetic variants may each contribute a portion to disease risk.
In terms of detecting these multiple associations, both the single marker and haplotype
based approaches lose power, though the latter suffers less (Slager et al., 2000). The
haplotype based tests offer the largest benefit in terms of power compared to the single
locus tests when the markers are in strong LD with the causal variants and not with
each other (Morris and Kaplan, 2002).
For haplotype methods, it is expected that surrounding the causal genetic variant
on the haplotypes of affected individuals (i.e. case haplotypes), there are significantly
longer stretches of DNA identical by descent (IBD) compared to randomly selected hap-
lotypes (Nolte, 2002). This is due to the inreased relatedness of the regions around the
predisposing mutation in the case haplotypes in contrast to randomly selected haplo-
types. Furthermore, the haplotype is the result of genetic drift and past mutational and
recombinational events, i.e. it is a reflection of evolution as it is transmitted through-
out generations. Therefore, approaches that measure the amount of sharing among
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haplotypes account for the evolutionary history of the sample (Beckmann et al., 2005),
whereas single locus tests do not.
Despite these reasons to employ haplotypes in gene mapping strategies, there are
several difficulties. First, including rare haplotypes in analyses inevitably increases the
degrees of freedom and thus reduces power (Balding, 2006). Second, in most cases
haplotypes are not directly measured and must be statistically inferred using unphased
genotype data. However, in order to empirically determine haplotype phase in the
laboratory, molecular haplotyping methods have been developed such as pyrosequencing
(Odeberg et al., 2002), intracellular ligation (McDonald et al., 2002), and clone-based
systematic haplotyping (Burgtorf et al., 2003), to name a few. Haplotyping methods
are not widely used because a relatively large number of samples cannot be processed
in a relatively short period of time, they are costly to implement, and technical issues
have not been fully addressed (Niu, 2004). Therefore, the current viable alternative is
to infer haplotypes using algorithms, though assessing the overall statistical significance
is problematic when there are phase uncertainties (Balding, 2006).
Third, the standard use of automated genotyping procedures unavoidably results in
ambiguities when scoring genotypes (Kang et al., 2004), which could lead to genotyping
errors since almost all genotyping machines assign a genotype despite the presence
of ambiguities (Niu, 2004). Thus, because of genotyping error, two haplotypes may
be similar yet not completely identical though they may share a common ancestor.
The dissimilarity may also be due to recombination events or mutations (Lange and
Boehnke, 2004). If both contain the causal variant, their separate effects on disease
risk may not be detectable unless they are jointly examined.
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1.4 Definitions
Alleles: “alternate forms of a gene or genetic locus that differ in DNA sequence”
(Ellsworth and Manolio, 1999a)
Base pair: The pair of nitrogenous bases, consisting of a purine linked by hydrogen
bonds to a pyrimidine, that connects the complementary strands of DNA or of hybrid
molecules joining DNA and RNA. The base pairs are adenine-thymine and guanine-
cytosine in DNA, and adenine-uracil and guanine-cytosine in RNA.
CentiMorgan (cM): “unit for expressing relative distance between genes or markers
on a chromosome equal to 1% recombination; one cM corresponds roughly to a physical
distance of one megabase (Mb, one million base pairs)” (Ellsworth and Manolio, 1999b)
Chromosome: A threadlike linear strand of DNA and associated proteins in the nu-
cleus of eukaryotic cells that carries the genes and functions in the transmission of
hereditary information.
Complex trait: “. . . refers to any phenotype that does not exhibit classic Mendelian
recessive or dominant inheritance attributable to a single gene locus.” (Lander and
Schork, 1994)
Crossover: see recombination
Deoxyribonucleic acid (DNA): “. . . a macromolecule that carries genetic informa-
tion and represents the molecular basis of heredity. . . There are four common nitroge-
nous bases in DNA: two purines—adenine (A) and guanine (G) and two pyrimidines—
cytosine (C) and thymine (T). The double-stranded molecule is twisted in the form of
a helix with a constant width maintained by restrictions to base pairing such that A
only pairs with T and G only pairs with C.” (Ellsworth and Manolio, 1999a)
Founder populations: “Populations that have been derived from a limited pool of
individuals within the last 100 or fewer generations.” (Hirschhorn and Daly, 2005)
“. . . and have undergone a demographic expansion with negligible migration afte foun-
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dation.” (Bourgain et al., 2000)
Gene: A hereditary unit consisting of a sequence of DNA that occupies a specific
location on a chromosome and determines a particular characteristic in an organism.
Genes undergo mutation when their DNA sequence changes.
Genetic drift: “The random fluctuation in allele frequencies as genes are transmitted
from one generation to the next.” (Cardon and Bell, 2001)
Genotype: The combination of alleles located on homologous chromosomes that de-
termines a specific characteristic or trait.
Genotyping: The process of determining the genotype of an individual by the use of
biological assays.
Haplotype: “The specific set of alleles observed on a single chromosome, or part of a
chromosome. . . ” (International HapMap Consortium, 2003)
Haplotyping: The process of determining the haplotypes of an individual by the use
of biological assays.
Hardy-Weinberg equilibrium: “Holds at a locus in a population when the two al-
leles within an individual are not statistically associated.” (Balding, 2006) or “The
binomial distribution of genotypes in a population, such that frequencies of genotypes
AA, Aa and aa will be p2, 2pq, and q2, respectively, where p is the frequency of allele A,
and q is the frequency of allele a. Hardy-Weinberg equilibrium applies in a population
when there are no factors such as migration or admixture that cause deviations from
p2, 2pq, and q2.” (Hirschhorn and Daly, 2005)
Heterozygote: An organism that has different alleles at a particular gene locus on
homologous chromosomes.
Homozygote: An organism that has the same alleles at a particular gene locus on
homologous chromosomes.
Identity by descent (IBD, see identity by state): “. . . the identity of two stretches
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of DNA due to inheritance from a common ancestor without recombinations and mu-
tations . . . ” (Nolte and te Meerman (2002)) or “Alleles that trace back to a shared
ancestor. For sibs, refers to inheritance of the same allele from a given parent.” (Risch,
2000)
Identity by state (IBS, see identity by descent): “Alleles are IBS if they are
simply of the same type.” (Schork and Chakravarti, 1996)
Linkage: “the proximity of multiple genes or markers on the same chromosome re-
duces the probability that recombination events will occur between them and increases
the probability that certain combinations of alleles at these genes or markers will be
inherited together as a linkage group or haplotype” (Ellsworth and Manolio, 1999b)
Linkage disequilibrium (see linkage equilibrium): “the nonrandom transmission
from parents to offspring of alleles from genes or markers that are located on the same
chromosome. Because alleles at tightly linked loci are often inherited together, linkage
disequilibrium is useful for detecting regions of the genome that historically have been
inherited as a linkage group and may help identify the approximate location of genes
that contribute to disease (fine mapping)” (Ellsworth and Manolio, 1999b)
Linkage equilibrium (see linkage disequilibrium): the converse of linkage dise-
quilibrium
Locus (plural: loci): “a position on a chromosome or segment of DNA, usually used
in reference to a gene or genetic marker” (Ellsworth and Manolio, 1999b)
Marker: “an identifiable physical location on a chromosome or DNA segment useful
in genome mapping and linkage analysis. Numerous types of sequences are considered
markers including functional genes, portions of expressed sequences (expressed sequence
tags or ESTs), short DNA segments that are detected by PCR (sequence-tagged sites
or STSs), microsatellites, restriction fragment length polymorphisms (RFLPs), and
single-nucleotide polymorphisms (SNPs)” (Ellsworth and Manolio, 1999b)
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Megabase (Mb): “unit of physical measurement for nucleic acids equal to one mil-
lion base pairs, roughly equivalent to a genetic distance of one centiMorgan (cM)”
(Ellsworth and Manolio, 1999b)
Mendelian inheritance: A set of primary tenets relating to the transmission of
hereditary characteristics from parent organisms to their children; it underlies much of
genetics.
Minor allele: the less abundant allele
Minor allele frequency: the frequency of the less abundant allele
Mutations: “occasional errors that occur during DNA replication” (Ellsworth and
Manolio, 1999a)
Penetrance: The proportion of individuals carrying a particular variation of a gene
(allele or genotype) that also express an associated trait (phenotype).
Phenotype (see genotype): any observable characteristic or trait of an organism.
Polymorphism: “the existence of multiple forms of a gene or genetic locus (alleles)
that differ in DNA sequence” (Ellsworth and Manolio, 1999a)
Population admixture: see population stratification
Population stratification (see population admixture and structure): “The
presence of multiple subgroups with different allele frequencies within a population.
The different underlying allele frequencies in sampled subgroups might be independent
of the disease within each group, and they can lead to erroneous conclusions of linkage
disequilibrium or disease relevance.” (Cardon and Bell, 2001)
Population structure: see population stratification
Quantitative trait locus (QTL): “a genetic factor believed to influence a quantita-
tive trait such as blood pressure lipoprotein levels” (Ellsworth and Manolio, 1999b)
Recombination: “process by which homologous chromosomes physically exchange
segments of DNA (also known as crossing-over)” (Ellsworth and Manolio, 1999c)
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Single nucleotide polymorphism (SNP, pronounced ‘SNiP’ or ‘S’ ‘N’ ‘P’):
“polymorphism where a single base substitution has created two forms of a DNA se-
quence that differ by a single nucleotide - currently of great interest for locating genes
associated with complex diseases” (Ellsworth and Manolio, 1999c)
tag SNP: “Single nucleotide polymorphisms that are correlated with, and therefore
can serve as a proxy for, much of the known remaining common variation in a region.”
(Hirschhorn and Daly, 2005)
Transmission disequilibrium test (TDT): “A family-based test for association that
is immune to population stratification. The transmission of alleles from heterozygous
parents to affected offspring is compared to the expected 1:1 ratio.” (Hirschhorn and
Daly, 2005)
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CHAPTER 2
USING PUBLIC CONTROL
GENOTYPE DATA TO
INCREASE POWER AND
DECREASE COST OF
CASE-CONTROL GENETIC
ASSOCIATION STUDIES
2.1 Introduction
Large-scale commercial genotyping platforms have facilitated the identification of nu-
merous common single nucleotide polymorphisms (SNPs) that are associated with com-
plex genetic diseases. The newest commercial genotyping platforms now contain over 1
million SNPs spread across the human genome. While the cost per genotype on these
platforms have decreased considerably over the past several years, the cost per sample
remains prohibitive for many scientific investigators who are interested in performing
a genome-wide association (GWA) study using their own samples.
The high-cost of GWA studies has lead to the utilization of multi-stage study de-
signs, a strategy routinely used in clinical trials. Two-stage genotyping designs typically
involve genotyping a fraction of the entire sample on a commercial genotyping platform
containing all SNPs of interest in stage 1, performing systematic tests of association
using stage 1 samples, and genotyping stage 2 samples on only the SNPs of greatest
interest as determined in stage 1 (Satagopan et al., 2002). Two-stage genotyping de-
signs have been shown to maintain power comparable to a single-stage study employing
all samples while substantially decreasing overall genotyping costs (Satagopan et al.,
2002; Satagopan et al., 2004; Skol et al., 2006; Thomas et al., 2004). The data col-
lected from the second stage of a two-stage GWA study is either analyzed separately as
a replication-based sample or the data is combined with data from the first stage and
the combined data is analyzed jointly. The replication-based approach requires a less
stringent significance threshold, due to a smaller multiple test correction factor that is
based on only the number of markers followed up in stage 2 samples, than the joint
analysis approach, that uses a correction factor that accounts for the entire number of
markers studied in stage 1. The joint analysis approach benefits from using all of the
available data as opposed to just the data from samples genotyped in the second stage.
A recent alternative approach for reducing the cost of a large-scale case-control ge-
netic association study is to use freely available genotype data from previous genome-
wide association scans as control data in the current study. The effective use of a
common control dataset for comparison with multiple case datasets for different phe-
notypes was illustrated by the Wellcome Trust’s Case Control Collaboration (WTCCC)
GWA study on 14,000 cases of seven common diseases and 3,000 shared controls (Well-
come Trust Case Control Consortium, 2007). In this study, based on British subjects of
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European descent, the WTCCC identified 24 independent associations (p < 5 x 10-7)
for bipolar disorder, coronary artery disease, Crohns disease, rheumatoid arthritis, type
1 diabetes and type 2 diabetes using 2,000 independent cases for each disorder. The
WTCCC demonstrated that utilizing a common control dataset can be a powerful and
cost effective approach for performing future GWA studies.
For investigators that have collected a well-matched group of cases and controls who
wish to preserve many of the benefits of their sample collection design, we describe a
two-stage replication-based case-control genetic association study design that uses free
genotype data from public controls in stage 1, well-matched study controls in stage 2,
and study cases distributed over stages 1 and 2. We compare the power and relative
cost of our two-stage approach to single-stage approaches that strictly use either free
public control genotype data or genotype data from study controls and to the single-
stage approach that combines public and study controls. We discuss the advantages
and limitations of each of the four sampling designs and show that the proposed two-
stage replication-based study design using both public and study controls is robust to
high proportions of mismatched public controls and batch genotype effects that can
result from genotyping samples different populations at different times.
2.2 Methods
We assumed an investigator had a sample of NA study cases, NU study controls and
access to free genotype data on NPU public controls. We further assumed that study
controls may or may not be screened for disease and that public controls had not been
screened for disease. We performed a series of calculations over a range of alternative
models comparing the power achieved in an association study using four different sam-
pling approaches: 1) a single-staged association study that used all NA study cases
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and NU study controls; 2) a single-staged association study that utilized all NA study
cases and NPU public controls; 3) a two-staged replication-based study that used all
NPU public controls in stage 1, all NU study controls in stage 2 and all NA cases ap-
portioned between stages 1 and 2; 4) a single-staged association study that used all
NA cases and combined all NU study and NPU public controls. We assumed an under-
lying multiplicative genetic mode-of-inheritance risk model for a bi-allelic locus with
alleles D and d and corresponding allele frequencies of fD and fd, respectively. For
each alternative model, we set the population frequency of the susceptibility allele D
in the general population, the prevalence (K) of the disease in the population, and the
locus specific genetic relative risk (GRR) = Pen(DD) / Pen(Dd) = Pen(Dd) / Pen(dd),
where Pen(dd), Pen(Dd), and Pen(DD) were the penetrances for the dd, Dd, and DD
genotypes, respectively. Consistent with many genetic power calculators, our power
calculations are for the main effects of a directly genotyped locus and, as such, do not
rely on additional assumptions regarding the extent of linkage disequilibrium between
this locus and an untyped causal locus. All power analyses were programmed into the
freely available statistical software R version 2.4.1 (R Development Core Team, 2006).
2.2.1 Single-stage Power Calculations
Assuming Hardy-Weinberg equilibrium in the general population from which the cases
and controls were selected, we used our model assumptions (allele frequencies, disease
prevalence and GRR) to calculate the penetrance functions and we used Bayes’ the-
orem to ascertain the conditional probability of each genotype given affection status,
Pji, where j = 0 (cases), 1 (controls) and i = 0 (dd), 1 (Dd), 2 (DD). Namely, for the
cases these probabilities were P00 = Pr(dd | case), P01 = Pr(Dd | case), and P02 =
Pr(DD | case) and for the unaffected (screened) controls the probabilities were P10 =
Pr(dd | unaffected control), P11 = Pr(Dd | unaffected control), P12 = Pr(DD | unaf-
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fected control). We assume no disease misclassification among study cases or screened
study controls. Derivations of the conditional genotype probabilities are provided for
the multiplicative model in the Supplementary materials. For unscreened and public
controls, the genotype probabilities for controls were set to the genotype probabilities
in the general population, namely P10 = f
2
d , P11 = 2fdfD, P12 = f
2
D, since affection
status was not assumed to be known.
We calculated asymptotic power for the Cochran-Armitage trend test (Armitage,
1955; Cochran, 1954) by specifying the non-centrality parameter based on work by
Chapman and Nam (1968) and we set the vector of scores to x = (0, 1, 2) for genotypes
(dd, Dd, DD), respectively (Slager and Schaid, 2001). In particular, the non-centrality
parameter, explicitly stated by Ahn et al. (2007), was
(2.1)
where NA and NU (or optionally NPU) were the sample sizes of the cases and screened
(or public) controls, respectively, xi was the score for the i-th genotype (i = 0, 1, 2
for genotypes dd, Dd, DD), and P0i and P1i were the probabilities of the i-th genotype
for the cases and controls, respectively. Power was then taken to be 1− β, where was
the type II error and was the cumulative distribution function of the non-central χ2
distribution with 1 degree of freedom and non-centrality parameter λ, evaluated at the
100(1 − αBonferroni) percentile of the central χ2 distribution with 1 degree of freedom.
For single-stage designs, the overall family-wise error rate was set to α = 0.05 by using a
Bonferroni corrected significance threshold αBonferroni = 0.05/M, where M is the number
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of markers evaluated.
2.2.2 Two-stage Power Calculations
Using the formulas described above for one-stage power, we calculated power for a
replication-based two-stage design. For a two-stage replication-based design, the overall
power for a SNP was simply calculated as the product of the power for the first stage
times the power of the second stage. Following the notation in Skol et al. (2006),
the power for the first-stage was calculated using a significance threshold defined as
the proportion of markers followed in stage 2, pimarkers. Power for the second-stage was
calculated using a significance threshold (assuming a two-sided test) equal to α/(M ·
pimarkers), i.e. the Bonferroni corrected cutoff, where M was the number of markers
typed and interrogated in stage 1. Setting the significance cutoff at markers in stage 1
on average resulted in markers being the type I error. Similar to Skol et al. we also
calculated the power for a one-sided test in stage 2 samples, requiring the effect for the
SNP to be in the same direction in both stage 1 and stage 2 samples.
While Skol et al. allowed markers to be any possible value, we restricted the number
of SNPs for follow-up analysis in stage 2 to be values that approximate numbers that
would typically be considered given todays currently available commercial genotyping
platforms. Namely, we considered follow-up platforms of size 100, 375, 1,500, 7,500,
and 16,500 SNPs. For each follow-up genotyping platform, we then found the optimal
proportion of cases, cases, to be genotyped in stage 1 that optimized the power of the
two-stage design. Specifically, we used the “optimize” function in R to search for the
maximum power in the continuous space of cases. This method combines the golden
section search and successive parabolic interpolation algorithms.
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2.2.3 Single-stage power calculation for combined public and
screened study controls
We used simulations to estimate the power of the single-stage study design that com-
pared allele frequencies between study cases and the combined sample of public and
screened study controls. Specifically, we simulated 10,000 data sets for each model
condition and used the Cochran-Armitage trend test, implemented in R, to test for
association between marker and disease. Similar to the other single-stage designs, the
overall family-wise error rate was set to α = 0.05 by using a Bonferroni corrected signif-
icance threshold αBonferroni = 0.05/M, where M was the number of markers evaluated.
2.2.4 Examples of Power Approximations for 1- and 2-Stage
Designs
We calculated power for three models to demonstrate the difference in power between
the competing approaches. For all three models, we assumed a multiplicative model
with a GRR = 1.3, and a susceptibility allele frequency fD = 0.3 in the general popu-
lation. In addition, for all three models we performed the calculations assuming study
controls (in stage 2) have or have not been screened for disease. Model 1 was a GWA
scan on M = 500,000 SNPs for a study sample of NA = 2,000 study cases and NU =
2,000 study controls. Model 2 was identical to Model 1, except that there were fewer
study controls, NU = 1,000. Model 3 was designed to mimic a targeted follow-up study
to a previous GWA study. For Model 3, M = 7,500 and NA = NU = 1,250. For all three
models we considered a wide range of disease prevalence values of K = 1 x 10−4, 0.01,
0.05, 0.1, 0.25, and 0.5 and we assumed available genotype data on samples of NPU
= 1,000, 3,000, 5,000 and 10,000 public controls. We calculated power for the single-
stage designs using only study controls, only public controls, or both control samples
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combined. We also calculated the power for the optimal two-stage replication designs
using one- and two-sided hypothesis tests in stage 2. For each optimal two-stage model
we define the optimal platform and proportion of cases, cases, genotyped in stage 1.
Finally, in order to test how power the 1- and 2-stage designs are impacted by different
possible combinations of disease allele frequency, disease prevalence, and GRR, we cal-
culated power for Model 1 (assuming NPU = 5,000) using disease susceptibility allele
frequencies of fD = 0.1 and 0.5, disease prevalences of K = 0.01, 0.1 and 0.25, and
GRRs ranging from 1.1 to 1.5.
In the above power calculations, for the two-staged replication approach we chose
the follow-up platform and proportion of cases genotyped in stage 1 that optimized
power under a specific alternative hypothesis, namely, the relative risk and disease
allele frequency (in the general population) were explicitly defined. In practice the true
alternative model is unknown. A desirable quality of any two-stage approach is that
the optimal choice of follow-up platform and the optimal proportion of cases genotyped
on the follow-up platform are robust to the underlying relative risk and disease allele
frequency. We performed additional power calculations to assess the robustness of
the choice of follow-up platform and the proportion of cases, cases, genotyped on the
follow-up platform across a range of alternative models. Specifically, assuming a GWA
study on M = 500,000 SNPs using NA = 2,000 study cases, NU = 2,000 screened study
controls and NPU = 5,000 public controls for a multiplicative trait with a prevalence
K = 0.1, we calculated the maximum power and corresponding proportion of cases
genotyped in stage 1, across a range of relative risks (GRR = 1.25-1.5) and disease
allele frequencies (fD = 0.1, 0.3, and 0.5) based on follow-up platforms containing 100,
375, 1,500, 7,500 and 16,500 SNPs. In addition, assuming a relative risk of 1.3 and
disease allele frequency of 0.3, we calculated power across a range of proportion of
cases, cases, genotyped for each of the 100, 1,500, 7,500, and 16,500 SNP follow-up
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platforms to assess the decrease in power when using a higher or lower proportion of
cases in stage 1 compared to the optimal proportion for each platform.
In the supplementary material, we performed additional power calculations using
the general model (co-dominant) test of association (two-degree-of-freedom Chi-square
test) under the same multiplicative alternative hypothesis models we considered for the
Cochran-Armitage trend test. In addition, power was also calculated for several dom-
inant and recessive inheritance models using the single-degree-of-freedom Chi-square
test.
2.2.5 Impact on Power of Ancestrally Poorly-Matched Public
Controls and Batch Genotype Effects
In the previous calculations, we did not consider the impact of ancestrally poorly-
matched public controls and batch genotype effects on power that can occur when
genotyping samples of cases and public controls from different populations at different
times. We evaluated the impact of these factors for a study design that included
2,000 study cases, 2,000 study controls, and 5,000 public controls for a multiplicative
disease model with susceptibility allele frequency = 0.3, K = 0.10 and GRR = 1.3.
For ancestrally poorly-matched public controls (with respect to our study cases), we
measured the reduction in power by decreasing the effective sample size of the public
control sample. Specifically, for the purpose of these calculations, we have assumed that
a fraction (we considered a range from 0% to 90%) of public controls will be removed
from consideration after genotyping study cases (when comparisons of ancestry can be
made between study cases and public controls using genome-wide data) and prior to
performing association testing. We have additionally assumed that the proportion of
cases genotyped in stage 1 of our two-stage replication design is optimized and chosen
prior to the removal of any public controls. Power calculations were also performed
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for the two one-stage designs that utilize public controls after eliminating ancestrally
poorly-matched public controls.
To help assess the impact of batch genotype effects on our proposed two-stage
design we calculated power using more stringent significance thresholds for stage 1. We
assumed that batch genotype effects in stage 1 would lead to an excess of SNPs, under
the null hypothesis, with low p-values and that the SNP associated with disease was
not subject to batch genotype effects. The impact of batch genotype effects under these
assumptions was that truly associated SNPs were required to reach a higher significance
level in stage 1 than anticipated in order to be included in stage 2 genotyping. We
calculated power in stage 1 of our two-stage replication design by varying the magnitude
of the departure of the required significance threshold from markers in stage 1 (p-value
required for a SNP to be genotyped in stage 2) to be between 0.99 x pimarkers and
0.1 x pimarkers. The proportion of cases genotyped in stage 1 was optimized under the
erroneous assumption of no batch genotype effects (i.e. markers was assumed to be
the significance threshold required for a SNP to be subsequently genotyped in stage
2). Power calculations that included batch genotype effects were not performed for the
three one-stage designs.
2.2.6 Example of Genotyping Costs for Different Genotype
Sampling Strategies
To understand the financial impact of the different genotyping sampling strategies, we
estimated the relative cost of each genotype sampling design for a GWA study based on
M = 500,000 SNPs using NA = 2,000 study cases, NU = 2,000 screened study controls
and NPU = 5,000 public controls. We assumed a multiplicative trait with a prevalence
K = 0.1, GRR = 1.3 and fD = 0.3 (Model 1). We calculated the relative costs of
performing the three single-stage studies that used either study or public controls or
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both. For these single-stage sampling designs, all samples were assumed to be genotyped
on all 500,000 SNPs; genotype data for public controls were assumed to be available at
no expense. In addition, we calculated the relative cost of the optimal (highest power)
replication-based two-stage study design for each follow-up platform. For the purpose
of our calculations, we assumed the Illumina Human660W-Quad platform would be
used for genotyping 500,000 viable SNPs in stage 1 and Illuminas GoldenGate 96, 384
and 1,536 SNP panels and Illuminas Custom iSelect Infinium 7,600 and 16,720 SNP
panels would be used as the follow-up platforms for stage 2. Given that genotyping
costs are constantly changing, rather than use dollar amounts, we report the relative
cost of genotyping based on the most current prices. Using the cost of genotyping
500,000 SNPs in a GWAS as a baseline, the relative cost of genotyping 16,000, 7,500,
1,500, 375 and 100 SNPs were assumed to be 1/2, 1/3, 1/5, 1/10 and 1/12 of the cost,
respectively, based on the most recent genotype prices at the CIDR genotyping facility
(www.cidr.jhmi.edu/pricing.pdf).
Skol et al. (2006) demonstrated that a joint analysis two-stage study design could
effectively achieve equivalent power to a single-stage study for a fraction of the cost.
Consequently, for the three single-stage sampling designs, we also estimated the rela-
tive cost of performing a joint analysis two-stage association study for each follow-up
platform. For each combination of sampling design and follow-up platform, we iden-
tified the least expensive joint analysis two-stage sampling design that obtained an
estimated power within 0.01 of the power obtained from the corresponding single-stage
study. For the sampling design that used only public controls, cases were to be divided
and genotyped in stages 1 and 2 while all public controls were assumed to be available
in stage 1. For the sampling design that included both study and public controls, all
study controls were assumed to be genotyped in stage 2, and all public controls were
assumed to be available in stage 1. Cases were divided and genotyped in stages 1 and
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2. For each study design, we simulated 50,000 replicate data sets to determine the
optimal partitioning of study samples into stages 1 and 2 that resulted in the lowest
total cost while preserving statistical power.
2.3 Results
We performed power calculations for a range of study designs and disease models.
Power is described for the frequency of the risk allele in the general population (the
frequency of the risk allele in cases and study controls for different values of K are
provided in the table footnotes). Our results showed that utilizing free genotype data
from public controls increases statistical power when the number of available public
controls is sufficiently large over studies that do not include these data. As expected,
combining screened study controls with public control genotype data increased power
over sampling designs that included just one or the other for all models considered, re-
gardless of the underlying disease prevalence (Table 2.1). The single-stage study design
based solely on public controls had greater power than the single-stage study design
based solely on screened study controls for many alternative models when the number
of public controls was greater than the number of study controls. However, when the
population prevalence of disease was high (K > 0.25), the single-stage study design
using screened study controls had, in some instances, greater power than the single-
stage study using public controls, even when the number of public controls was large.
Overall, the same general patterns of results were observed when varying GRR and fre-
quency of the disease susceptibility allele (Supplementary Figure 2.2), when analyzing
the genotype data using a general (co-dominant) 2-df inheritance model (Supplemen-
tary Table 2.7), and when considering dominant or recessive genetic inheritance models
(Supplementary Tables 2.8 and 2.9, respectively).
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Power for the proposed replication-based two-stage design was typically greater than
the power of the one-stage design based only on study controls for most genetic models
provided the prevalence of the disease was not high (K < 0.25). For example, for Model
1, assuming screened (unaffected) study controls and a disease prevalence of K = 0.05,
we had power equal to 0.68 when using only screened study controls. Power increased
to 0.69, 0.81, 0.86 and 0.88 when applying our proposed two-staged replication-based
approach (with a one-sided test in stage 2) when including available genotype data
from 1,000, 3,000, 5,000 and 10,000 public controls, respectively, in stage 1 (Table 2.1).
As seen in Model 2, the difference in power between the two-stage replication approach
and the single-stage study that used only study controls was more dramatic when
the number of available study controls was only half as large as the number of cases.
Gains in power were also observed when the initial platform in stage 1 contained only
7,500 SNPs (Model 3), as might be used in a more focused follow-up study of previous
GWA scans. Compared to studies using screened study controls, power noticeably
decreased for studies using unscreened study controls when K > 0.05 (Supplementary
Table 2.6). However, the loss in power for the two-stage replication-based approach
using unscreened study controls was less dramatic than the drop experienced by the
single-stage study based solely on unscreened study controls.
Our results showed that the optimal choice of follow-up platform and proportion of
cases used in stage 1 for our proposed two-stage replication sampling design are robust
across a range of different possible alternative models. In Table 2.2, we observed that
the smallest follow-up platform, containing 100 SNPs, consistently provided the greatest
power compared to the other follow-up platforms over the considered range of GRRs
and disease allele frequencies, though the differences in maximum power between the
different follow-up platform choices was, in most cases, modest. We also noted that
the optimal choice of the proportion of cases, cases, to be genotyped in stage 1 varied
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considerably between the different platforms (as expected, a larger proportion of cases
were necessary to be genotyped in stage 1 for the smallest follow-up platform) but,
importantly, varied little within a given platform across the considered range of GRRs
and disease allele frequencies. In fact, we noted that for a given follow-up platform, the
optimal choice of cases was also robust to analytic strategy (i.e. similar optimal values
of cases were observed for the general 2-df test as for the trend test) (Supplementary
Table 2.10) and genetic inheritance model (i.e., similar optimal values of cases were also
observed for the dominant and recessive models) (Supplementary Tables 2.11 and 2.12).
In Figure 2.1, we observed that for each platform, the power dropped very modestly
when the choice of the proportion of cases to be genotyped in stage 1 was within 0.05
of the optimal choice. Together these results suggest that it is reasonable to choose
an optimal two-stage replication-based study design, namely the choice of follow-up
platform and the proportion of cases, cases, to be genotyped in stage 1, based on a
specific genetic models and that power should be robust to this choice across a range
of alternative genetic models.
We have also demonstrated that our two-stage replication-based study design using
public controls is robust to high proportions of ancestrally mismatched public controls
(that would have to be eliminated prior to data analyses) and batch genotype effects
in stage 1. Specifically, even when eliminating 50% of public controls due to poorly-
matched ancestry with study cases, power of the two-stage design was greater than that
for the single-stage design based solely on study controls for the model we considered
across all stage 2 follow-up platforms (Table 2.3). Interestingly, the larger follow-up
platforms were noticeably more robust than the smaller follow-up platforms with respect
to the removal of mismatched controls. The single-stage study design that includes only
public controls was most strongly impacted by removal of public controls due to ancestry
mismatching while the single-stage study design that includes both public and study
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controls maintained the greatest power versus all other study designs. Our two-stage
replication-based study design was also robust to the increased significance threshold
in stage 1 due to batch genotype effects (Table 2.4). Of note, increasing the stage 1
significance threshold required for a SNP to be genotyped in stage 2 by a factor of 2
(0.50 x pimarkers) had only a small impact on power. Power remained relatively strong
even when requiring an order of magnitude higher level of statistical significance in
stage 1 (0.10 x pimarkers) for a SNP to be subsequently genotyped in stage 2.
In addition to increased power, in Table 2.5 we illustrate that substantial cost sav-
ings can be achieved for a GWA study when including public controls. We compared
the relative cost of one- and two-stage study designs that include study controls, public
controls or both. As expected, the most expensive study designs were the one-stage
study designs that genotyped all samples (excluding public controls – which provide
genotype data at no expense) on all SNPs. Significant cost savings were observed when
using the joint-analysis-based two-stage design described by Skol et al. (2006). For
example, when utilizing the joint-analysis-based two-stage design following-up the top
1,500 SNPs (corresponding to the 1,536 SNP Illumina GoldenGate custom panel) in
stage 2, a 36%, 44% and 60% cost savings was achieved relative to the correspond-
ing one-stage design for sample designs that included only study controls, only public
controls and both study and public controls, respectively. The total cost of our pro-
posed replication-based two-stage design was consistently less than the joint-analysis
two-stage designs for sample designs that included only study controls or both public
and study controls. The study design that included only public controls in a two-stage
joint analysis was the least expensive. In addition to having the lowest power, the
sampling design that included only study controls was substantially more expensive
than any other sampling design.
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TABLE 2.1: Power of the Cochran-Armitage trend test for 1- and 2-stage study designs
across a range of sample sizes, SNPs in stage 1, and disease prevalences. Study controls
are assumed to be screened and disease free.
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TABLE 2.2: Power for the Cochran-Armitage trend test and the proportion of cases
in stage 1 that optimizes power (in parenthesis) in a two-stage replication-based GWA
study with 2,000 Cases / 5,000 public controls (stage 1) / 2,000 screened controls (stage
2). Power calculated for one-sided hypothesis test in stage 2.
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TABLE 2.3: Statistical power calculations accounting for poor ethnic matching between
study cases and public controls. Calculations are for one- and two-stage study designs
including study controls (n = 2,000), public controls (n = 5,000) or both. Calculations
assume 2,000 cases, M = 500,000 markers in stage 1, a multiplicative genetic model
with susceptibility allele frequency = 0.3, K = 0.10 and GRR = 1.3. Power calculated
for a range of effective sample-size reductions in public controls due to poor ancestry
matching; proportion of cases genotyped in stage 1 analyses of two-stage replication
design based on optimized value obtained assuming (a priori) that all 5,000 public
controls are ethnically matched to study cases.
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TABLE 2.4: Statistical power calculations for two-stage replication design accounting
for batch genotype effects between study cases and public controls. Calculations assume
2,000 study cases (spread across stages 1 and 2), 5,000 public controls (stage 1), 2,000
public controls (stage 2) and M = 500,000 markers in stage 1. Power calculated for a
multiplicative genetic model with susceptibility minor allele frequency = 0.3, K = 0.10
and GRR = 1.3 across a range of alternative significance thresholds in stage 1 due to
batch genotype effects. The proportion of cases genotyped in stage 1 of the two-stage
replication design is based on the optimized value obtained assuming (a priori) that
there are no batch effects (i.e. significance threshold in stage 1 = pimarkers).
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TABLE 2.5: Estimated relative cost* (power/proportion of total study samples geno-
typed in stage 1) of GWA study (M = 500,000 SNPs) for one- and two-stage study
designs that include only study controls (n = 2,000), only public controls (n = 5,000)
or both. Relative cost estimates assume 2,000 cases, a multiplicative genetic model
with susceptibility minor allele frequency = 0.3, K = 0.10 and GRR = 1.3. The rela-
tive costs of genotyping 16,000, 7,500, 1,500, and 100 SNPs was assumed to be 1/2, 1/3,
1/5, and 1/12 of the cost of genotyping all 500,000 SNPs on GWA panel, respectively.
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2.4 Discussion
Large-scale case-control genetic association studies have proven to be successful in iden-
tifying genetic polymorphisms associated with human disease. It has become increas-
ingly clear that the majority of common genetic variants associated with most human
disease explain, individually, a relatively small amount of the total disease suscepti-
bility. The modest underlying genetic risk from a given susceptibility allele combined
with the high toll of multiple testing inherent with contemporary genotyping platforms
necessitates large sample sizes to achieve sufficient statistical power to detect an as-
sociation. Unfortunately, the sample sizes of todays genetic association studies are
constrained by the high cost of genotyping and sample collection. One mechanism
that can increase power in genetic association studies of dichotomous traits is to in-
clude additional control samples from other studies. Genome-wide genotype data from
many different populations are becoming increasingly freely available to scientific re-
searchers through public databases funded by the U.S. National Institutes of Health
and other public funding agencies and from private company efforts such as Illuminas
iControlDB database. Of note, several recent high-profile GWA studies have included
Illuminas iControlDB genotype data demonstrating, empirically, the value of using free
public genotype data (Hom et al., 2008; Silverberg et al., 2009; Wrensch et al., 2009).
We illustrate, through examples, the gains in statistical power that can be obtained
by combining study controls with free public genotype data on unscreened population
samples. We also demonstrate that in addition to increasing power, supplementing
study control data with free public control genotype data can dramatically decrease
overall study cost when utilizing two-stage genotyping designs. This cost reduction is
realized due to all study controls being genotyped on the smaller, less expensive, stage
2 genotyping platform and to a smaller proportion of study cases being genotyped in
stage 1.
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The utilization of free public genotype data is subject to certain limitations and
can increase the risk for increased type 1 errors compared to studies that exclude these
data. Obviously the biggest potential obstacle of including public control genotype
data is the availability of genotype data on a sufficient number of ethnically matched
public controls for the same set of SNPs that will be genotyped in study samples.
Commercial genotyping platforms are constantly changing, typically adding additional
SNPs to established sets of SNPs included on older platforms. This limitation is being
mitigated, somewhat, by a more streamlined mechanism for public release of genome-
wide SNP data and by collaborations between investigators that study the same or
different diseases.
Free public controls typically are not screened for the disease in the current study
while study controls often are. It is well known that disease misclassification can
reduce statistical power. However, the increasingly large number of free controls that
are available to genetic researchers will often overcome this limitation and, as we and
others have shown, result in studies with even greater statistical power than studies
using a smaller number of screened controls (Edwards et al., 2005; Moskvina et al.,
2005; Wellcome Trust Case Control Consortium, 2007; Zheng and Tian, 2005). This
benefit is particularly noticeable for traits with low prevalence. It should be noted that
in our power calculations, we assumed that free publicly available controls from the
general population were not screened for any disease and that screened controls have
no disease misclassification. In fact, many public control samples have been ascertained
from healthy populations and many disease-screening techniques commonly used to
identify controls are not 100% accurate. As a result, the assumptions we used in
our power calculations may exaggerate the increased relative power gained by using
screened controls when compared to public controls.
A larger concern for utilizing public control genotype data is that observed allele
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frequency differences between public controls and study cases may be the consequence
of systematic bias due to population stratification or batch effects from differential allele
calling between the two samples. Greater differences in background ancestry will likely
occur between public controls and cases than between cases and a carefully selected set
of controls from the same community. The concern of population stratification can be
largely remedied by employing appropriate analytic methods (Price et al., 2006; Roeder
and Luca, 2009; Yu et al., 2008), though there still is some concern for a relatively small
number of genetic markers under apparent selective pressure. Systematic differences in
genotyping calls from plate to plate can also cause bias in genetic association studies
(Moskvina et al., 2006; Neale and Purcell, 2008). Despite the availability of public
control data from many of the same commercial platforms that would be considered
for genotyping sample cases, the inability to account for systematic genotyping errors
through experimental design is a source of concern when relying solely on public con-
trols. Unfortunately, DNA is often unavailable on public controls making it difficult to
validate, through direct genotyping, any observed differences in genotype frequencies
between study cases and public controls. In some circumstances, individual marker
fluorescent intensity data from public control samples may be available to facilitate
combining these data with the marker data from cases genotyped on the same plat-
form; which would subsequently allow for renormalization and clustering of alleles for
the purpose of rescoring genotypes in the combined sample. Further work needs to
be done to evaluate the quality-control potential of this approach and, unfortunately,
to date these kinds of extensive data on public controls are not routinely available.
Given this limitation, the utilization of stringent quality control and including common
controls (e.g. HapMap samples) that are present in the public control dataset when
genotyping study samples can be critical for identifying individual problematic SNPs.
The availability of multiple public control datasets should also aide, through compar-
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ison of genotype frequencies among different control populations, in the identification
of SNPs that appear to be subject to batch genotype effects.
Public control datasets also typically lack valuable environmental exposure data
that is critical to understanding the interplay between genes and environment on the
etiology of disease. Even when environmental exposure data have been collected in
public controls, it is often not collected or scored in the same manner as in the case
study sample, thereby reducing the effectiveness of these data. Furthermore, public
controls and cases will usually come from different communities with each community
having its own unique set of unmeasured risk factors. These limitations substantially
reduce the ability of investigators to evaluate gene-by-environment interactions that
are increasingly thought to play a central role in genetic susceptibility.
Recent results from several GWA studies that have included public control genotype
data on Caucasian samples have revealed little evidence of strong systematic differences
in allele frequencies between previously genotyped public controls and study samples
(Hom et al., 2008; Luca et al., 2008; Silverberg et al., 2009; Wrensch et al., 2009; Yu
et al., 2008). While the results from these studies are encouraging with respect to
control of the overall type I error rate when using public controls, any single result
based on public control data should be viewed with some degree of skepticism. It is
plausible, given the high quality of genotyping on modern commercial panels, that many
SNPs are not subject to strong batch effects when genotyped at different times on the
same or different genotyping platforms, but it is very likely that some SNPs are. The
recent study by the WTCCC found highly significant differences in allele frequencies
for a small number of loci between samples of Caucasians from different communities
in Great Britain (Wellcome Trust Case Control Consortium, 2007). The differences
were attributed to natural selection, reflecting the historical settlement of ancestors in
these different communities from different parts of Europe. It is difficult to control for
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the effects of selection using modern analytic methods, such as principal components,
when the number of loci under such pressure is small. In the WTCCC study, study
cases, like the controls, were largely ascertained across Great Britain, thus substantially
reducing the potential impact of bias due to selection. Many studies, however, that will
use public control data will include cases and public controls that have been selected
from entirely different communities or, possibly, different countries.
We have introduced a replication-based two-stage genotyping design, including both
public and study controls, that addresses many of the limitations and concerns re-
garding the use of public controls while still providing increased power and decreased
genotyping costs compared to studies that use only study controls. In this design,
public controls and a subset of study cases are used to select a reduced list of SNPs
for independent association testing between study controls and the remaining study
cases. By this design, the final assessment of whether a SNP is associated with the
disease outcome is based entirely on genotype results from study controls, which will
be presumably selected from the same community and genotyped at the same time and
on the same platform as the set of study cases that have been included in stage 2.
In our power calculations, we have attempted to address the impact of poorly
matched (with respect to genetic ancestry) public controls and systematic differences
in allele calls for a subset of SNPs under consideration. We have shown, under certain
assumptions, that the effect of poorly matched public controls, with respect to ancestry,
can have a major impact on studies limited to public controls. However, our proposed
two-stage study design, which uses public controls in stage 1 and study controls in
stage 2, appears to be relatively robust to this problem even when it is not accounted
for in the initial study design. In addition, we have also shown that the proposed two-
stage design is robust to batch genotype effects when the SNP associated with disease
outcome is not subject to batch genotype effects (or under selection pressure). Should
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the SNP associated with the outcome also be subject to batch effects then the impact
on power would depend on the direction of the batch effects. Should the direction
of the batch effects be the same as the true effect (under the alternative) then power
would be increased in stage 1 and the associated SNP would even be more likely to
be included in stage 2 genotyping efforts. On the other hand, should the direction of
the batch effects be in the opposite direction then power would be decreased in stage
1 and the SNP would be less likely to be included in stage 2 genotyping. Extensive
simulations showing the impact of directional batch effects on the SNP associated with
disease warrants further future consideration.
The proposed two-stage replication-based approach ensures that the final main-
effects analyses, based on stage 2 samples, will be able to incorporate critical environ-
mental exposure data that has been collected from cases and study controls. Further-
more, all study controls and all study cases will have genotype data available on all
SNPs that demonstrate a modest degree of evidence of main effects in stage 1, making
the study of gene-by-environment interactions feasible for all SNPs genotyped in stage
2 using the complete set of study samples. It has been shown previously that greater
power to detect the most plausible gene-by-environment interactions can be achieved
by focusing attention on the reduced number of SNPs that demonstrate some evidence
of main effects (Kooperberg and Leblanc, 2008).
Our proposed two-stage replication-based sampling design could be particularly
valuable for studies that have collected a limited number of study controls (see Model
2, the 2nd example in Table 2.1) or for collaborative studies where some study sites
have only collected case samples while other studies have collected sets of matched cases
and controls. Collecting new sets of unrelated controls can be problematic for studies
that have not already done so (such as family linkage studies). Provided there is not a
lot of heterogeneity between the case samples from the various studies, this mechanism
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would facilitate the inclusion of additional cases and potentially thousands of public
controls, resulting in increased power and likely decreased cost for the combined study.
We have focused our calculations primarily on a study design for a GWA study
based on 500,000 SNPs. We have also shown (see Model 3, the 3rd example in Table
2.1) that using public control genotype data in our proposed two-stage design can sig-
nificantly increase power for smaller follow-up studies as well. Commercial companies
are constantly increasing the number of SNPs included on their panels while the cost,
per SNP, is declining. It is expected that the results from the 1,000 Genomes Project
could lead to commercial genotyping panels that contain millions of SNPs. As a con-
sequence, the examples for which we report power calculations may not reflect study
designs in the not too distant future. However, our underlying conclusion that the
proposed two-stage genotyping design utilizing public controls can increase statistical
power to detect an association and decrease overall study cost while preserving many
of the advantages of a well-matched case-control design should hold for future study
designs that include more SNPs. We have R software code that is available for inves-
tigators who would like to calculate power and make the comparisons for their own
studies.
2.5 Supplemental Methods
2.5.1 Explicit Cell Probabilities of the Case-Control Contin-
gency Table
The cell probabilities of the case-control contingency table for the cases were Pr(dd
| case), Pr(Dd | case), and Pr(DD | case) and for the controls were Pr(dd | control),
Pr(Dd | control), and Pr(DD | control), where d and D were the alleles at a bi-allelic
locus and dd, Dd, and DD were the genotype possibilities. The allele frequencies of
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d and D were fd and fD, respectively, and we assumed Hardy-Weinberg Equilibrium
such that the dd, Dd, and DD genotype frequencies were fdd = f
2
d , fDd = 2fDfd, and
fDD = f
2
D. The disease prevalence, K, was defined to be
(2.2)
Multiplicative Genetic Mode-of-Inheritance Risk Model
The genetic relative risk (GRR) under a multiplicative genetic mode-of-inheritance risk
model was defined to be
(2.3)
We had two equations and sought to determine the case and control cell probabilities
of the contingency table as described above. From Equation 2.3 followed
(2.4)
which we substituted into Equation 2.2 to yield
(2.5)
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Thus,
(2.6)
Applying Bayes’ Law and then substituting the above penetrances gave us the cell
probabilities for the cases,
(2.7)
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For the study controls, the penetrances followed from the cases’ penetrances,
(2.8)
Applying Bayes’ Law and then substituting the study controls’ penetrances gave us the
cell probabilities for the study controls, as we similarly did for the cases,
(2.9)
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Dominant Genetic Mode-of-Inheritance Risk Model
The GRR under a dominant genetic mode-of-inheritance risk model was defined to be
(2.10)
Similarly to the proof shown above for the multiplicative model, the genotype proba-
bilities for the cases were
(2.11)
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and the genotype probabilities for the controls were
(2.12)
Recessive Genetic Mode-of-Inheritance Risk Model
The GRR under a recessive genetic mode-of-inheritance risk model was defined to be
(2.13)
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Similarly to the proof shown above for the multiplicative model, the genotype proba-
bilities for the cases were
(2.14)
and the genotype probabilities for the controls were
(2.15)
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Unscreened and Public Controls
For unscreened and public controls, the genotype probabilities for controls were set to
the genotype probabilities in the general population, namely
(2.16)
Of note was the observation that the cases’ genotype probabilities were not a function
of K for the multiplicative, dominant, and recessive genetic mode-of-inheritance risk
models (as shown in the above sections), whilst the study controls’ genotype proba-
bilities were indeed a function of K. This provided justification for the result in Table
2.1 of the manuscript whereby the power for the 1-stage design with “Study Controls
Only” varied with varying levels of K, but the power for the 1-stage design with “Public
Controls Only” did not vary with varying levels of K (and similarly for the analogous
tables in which the true genetic mode-of-inheritance risk models were dominant and
recessive).
2.5.2 Alternative 1- and 2-df Tests
The results in the main manuscript were based on the Cochran-Armitage trend test
and assuming an underlying multiplicative genetic mode-of-inheritance risk model. In
Supplemental Figure 2.2, we present power curves for the one- and two-stage designs
using 2,000 cases, 2,000 study controls and 5,000 public controls over a range of GRRs,
disease prevalences, and susceptibility allele frequencies. In Supplemental Table 2.6, we
calculated the Cochran-Armitage trend test for the three models considered in Table 2.1
in the main manuscript, but under the assumption that study controls were unscreened
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for disease. Supplemental Tables 2.7 through 2.12 present analogous results to Tables
2.1 and 2.2 in the main manuscript, though utilizing the general 2-df, dominant 1-df,
and recessive 1-df tests under multiplicative, dominant, and recessive models, respec-
tively. Specifically, Supplemental Tables 2.7, 2.8, and 2.9 are the general, dominant,
and recessive versions of Table 2.1 in the main manuscript and Supplemental Tables
2.10, 2.11, and 2.12 are analogous to Table 2.2. The single- and two-staged association
study designs as described in the methods of the main manuscript were also used for the
Supplemental Tables in terms of the number of study cases, study controls, and public
controls and the size of the GWA and follow-up genotyping platforms (Models 1, 2, and
3 of the main manuscript). In addition, the same disease prevalences were specified.
However, depending on the genetic model, we allowed the risk allele frequency (fD) and
GRR to vary. For the 1- and 2-df tests, we computed power using the “cost effective”
(CE) method proposed by Buksza´r and van den Oord (Buksza´r and van den Oord,
2006a). The CE is an approximation for computing the power of Pearson’s statistic for
2 x m (where m refers to the number of categories) contingency tables that is accurate
and efficient in terms of computer time. The authors point out (Buksza´r and van den
Oord, 2006b) that the CE is very close to the true value of the distribution of Pear-
son’s statistic and more accurate than a commonly used approximation (based on a
non-central chi-square) that overestimates power in some scenarios and underestimates
it in others.
General 2-df Test
For Supplemental Tables 2.7 and 2.10, the general 2-df test was employed assuming an
underlying multiplicative genetic mode-of-inheritance risk model. The specific genotype
cell probabilities for the cases and controls are shown above. For Supplemental Table
2.7, as in the main manuscript, fD and GRR were set to 0.3 and 1.3, respectively. In
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order to compute power using the general 2-df test, we carried out the CE for 2 x m
tables where m = 3 columns / categories (genotypes dd, Dd, and DD) and the rows
pertained to the cases and controls, using the R script costeff2by3 provided by Buksza´r
and van den Oord (http://www.vipbg.vcu.edu/ edwin/). Contrary to the 1-df test,
closed form analytical formulae did not exist for the 2 x 3 tables, though numerical
solutions were computed with the costeff2by3 R code.
Dominant 1-df Test
For Supplemental Tables 2.8 and 2.11, the dominant 1-df test was employed assuming
an underlying dominant genetic mode-of-inheritance risk model. The specific genotype
cell probabilities for the cases and controls are shown above. For Supplemental Table
2.8, fD was set to 0.3 (as with the multiplicative model), though the GRR was set to
1.4. In order to compute power using the dominant 1-df test, we carried out the CE
for 2 x m tables where m = 2 columns / categories (genotypes dd and Dd, or DD, i.e.
the Dd and DD genotype columns were combined) and the rows pertained to the cases
and controls. The power for critical value c (corresponding to the 1 - type I error) of a
central chi-square distribution was (Buksza´r and van den Oord, 2006a)
(2.17)
where λ was the largest eigenvalue of matrix J (discussed by Buksza´r and van den
Oord) and Fχ2 was the cdf of the non-central chi-square distribution with 1 degree of
freedom and non-centrality parameter
(2.18)
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where n was the total sample size, p was the proportion of controls in the total sample,
q = 1 - p was the proportion of cases in the total sample, and subscripts 1 and 2 referred
to the two genotype categories. These computations were carried out with the R script
costeff2by2 provided by Buksza´r and van den Oord (http://www.vipbg.vcu.edu/ ed-
win/).
Recessive 1-df Test
For Supplemental Tables 2.9 and 2.12, the recessive 1-df test was employed assuming
an underlying recessive genetic mode-of-inheritance risk model. The specific genotype
cell probabilities for the cases and controls are shown above. For Supplemental Table
2.9, fD and GRR were set to 0.5 and 1.45, respectively. The power calculations were
performed in the same manner as the dominant 1-df test detailed above though the 2
x 2 table was constructed differently, namely, the dd and Dd columns were merged.
2.6 Supplemental Results
Under a multiplicative, dominant, and recessive genetic mode-of-inheritance risk model
and conducting a general 2-df, dominant 1-df , and recessive 1-df test, respectively, the
overall observations discussed in the main manuscript pertaining to the performances
of the study designs when using the Cochran-Armitage trend test (Table 2.1) were
applicable for the alternative tests (Supplemental Tables 2.7, 2.8, and 2.9). For instance,
the power of the proposed two-stage replication-based design that used both public and
study controls was significantly greater than the power for the single-stage study design
that used only study controls for nearly all study designs considered. The single-stage
study design based solely on public controls had greater power than the single-stage
study design based solely on screened study controls for many alternative models when
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the number of public controls was greater than the number of study controls. The
two-stage replication-based study design compared favorably to the singe-stage study
design that used public controls under most alternative models, particularly for smaller
public control samples and higher disease prevalences.
When carrying out a general 2-df test under a multiplicative model, as expected
almost all of the study designs across varying levels of disease prevalences resulted in a
loss of power (Supplemental Table 2.7), compared to the Cochran-Armitage trend test
(Table 2.1).
For the alternative tests assuming multiplicative, dominant, and recessive models,
our results showed that the optimal choice of the proportion of cases used in stage 1
were robust across a range of different possible alternative models (Supplemental Tables
2.10, 2.11, and 2.12), which we had also noted in the main manuscript (Table 2.2) for
the Cochran-Armitage trend test under a multiplicative model. The other observations
discussed in the main manuscript also applied to Supplemental Tables 2.10, 2.11, and
2.12.
In Supplemental Table 2.10, we noted that the powers for our two-stage design
across a range of GRRs, fDs, and follow-up platforms were lower for the general test
as compared to the Cochran-Armitage test (Table 2.2 of the main manuscript). Lastly,
despite the genetic inheritance model and test conducted, the proportion of cases in
stage 1 across the ranges of GRRs, fDs, and follow-up platforms were about the same
as the proportions seen in Table 2.2.
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TABLE 2.6: Power of the Cochran-Armitage trend test for 1- and 2-stage study designs
across a range of sample sizes, SNPs in stage 1, and disease prevalences. Study controls
are assumed to be unscreened for disease and to have the same disease risk as the
general population. Note, under this assumption, power is constant across different
values of disease prevalence for all study designs.
TABLE 2.7: Power of the general 2-df test for 1- and 2-stage study designs across a
range of sample sizes, SNPs in stage 1, and disease prevalences. Study controls are
assumed to be screened and disease free.
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TABLE 2.8: Power of the dominant test for 1- and 2-stage study designs across a range
of sample sizes, SNPs in stage 1, and disease prevalences. Study controls are assumed
to be screened and disease free.
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TABLE 2.9: Power of the recessive test for 1- and 2-stage study designs across a range
of sample sizes, SNPs in stage 1, and disease prevalences. Study controls are assumed
to be screened and disease free.
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TABLE 2.10: Power for the general 2-df test and the proportion of cases in stage
1 that optimizes power (in parenthesis) in a two-stage replication-based GWA study
with 2,000 Cases / 5,000 public controls (stage 1) / 2,000 screened controls (stage 2),
assuming a multiplicative model.
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TABLE 2.11: Power for the dominant test and the proportion of cases in stage 1 that
optimizes power (in parenthesis) in a two-stage replication-based GWA study with 2,000
Cases / 5,000 public controls (stage 1) / 2,000 screened controls (stage 2), assuming a
dominant model.
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TABLE 2.12: Power for the recessive test and the proportion of cases in stage 1 that
optimizes power (in parenthesis) in a two-stage replication-based GWA study with 2,000
Cases / 5,000 public controls (stage 1) / 2,000 screened controls (stage 2), assuming a
recessive model.
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FIGURE 2.1: Power for the Trend Test in 2-Stage Replication-Based GWA Study
Designs with 500,000 SNPs Across a Range of Follow-up Platforms, Using 2,000 Cases,
5,000 Public Controls (Stage 1), 2,000 Screened Controls (Stage 2) and Assuming a
Multiplicative Model. The different line types reflect the power curves for different
follow-up platforms across the possible range of proportion of cases genotyped in stage
1. The follow-up platforms are defined by the number of markers genotyped in stage 2:
a) solid line 16,500 SNPs; b) short-dash line 7,500 SNPs; c) dotted line 1,500 SNPs;
d) long-dash line 100 SNPs. We assumed the population prevalence of disease (K),
the risk allele frequency (fD), and genetic relative risk (GRR) was 0.10, 0.3, and 1.3,
respectively. The maximum power and the corresponding proportion of cases genotyped
in stage 1 (at which maximum power occurred) for the various study designs were: a)
16,500 0.836 and 0.27; b) 7,500 0.848 and 0.31; c) 1,500 0.868 and 0.40; d) 100 0.889
and 0.55.
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FIGURE 2.2: Power for the Trend Test in 1- and 2-Stage GWA Study Designs Assuming
500,000 Markers, 2,000 Cases, 5,000 Public Controls, and 2,000 Screened Controls.
Results are Presented Across a Range of Genotype Relative Risks and Assuming a
Multiplicative Risk Model, Risk Allele Frequency (fD) of 0.1 and 0.5, and Disease
Prevalences (K) of 0.01, 0.10, and 0.25. Each panel presents power curves for disease
prevalences (K) of 0.01, 0.10, and 0.25. Grey and black lines depict power when the
frequency of the disease susceptibility allele (fD) is 0.1 and 0.5, respectively. Solid
lines correspond to the optimal two-stage GWA study based on 5,000 public controls in
stage 1 and 2,000 screened controls in stage 2. Dashed lines represent a one-stage GWA
study using 5,000 public controls. Dotted lines represent a one-stage GWA study with
2,000 screened controls. Dot-dash lines represent a one-stage GWA study combining
2,000 screened controls with 5,000 public controls. The overall type I error (α) was set
at 0.05.
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CHAPTER 3
HAPLOTYPE SHARING
METHODS IN ASSOCIATION
STUDIES
3.1 Introduction
Genome-wide association (GWA) studies offer a promising approach to discover com-
mon genetic determinants of disease. Publicly accessible data on human genetic vari-
ation from the International HapMap Project (International HapMap Consortium,
2005), plunging genotyping costs, and the availability of high-throughput commercial
genome-wide platforms have contributed to its widespread use. GWA studies represent
a hypothesis-generating approach since the genomic location of disease susceptibility
variants is not assumed, but rather the aim is to uncover these variants (Borecki and
Suarez, 2001; Hirschhorn and Daly, 2005). To date numerous common genetic variants
have been identified to be associated with common diseases such as type 2 diabetes,
prostate cancer and psoriasis.
Barrett and Cardon (2006) evaluated genomic coverage for common and rare SNPs
using HapMap’s Phase II and ENCODE (International HapMap Consortium, 2005)
data, respectively, in several of Illumina’s and Affymetrix’s platforms. These platforms
were designed to capture common variation. In particular, the Illumina HumanHap300
and Affymetrix 500K panels captured 75% and 65% of the common SNPs, respec-
tively, in Americans of European ancestry (CEU). On the other hand, none of the
genome-wide products captured rare SNPs well, at a frequency of less than 10% in
the CEU, Yoruba from Nigeria, Japanese from Tokyo, and Han Chinese from Bei-
jing. This deficit in coverage of rare SNPs is still observed as the number of SNPs
on commercial genotyping platforms continues to expand. A major limitation for the
study of diseases associated with rare variants is that commercial genotyping platforms
(particularly Illumina) select SNPs for inclusion on their panels based on available
genotype and linkage disequilibrium information in the HapMap Phase I and II sam-
ples. Unfortunately, most rare SNPs were missed in HapMap samples because SNP
discovery has been limited to a small number of subjects. The 1000 Genomes Project,
which significantly expands the number of samples with genomic sequencing informa-
tion (www.1000genomes.org), is an ongoing project designed to specifically discover
rare genetic variants. This discovery should lead to inclusion of many new rare vari-
ants on next generation genotyping platforms. Currently there is a renewed interest
in identifying rarer functional variants that are associated with disease and these ex-
panded genotyping platforms should facilitate these studies in an economically sensible
way. However, disease-specific highly-penetrant-but-rare-founder mutations will likely
not be detected during the 1000 Genomes Project sequencing efforts and hence not
included on future genotyping platforms.
Due to the computational burden of analyzing large datasets generated from GWA
studies using commercial platforms, single SNP tests are the analytical tool of choice
(Balding, 2006). However, it has been suggested that haplotype ‘blocks’ define the se-
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quence variation throughout the genome, in which the blocks are more conserved than
in other regions (Daly et al., 2001; Jeffreys et al., 2001; Patil et al., 2001; Gabriel et al.,
2002). In many circumstances, haplotypes better capture an underlying untyped causal
variant than any single genotyped genetic marker. An alternative analytic approach
to capture unmeasured genetic risk variants is genotype imputation; however, this ap-
proach too relies on the directly causal variants being genotyped in large data sets such
as the HapMap samples. Genotype imputation of rare variants, utilizing data avail-
able from the 1000 Genomes Project, should increase efficiency/power when evaluating
many rare functional variants associated with common disease but such an approach
is not likely to be useful for capturing the rare-high-penetrant disease specific founder
mutations that likely exist for many rarer disorders. Haplotype analyses are still the
best analytic method for detecting founder-mutation disease associations. Ultimately
direct high-throughput sequencing may be the solution, particularly if the disease gene
location can be significantly narrowed using additional genetic information such as link-
age analysis, but this technology is relatively new and is currently prone to high error
rates and likely substantial noise (many mutations will be observed) masking any true
signals.
Haplotype-based association studies should be particularly useful for identifying
susceptibility genes, where susceptibility is conferred by a small number of very rare
but highly penetrant variants or mutations that are passed down from generation to
generation. These variants/mutations will likely not be identified by the ongoing efforts
of the 1000 Genomes Project or other large-scale sequencing efforts that are not specif-
ically focused on the gene of interest. Such rare variants/mutations will typically be
relatively recent, as random drift typically influences the frequency of rare mutations to
extinction. As a consequence, the haplotype surrounding a rare variant/mutation will
be highly conserved due to the relatively small number of generations of recombination
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since the variant/mutation occurred. Utilizing extended haplotype sharing between
affected individuals around the disease susceptibility variants/mutations has proven to
be very powerful for fine-mapping the underlying causal gene for many diseases includ-
ing ataxia-telangiectasia, Huntington’s disease, cystic fibrosis and breast cancer. In
all cases, an excess of long-range shared haplotypes between affected individuals, and
the break-points in these extended shared haplotypes, pinpointed the location of the
susceptibility gene. Success was enjoyed despite the fact that there were many differ-
ent founder mutations associated with these diseases (allelic heterogeneity), a scenario
which can have detrimental effects on power for single SNP studies. One strategy that
has previously been shown to be effective is to restrict association studies looking for
founder effects to population isolates, where the expected number of unique founder
mutations is expected to be considerably less than outbred/mixed populations such as
the U.S.. As long-range sequencing becomes more economically feasible and the quality
improves, the identification of long-range shared haplotypes between affected subjects
should aid in targeting specific regions for sequencing.
There are caveats to haplotype-based approaches. One of which is that in most
cases haplotypes are not directly measured and must be statistically inferred using
unphased genotype data. Algorithms for population based haplotype inference have
been proposed by Excoffier and Slatkin (1995), Clark et al. (1998), and Stephens et al.
(2001), among others. Alternatively, in order to empirically determine haplotype phase
in the laboratory, molecular haplotyping methods have been developed (McDonald
et al., 2002; Odeberg et al., 2002; Burgtorf et al., 2003) though are not widely used
because they are not high-throughput, are costly to implement, and have unresolved
technical issues (Niu, 2004). For this investigation, haplotype phase was assumed.
The haplotype χ2 test of association (Sham, 1998) is a traditional approach, in which
haplotypes are categorized together if their ordered set of contiguous alleles match at
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each genetic marker, the size and location of the window spanning the haplotypes are
designated a priori by the analyst. For cases and controls, a 2×c (where c is the unique
number of haplotypes) contingency table is then constructed such that disease status
and haplotype signatures define the rows and columns, respectively, and a test of no
association is conducted. Other traditional haplotype association methods such as that
of Clayton (1999) (for family-based studies) and that described by Schaid (2004a) (for
case-control studies) are likelihood-based and, as with the haplotype χ2 test, also re-
quire a predefined set of markers for analysis, which can present several problems (Lange
and Boehnke, 2004). Assigning windows with too few markers can limit the ability of
haplotypes to capture the important variability in the region of interest. Assigning
windows that contain too many markers could result in haplotypes with low frequen-
cies (i.e. sparse data) and unnecessarily increase the degrees of freedom. In addition,
including too many markers can separate haplotypes containing identical-by-descent
segments immediately surrounding the susceptibility variant. All of these limitations
can attenuate associations with disease, reducing the power to detect associations if
they exist.
As an alternative to the fixed window approach, Van der Meulen and te Meerman
(1997a, 1997b) proposed the Haplotype Sharing Statistic (HSS). At the time of their
proposal, they motivated their approach with the population genetic assumption that
a few of the affected individuals’ haplotypes from a founder population not only bear
the predisposing disease variant, but also surrounding this locus many alleles are iden-
tical by descent (IBD). Nolte and te Meerman (2002) later showed that in comparing
two haplotypes at a locus, as the number of identical by state (IBS) marker alleles
increases, the probability that the haplotypes are IBD increases. In other words, in-
creased sharing between two haplotypes at a locus suggests that they are IBD. The
HSS was designed for nuclear families with one or more affected offspring. A reference
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marker is chosen and sharing is assessed upstream and downstream of this location.
All possible pairings of haplotypes are considered and for a given pair of haplotypes,
the distance recorded represents the length of contiguous matching between alleles at
each marker locus surrounding the reference marker. At a given marker locus, alleles
match if they are IBS. The HSS is then computed to be the standard deviation among
the entire sample of recorded shared distances. Unlike traditional haplotype methods
that restrict analysis to a small subset of markers, Van der Meulen and te Meerman
offer a data driven approach that allows the use of all available marker data (Lange
and Boehnke, 2004). Unlike traditional haplotype-based approaches, the inclusion of
additional markers should always result in greater power as highly similar yet not com-
pletely identical haplotypes still contribute to the detection of a possible association.
Van der Meulen and te Meerman’s HSS reflects an approach in which similarity
scores are first generated for all possible pairs of haplotypes, then a summary mea-
sure (e.g. the HSS) is computed that incorporates these scores, and lastly statistical
significance of the summary measure is determined. Others have proposed alternative
methods to score haplotype pairs. Tzeng et al. (2003) and defined the ‘matching’,
‘length’, and ‘counting’ measures for case-control studies. Similar to traditional haplo-
type methods, these measures require a predefined window of markers to analyze. For
a given pair of haplotypes and within the prescribed window, the matching measure
assigns a score of 1 if all the alleles match and 0 otherwise, the length measure is the
length spanned by the longest continuous interval of alleles IBS, and the counting mea-
sure is the number of concordant alleles, which does not require matching alleles to be
adjoining. One of the drawbacks of these measures is the specification of the window,
as is with traditional haplotype tests.
Lange and Boehnke (2004) developed the conserved haplotype sharing statistic
(CHSS) and described it in the context of family trios comprising one affected indi-
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vidual and his or her parents, the parents may or may not be diseased. For each pair of
haplotypes among all pairings, the CHSS is constructed by evaluating alleles to the left
and right of a chosen reference marker. To control for possible genotyping errors and
marker allele mutations, one marker mismatch on both sides of the reference marker is
allowed, at the expense of a user-defined penalty parameter. Rare alleles that match
are given more weight than common alleles, by taking the inverse of the estimated allele
frequencies when computing the CHSS. Ambiguous phase and missing marker data are
accounted for in the scoring algorithm.
Once similarity scores are generated, then a summary statistic may be computed
with the intention of assessing its statistical significance. Lange and Boehnke (2004)
introduced the Haplotype Runs Test (HRT) statistics that strictly consider scores from
transmitted haplotypes (i.e. ‘case’ haplotypes) in the family trio setting. Also for the
trio design with affected offspring, Bourgain et al. (2000) defined the Maximum Identity
Length Contrast (MILC), which measures pairs of haplotypes in the same way as Van
der Meulen and te Meerman’s (1997a, 1997b) method. However, the MILC contrasts
the transmitted and non-transmitted samples of haplotypes differently, by subtracting
the mean of the scores formed from all possible haplotype pairs of the non-transmitted
haplotypes from that of the transmitted haplotypes. Lange and Boehnke (2004) in-
vestigated the power of summing only the transmitted haplotypes versus subtracting
off the sum of the non-transmitted from the sum of the transmitted haplotypes. They
discovered that the former method was much more powerful, postulating that under the
alternative hypothesis, for the groups of transmitted and non-transmitted haplotypes,
the within group similarity is high while the between group similarity is low. Thus, the
sums of scores corresponding to each group would both have reasonably high values
and subtracting the non-transmitted from the transmitted scores would obscure this
grouping effect.
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Neither of the above mentioned methods of summing the scores include scores from
discordant pairs of haplotypes, i.e. a transmitted (case) paired with a non-transmitted
(control) haplotype, are not incorporated into the summary statistics. Beckmann et al.
(2005) defined a statistic that uses all of the available haplotype similarity measures
such that each score is weighted. They motivated the weights with the argument that
in comparing haplotypes, the corresponding phenotypes, be they continuous traits or
measured dichotomously, that deviate the most from the phenotypic mean are the most
influential (Elston et al., 2000; Forrest, 2001). For example, in the case-control setting,
as the population frequency of disease becomes more rare, pairs of case haplotypes
(i.e. haplotypes that deviate most from the norm) are given more weight than pairs of
control or discordant haplotypes. Analogously, pairs of control haplotypes weigh more
as disease prevalence becomes more common.
In this investigation, we made slight modifications to Lange and Boehnke’s (2004)
CHSS statistic in that when considering a pair of haplotypes, the alleles at the reference
marker must match in order for the CHSS to build up and downstream and we did
not allow any mismatches on either side of the reference marker. In addition, we
investigated the power of the Length and Count measures. The Length score was based
on Van der Meulen and te Meerman’s (1997a, 1997b) scoring method in constructing
the HSS that measured the shared genetic distance. For matching alleles, the Count
score simply counted the number of matching alleles. Furthermore, Lange and Boehnke
created an indicator variable from the CHSS values and a predefined threshold value,
aiming to distinguish between haplotypes that have extended sharing (thus, more likely
to be IBD) and those that share for shorter stretches. Additionally, a haplotype pair or
a small number of pairs that are abundantly similar may dominate the test statistic, so
using an indicator variable would guard against this. The problems with this approach
are interpreting the meaning of this chosen value and knowing a priori an adequate
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threshold given the data. To address these issues, thresholds are determined from
designated percentiles of the ordered array of scores. Thus, the threshold is data driven
and more interpretable. Then, we recode each of the similarity measures in two ways.
First, we follow the design of the indicator variable as initially proposed by Lange and
Boehnke, though we use the percentile based thresholds. Second, we introduce a second
score based on thresholds that instead of assigning zeros to scores that are less than
the threshold, we divide these scores by the threshold value to construct normalized
scores less than one, and scores greater than or equal to the threshold are recoded to
one (in essence resulting in a truncated score with a threshold ceiling value).
For each of these similarity measures and recoded variables we employ the summary
methods as previously described and then assess statistical significance using permuta-
tion tests, similar to Lange and Boehnke (2004). Finally, we introduce a novel approach
that exploits the observation that similar haplotypes form clusters. As opposed to per-
mutation tests that are computationally burdensome, this novel approach is quick and
efficient in that contingency tables are constructed using the percentile based thresholds
and a p-value is computed with Pearson’s χ2 statistic.
We found that the log10 version of the CHSS outperformed the other reference
marker scores, dichotomizing the haplotype sharing scores with a threshold based on
percentiles increased power, using fixed windows was detrimental to power, removing
rare SNPs and SNPs in high LD with each other was not recommendable, and our
novel clustering algorithm had competitive power and was significantly faster than
permutation testing, which is desirable for genome-wide scans.
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3.2 Methods
We assumed that our sample consisted of an equal number of N cases and N controls,
unrelated and independent, for a total of 2N subjects and 4N haplotypes. All subjects
were assumed to be genotyped at M genetic polymorphic markers (for example, the
markers could be single nucleotide polymorphisms [SNPs], microsatellites, short tan-
dem repeats, etc.) with no missing data and the markers were ordered by physical
location. For the pool of 4N total haplotypes, we considered all possible
(
4N
2
)
pairings
of haplotypes, such that case (control) haplotypes were paired with other case (con-
trol) haplotypes as well as case haplotypes paired with control haplotypes. We assumed
Hardy-Weinberg Equilibrium and thus haplotypes within individuals were regarded as
independent and also included as a possible pairing. We generated a multitude of shar-
ing statistics for each pair of haplotypes, so that for each sharing statistic there were(
4N
2
)
scores.
The sharing statistics were constructed based on either a reference marker or fixed
window of markers. In the reference marker approach, an initial starting (or “ref-
erence”) marker was chosen and scores were computed up- and downstream of the
reference marker up to, but not including, the first mismatched pair of alleles. Thus,
for long stretches of consecutive haplotype sharing, the reference marker approach did
not restrict the magnitude of the sharing statistic to a predetermined number of mark-
ers. On the other hand, with the fixed window method we specified a region of markers
to be considered upon calculating the particular sharing statistic, such that markers
outside of this region were not considered.
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3.2.1 Reference Marker Approach
We calculated the conserved haplotype sharing statistic (CHSS) as proposed by Lange
and Boehnke (2004). Specifically, for a given pair of haplotypes, at the chosen reference
marker, r, within the ordered set of markers, 1 ≤ r ≤M , the observed alleles were re-
quired to be identical by state (IBS) in order for the CHSS to be constructed, otherwise
the CHSS was set to 1. Let Aji be the specific allele at marker i, 1 ≤ i ≤M , on haplo-
type j (j = 1, 2) of the haplotype pair and let fˆi(A
j
i ) be the estimated population-based
frequency of allele Aji computed using the entire sample of case and control alleles. De-
fine markers a and x (1 ≤ a ≤ r ≤ x ≤ M) such that a (x) is the first marker to
the left (right) of the reference marker that fails to match alleles IBS between the two
haplotypes. Given that the alleles matched at r, the CHSS was then defined to be the
product of the reciprocal of the fˆi’s across the contiguous interval of alleles IBS for a
given pair of haplotypes. Namely,
CHSSr =
x−1∏
i=a+1
(
fˆi(A
1
i )
)−1
(3.1)
Since the values of the allele frequencies were between 0 and 1, computing the
reciprocal of the fˆi’s gave much greater weight to matching alleles that were more
rare (i.e. as fˆi → 0, fˆ−1i → ∞). In contrast, identical alleles that were common (e.g.
0.20 ≤ fˆi < 1 corresponded to 1 < fˆ−1i ≤ 5) contributed much less to the magnitude
of the CHSS.
We also considered the CHSS in log base 10 space upon motivating the summary
statistics of the haplotype scoring measures. The CHSS in (3.1) was then
log10(CHSS
r) =
x−1∑
i=a+1
log
(
fˆi(A
1
i )
)−1
(3.2)
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Starting at the reference marker r and for each pair of haplotypes, we calculated
the total length of the continuous region over which all markers were IBS. This was
similar to the scoring measure used in the Maximum Identity Length Constrast (MILC)
statistic as described by Bourgain et al. (2000). In particular,
Lengthr = Pos(x− 1)− Pos(a+ 1) (3.3)
where Pos was the relative position on the chromosome at either marker x− 1 or a+1.
For example, Pos could be the physical position in basepairs.
The final reference marker based sharing measure we examined was the Count. As
the name implies, for a given pair of haplotypes we counted the number of identical
alleles, beginning at r and then moving to the left and right of r until we reached
mismatching alleles.
Countr =
x−1∑
i=a+1
1 (3.4)
3.2.2 Fixed Window Approach
The haplotype sharing scores based on reference markers described in Section 3.2.1
were also implemented utilizing fixed windows. In other words, a region of markers
was defined and analogous measures to the CHSS, Length, and Count were computed
within this specified region, in addition to a binary score detailed by Tzeng et al.
(2003). For the CHSS and Count we simply considered all matching alleles within
this designated segment, regardless of any potential mismatches between markers. The
Length measure was defined to be the length of the longest continual interval within
the assigned window.
Define the lower and upper boundaries of the fixed window to be w1 and w2, re-
spectively, such that amongst the ordered set of M markers, 1 ≤ w1 ≤ w2 ≤ M . The
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CHSS under the fixed window approach, analogous to the CHSS based on a reference
marker (3.1), was then
CHSSw2w1 =
w2∏
i=w1
Ifˆi
(
fˆi(A
1
i )
)−1
(3.5)
where the indicator variable Ifˆi was set to 1 if at marker i the alleles for haplotypes 1
and 2 matched (i.e. A1i = A
2
i ), otherwise (i.e. A
1
i 6= A2i ) we set Ifˆi to fˆi, which effectively
did not increase the size of the CHSS score for alleles that were not IBS. Lange and
Boehnke (2004) did not investigate the CHSS using windows, rather the sharing scores
included in their report were restricted to scores constructed about a reference marker.
The log10 equivalent of CHSS
w2
w1
was
log10(CHSS
w2
w1
) =
w2∑
i=w1
log10
[
Ifˆi
(
fˆi(A
1
i )
)−1]
(3.6)
The following fixed window scores (Matchw2w1 , Length
w2
w1
, and Countw2w1) were described
by Tzeng et al. (2003).
The Match score for window w1 to w2 was
Matchw2w1 = I
w2
w1
(3.7)
where Iw2w1 was 1 if for a given pair of haplotypes all of the alleles within w1 and w2
were identical and 0 if there was at least one discordant pair of alleles (i.e. A1i 6= A2i ).
The window based version of the Length haplotype sharing score given k = 1, . . . , c
continuous segments within the specified window (w1 to w2) was
Lengthw2w1 = maxk
[
Pos(Uk)− Pos(Lk)
]
(3.8)
where Uk and Lk were the upper and lower markers that bounded the k-th continuous
interval. We found the largest such interval within w1 and w2 and set this to Length
w2
w1
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for a given pair of haplotypes.
The Count measure using windows was
Countw2w1 =
w2∑
i=w1
Ii (3.9)
where Ii was an indicator variable defined to be 1 for matching alleles (A
1
i = A
2
i ) and 0
for non-identical alleles (A1i 6= A2i ). The Countw2w1 counted all alleles IBS within w1 and
w2 and did not require that matching alleles be adjacent to one another.
3.2.3 Threshold Scores
We constructed threshold scores for each of the haplotype sharing measures based on
reference markers (Section 3.2.1) and windows (Section 3.2.2) in order to distinguish
between groups of haplotypes, with the exception of the Matchw2w1 (3.7) which by def-
inition was binary. The motivation was that across the
(
4N
2
)
haplotype pairings there
would be a varying degree of sharing scores, where smaller scores represented haplo-
types that failed to match or matched for only a few common alleles and larger scores
identified haplotypes that matched over an extended set of markers. The threshold
scores were aimed at separating these two contrasting sets of shared haplotypes. More
importantly, upon summing the haplotype sharing scores (described in Section 3.2.4),
a single or small number of haplotype pairs that exhibit a high degree of sharing would
not dominate the test statistic under a threshold score.
Lange and Boehnke (2004) proposed applying thresholds on their CHSS. They con-
sidered two threshold values, t = 100 and t = 10, 000, for which the modest threshold
value of t = 100 focused on excess sharing of short or common haplotypes whereas the
high threshold of t = 10, 000 focused on excess sharing of rare or extended haplotypes.
We further developed the idea of thresholds by defining thresholds based on percentiles
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of the set of
(
4N
2
)
haplotype sharing scores. The use of percentiles allowed the threshold
values to be driven by the data, instead of arbitrarily selecting these threshold values,
which could be adequate for some data sets but not for others. Furthermore, in con-
trast to the investigation of Lange and Boehnke (2004) in which the thresholds were
employed only for the CHSS, the use of percentiles permitted us to utilize thresholds
across a range of haplotype sharing methods and compare their performance in terms
of power.
Specifically, to ascertain the threshold values, TPk , given a set of percentiles (Pk
for k = 1, . . . , t) and a haplotype sharing score type (e.g. log10(CHSS), Length, and
Count), we ordered the entire set of
(
4N
2
)
scores, S(`) for ` = 1, . . . ,
(
4N
2
)
, and determined
the location L that demarcated Pk percent of the ordered scores, from (1) to (L). We
then defined Tk to be S(L). Since log10 is a one-to-one transformation, in building the
threshold based scores, we opted to compute threshold scores for log10(CHSS) and not
for CHSS (unlogged).
We defined two types of threshold scores that we used for both the reference marker
and window based haplotype sharing measures. The first was binary in nature,
I{S(`)≥TPk} =

1, S(`) ≥ TPk
0, S(`) < TPk
(3.10)
where S(`) could either be a score computed using a reference marker (e.g. log10(CHSS
r),
Lengthr, Countr) or a fixed window (e.g. log10(CHSS
w2
w1
), Lengthw2w1 , Count
w2
w1
). We note
that the actual value of TPk depended on the score type under assessment.
The second threshold score weighted the more similar haplotypes (i.e. the pairs of
haplotypes that had scores exceeding the corresponding threshold) equally and rendered
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the less similar haplotypes on a continuous scale. Specifically,
R{S(`)≥TPk} =

1, S(`) ≥ TPk
S(`)
TPk
, S(`) < TPk
(3.11)
where 0 ≤ S(`)
TPk
< 1. Haplotypes with a high degree of sharing, as determined by the
threshold TPk , were weighted in the same way as the binary threshold score I{S(`)≥TPk}.
However, for haplotypes that did not meet this threshold criterion, we assigned the
ratio S(`) to TPk , the particular score to the threshold. Haplotypes that were fairly
similar but did not quite surpass TPk had a ratio close to 1 while on the contrary
haplotypes that did not have any alleles IBS or had a few common alleles had a ratio
of 0 or close to 0. We intended that R{S(`)≥TPk} would utilize available information
about dissimilar haplotypes, as compared to simply assigning them a 0 which was the
approach of I{S(`)≥TPk}.
3.2.4 Summary Statistics
We considered three methods of summing the haplotype similarity measures. First, we
defined a summary statistic that compared the haplotype sharing amongst the cases
with that of the controls. Nolte et al. (2007) investigated such a statistic for which
they summed the pairwise haplotype sharing in the cases and controls separately and
then calculated the difference in these sums in the construction of their test statistic,
the haplotype-sharing statistic (HSS). This was in contrast to their earlier proposed
HSS (Van der Meulen and te Meerman, 1997a, 1997b) that utilized all pairs of “case”
haplotypes (Van der Meulen and te Meerman based their report on family data such
that “case” haplotypes were haplotypes transmitted from the parents to the offspring).
Bourgain et al. (2000) also applied this approach of subtracting out the effect of the
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controls (i.e. non-transmitted haplotypes) from the cases (i.e. transmitted haplotypes).
Nolte et al. (2007) claimed that such an approach, as applied to their HSS, could
correct for linkage disequilibrium (LD) other than that caused by the disease mutation.
Specifically, we defined this sum in (3.14) as
SumCase =
4N−1∑
i=1
4N∑
j=i+1
ICase,iICase,jSij (3.12)
SumCon =
4N−1∑
i=1
4N∑
j=i+1
ICon,iICon,jSij (3.13)
SumDiff = SumCase − SumCon (3.14)
where SumCase and SumCon were the sum of the given haplotype sharing scores Sij (as
described in Sections 3.2.1 and 3.2.2), i and j indexed the haplotypes of the pairing,
ICase,i(j) was set to 1 if the i(j)-th haplotype was from a case subject and 0 if it was from
a control, and likewise ICon,i(j) was the indicator variable for the control haplotypes.
Assuming Hardy-Weinberg equilibrium, case and control haplotypes within subjects
were included in SumCase and SumCon.
Lange and Boehnke (2004) investigated the power of SumCase and SumDiff in the con-
text of the parent-parent-affected offspring trio design in which the “case” and “control”
haplotypes were those haplotypes transmitted and not transmitted from the parents
to the offspring, respectively. They discovered that SumCase was much more powerful,
postulating that under the alternative hypothesis, for the groups of transmitted and
non-transmitted haplotypes, the within group similarity was high while the between
group similarity was low. Thus, SumCase and SumCon would both have reasonably high
values and computing their difference (SumDiff) would obscure this grouping effect. For
the second summary measure, we extensively studied the power of SumCase in order to
examine closely Lange and Boehnke’s claim.
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Lastly, the third summary measure we considered was the general approach of Man-
tel’s statistics for space-time clustering (Mantel, 1967) to correlate genetic and pheno-
typic similarity. Beckmann et al. (2005) proposed the use of Mantel’s statistic whilst
defining the phenotypic similarity. In contrast to SumCase and SumDiff that do not uti-
lize all
(
4N
2
)
scores, the Mantel statistic applies a weighting measure across all scores.
Namely,
M =
4N−1∑
i=1
4N∑
j=i+1
SijYSubji, Subjj (3.15)
where YSubji, Subjj was the phenotypic similarity for two haplotype copies i and j in
which the phenotypes were derived from subjects Subji and Subjj. Specifically,
YSubji, Subjj = (ySubji − µ)(ySubjj − µ) (3.16)
YSubji, Subjj was the mean corrected product where µ denoted the mean of the phenotype
and ySubji and ySubjj the phenotypes of subjects Subji and Subjj. The motivation
behind this definition was that either similar or different haplotype pairs farthest from
the mean µ would be the most influential (Elston et al., 2000; Forrest, 2001). There
were several possibilities to define µ and in the scenario of a binary phenotype such
as case/control status in our unrelated cases and controls design, we set µ to be the
disease prevalence and ySubji(j) was 1 if Subji(j) was a case and 0 if a control. µ was a
parameter that weighed the three possible comparisons between pairs of haplotypes, i.e.
1) both were from affected/exposed individuals; 2) both were from control individuals;
3) the haplotype pair was discordant, i.e. one was from an affected/exposed individual
and the other came from a control individual. For rare diseases, disease prevalence is
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close to 0 (i.e. µ ≈ 0), and it follows that
YSubji, Subjj = (ySubji − µ)(ySubjj − µ) =
≈ 1 if both haplotypes i and j were from affected individuals
≈ 0 if both haplotypes i and j were from unaffected individuals
< 0 if the haplotypes i and j were from discordant individuals
On the other hand, the more common the disease, i.e. as disease prevalence ap-
proaches 50% (µ → 0.5), the values of YSubji, Subjj for concordant affected and unaf-
fected haplotype pairs converge from 1 and 0, respectively, to 0.25, whereas scores for
discordant haplotype pairs (i.e. one haplotype comes from an affected individual and
the other from an unaffected) become more negative and reach −0.25. In this scenario,
concordant pairs, regardless of affection status, are scored equally and contrasted to
discordant pairs, thereby testing whether they have a tendency to share protective
haplotypes (Beckmann et al., 2005).
3.2.5 Significance Estimation of the Summary Statistics via
Permutation Testing
The asymptotic distributions of the various haplotype sharing scores generated by the
reference marker approach (Section 3.2.1) were mathematically intractable due to the
nature of these scores in which sharing was assessed for the length of the haplotype
pairs until a mismatch was encountered. Furthermore, we could not satisfactorily
approximate these distributions with any known distribution(s). Consequently, we
empirically estimated statistical significance of the summary statistics described in
Section 3.2.4 via permutation testing, for the sets of summary statistics pertaining to
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both reference marker and fixed window scores (Section 3.2.2).
In particular, we randomly shuﬄed the affection status labels across all N cases
and N controls. To save computational time and resources, for each score type we did
not regenerate the
(
4N
2
)
haplotype pairing scores, but rather we simply reassigned each
score with its corresponding pair of labels resulting from the given random shuﬄe. We
then computed the summary statistics, SumCase, SumDiff, andM (Equations 3.12, 3.14,
and 3.15, respectively) according to the permuted affection status labels. We carried
this out B times, resulting in a set of t(1), t(2), . . . , t(B) permutation summary statistics
for each summary statistic type relating to a given score. We defined the permutation
p-value to be
p =
∑B
b=1 I(t
(b) ≥ t)
B
(3.17)
where t was the observed summary statistic and I was the indicator function. For
t(b) = t, with one-half probability we set I to be one and zero otherwise.
3.2.6 Single Marker χ2 Test of Association
We compared the performance of the haplotype sharing measures and summary statis-
tics with the single marker χ2 test of association. At a given reference marker, r, we
performed an allelic association test of 1 degree of freedom. We constructed a 2 × 2
contingency table in the following manner. Disease status constituted the rows and
the alleles at r (e.g. d and D) were classified in the columns, such that each subject
contributed two counts to any given cell. Specifically, a homozygote dd was counted
twice in the d allele column, similarly for a homozygote DD in the D allele column,
and a heterozygote Dd contributed one count to the d column and another to the D
column. We employed Pearson’s 1 degree of freedom χ2 statistic, QP , to test the null
hypothesis of no association. We assumed Hardy-Weinberg equilibrium (HWE) in both
cases and controls.
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3.2.7 Haplotype χ2 Test of Association
We also assessed the power of the haplotype χ2 test of association. We used the same
fixed windows that we defined for the fixed window scores (Section 3.2.2) for the haplo-
type χ2 test. In particular, given a fixed window with lower and upper boundaries of w1
and w2, we searched the resulting pool of haplotypes for distinct haplotype signatures
and each signature was assigned a row in a R × 2 contingency table, where R was the
total number of rows (i.e. unique haplotype patterns) and there were 2 columns that
classified affection status. All haplotypes were then categorized into their corresponding
haplotype row and affection status column (i.e. haplotypes arising either from affected
or unaffected individuals were labeled as such). The cells of the R× 2 table contained
the counts of the categorized haplotypes.
To test the null hypothesis of no association, we computed the χ2 statistic that had
approximately a χ2 distribution with R−1 degrees of freedom. Beforehand we checked
for small haplotype row totals so that the number of rows (and hence the degrees of
freedom) would not be excessively large if many rare haplotypes were present in the
sample. Furthermore, the χ2 approximation was more appropriate when expected cell
sizes were 5 or greater. We implemented 2 approaches when haplotype row totals
were sufficiently small, i.e. < 10. First, we removed these rows entirely from the
table (“Delete” method). Second, we pooled together all rows with small sample sizes
(“Collapse” method).
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3.2.8 An Alternative to Permutation Testing: a Quick and Ef-
ficient Clustering Algorithm for Significance Estimation
of Haplotype Sharing Measures
We developed methods to assess statistical significance of excess haplotype sharing
amongst the cases as compared to the controls. Aside from the biological motivation,
these methods were computationally quick and efficient.
We investigated the haplotype sharing amongst 60 unrelated individuals (120 hap-
lotypes) of the CEPH sample (Utah Residents with Northern and Western European
Ancestry), genotyped as part of the HapMap project. Across all
(
120
2
)
= 7, 140 pairs
of haplotypes, we examined the number of contiguous alleles starting at a reference
marker in the PHB gene region. We chose 2 markers, one that was relatively common
(rs2233667, estimated minor allele frequency [MAF] = 0.328) and the other that was
rare (rs882031, estimated MAF = 0.025). Surprisingly, a fair amount of unrelated in-
dependent haplotypes shared a considerable number of adjacent alleles, regardless of
the MAF of the initial reference marker. We therefore hypothesized that case hap-
lotypes as well as control haplotypes in themselves shared a unique set of haplotype
patterns. This was similar to Lange and Boehnke’s 2004 assertion that under the alter-
native hypothesis, for the groups of transmitted and non-transmitted haplotypes in a
family-based study design, the within group similarity is high while the between group
similarity is low. Thus, we were prompted to design an approach that allowed affected
and unaffected haplotypes to cluster according to a relative measure of similarity and
to formally test the statistical significance of the observed clustering in the cases versus
the controls.
We carried out the clustering algorithm in the following manner. Begin cluster
formation with an arbitrary single haplotype, hc1,1, where c1 notated the first cluster
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being formed. The thresholds, TPk ’s, specific for a haplotype sharing score type (e.g.
reference marker and fixed window based log10(CHSS), Length, and Count) described
in Section 3.2.3 served as the cutoffs for which we designated haplotypes to be members
of a particular haplotype grouping.
1. Amongst the haplotype sharing scores pertaining to the haplotype pairings with
the initial haplotype in the cluster, search for any haplotype that meets or exceeds
TPk and include them in the cluster. Note, for hc1,1 the threshold scores searched
is a subset of 4N − 1 scores out of a total of (4N
2
)
haplotype pairing scores for
2N + 2N = 4N case and control haplotypes.
2. For each of the haplotypes entered at Step 1, search for any haplotype(s) to
further include in the cluster, based on the corresponding subset of haplotype
sharing scores.
3. Once the cluster can no longer include additional haplotype members, begin build-
ing another cluster starting with an arbitrary single haplotype, granted that there
are haplotypes that have not yet been grouped. Repeat Steps 1 and 2 for new
clusters to be formed.
4. As soon as no other clusters can be formed after iterating through Steps 1 through
3 and haplotypes remain that have not been assigned to any of the clusters, place
them in an “other” bin to be subsequently assessed.
In Steps 1 and 2, we searched scores corresponding to haplotypes that have not yet
been clustered, so haplotypes were not counted more than once. As a result, this also
saved computational time and resources when searching.
To illustrate the clustering algorithm, consider the following example. We begin
building a cluster with an arbitrary haplotype, hc1,1, for the reference marker based
log10(CHSS). We choose Pk to be the 99-th percentile, so the threshold value is T99.
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1. 3 other haplotypes (hc1,2, hc1,3, hc1,4) have log10(CHSS) values ≥ T99 from their
pairings with hc1,1, so these are included in cluster c1.
2. (a) 2 other haplotypes (hc1,5 and hc1,6) have log10(CHSS) values ≥ T99 from their
pairings with hc1,2, so are included in cluster c1.
(b) 3 other haplotypes (hc1,7, hc1,8, and hc1,9) have log10(CHSS) values ≥ T99
from their pairings with hc1,3, so are included in cluster c1.
(c) No haplotypes have log10(CHSS) values ≥ T99 from their pairings with hc1,4,
so no additional haplotypes are included in cluster c1.
3. Amongst the log10(CHSS) values computed from the haplotype pairings with each
of the haplotypes entered in Step 2 (hc1,5, hc1,6, . . . , hc1,9), no other log10(CHSS)
values were ≥ T99, therefore the construction of cluster c1 is complete and consists
of haplotypes hc1,1, hc1,2, . . . , hc1,9. We begin building another cluster, c2, starting
with arbitrary haplotype hc2,1.
4. After iterating through Steps 1 to 3 two more times, there are 3 clusters, c1, c2,
and c3, each containing haplotypes (hc1,1, hc1,2, . . . , hc1,9), (hc2,1, hc2,2, . . . , hc2,5),
and (hc3,1, hc3,2, . . . , hc3,24). However, there are still 4N − (9 + 5 + 24 = 38)
haplotypes remaining that were not clustered, and will be placed in the “other”
bin.
We employed various methods to handle clusters containing few haplotypes and hap-
lotypes that were categorized into the “other” bin. We postulated that these rare hap-
lotypes could potentially provide useful information in discerning associations between
clusters and affection status, therefore we assessed the performance of incorporating
these rare haplotypes compared to removing them entirely from the analysis.
The first technique we implemented was to not attempt to regroup “other” haplo-
types into any of the existing clusters (“No Regrouping”). We defined minimum cluster
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sizes (sizei for i = 1, . . . , Nsizes) and if the number of haplotypes in a given cluster was
not greater than or equal to sizei then we placed all of the haplotypes in this cluster in
the “other” bin.
The second method was to attempt to regroup “other” haplotypes into any of the
clusters (“Regrouping”) in a 3 step process. First, we regrouped “other” haplotypes per
criteria which we discuss below. Small clusters that did not fulfill sizei could possibly
be expanded at this step. Second, we imposed the cluster size constraints, sizei, across
all clusters. Third, we attempted to regroup “other” haplotypes once again, since some
clusters may have moved to the “other” bin in the previous step.
Our strategy to regroup “other” haplotypes into clusters was the following. For
each of the “other” haplotypes, we inspected all of the scores from the pairings with
the haplotypes already in clusters and found the maximum score. We regrouped the
“other” haplotype into the cluster in which the maximum score resided. We required
that the maximum score stemmed from a haplotype that was not originally in the
“other” bin. If more than one maximum score was found in multiple clusters, we did
not regroup the “other” haplotype in question.
In the third method, we collected all of the small clusters (i.e. all of the clusters
that were not as large as sizei) into one group instead of recategorizing them into the
“other” bin (“Small Cluster Row”). We did not attempt to regroup “other” haplotypes
into clusters for this method.
Once the clusters were created by way of the “No Regrouping”, “Regrouping”, and
“Small Cluster Row” methods, we constructed R × 2 contingency tables where the
number of rows, R, represented the number of clusters and the 2 columns categorized
affection status (i.e. if a haplotype originated from an affected or unaffected individual).
We cross classified the clusters by affection status in order to examine if case haplotypes
grouped together differently than control haplotypes. Regardless if such a difference
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existed or not, the R× 2 tables characterized across all of the clusters the frequency at
which the case and control haplotypes congregated based on a quantifiable measure of
haplotype sharing.
Similar to how we tested for association in the R×2 tables of the haplotype χ2 test
(Section 3.2.7), we computed the χ2 statistic with R−1 degrees of freedom. We assessed
the performance of including and removing haplotypes that did not assemble into any
clusters, which were plausibly the rare haplotypes, by either keeping or removing the
“other” group for each of the 3 methods discussed above (“Keep” or “Delete”). For the
Delete method, we removed entirely the row of “other” haplotypes, given that such a
row existed and that deleting the “other” row did not result in a table with 0 degrees of
freedom (i.e. a table with 1 row). On the other hand, for the Keep method, we simply
kept in the “other” row when calculating the χ2 statistic.
Finally, we formed 2× 2 tables for which affection status defined the columns and
the 2 rows consisted of the aggregated collection of clusters and the group of “other”
haplotypes. We did not attempt to regroup “other” haplotypes into the cluster row.
We computed the χ2 statistic to assess statistical significance.
3.2.9 Illumina’s iControlDB Public Resource: Acquisition, Clean-
ing, and Phasing of Genotype Data from Genome-wide
Platforms
For the purposes of simulation, described in subsequent sections (Section 3.2.10), we
obtained genotypes from a total of 5,444 subjects with diverse ethnic backgrounds
(e.g. Caucasians, African-Americans, Hispanics/Latinos, Asians, American Indians),
genotyped on Illumina’s HumanHap550 Genotyping BeadChip. We downloaded the
data with the Illumina iControlDB Client (version 1.1.2.0) upon agreeing to the Illumina
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Genotyping Control Database Download Agreement and applying for an Illumina iCom
account at www.illumina.com. Control subjects genotyped on versions 1 and 3 of the
HumanHap550 platform were available, each comprising 2,990 and 2,454 individuals,
respectively.
There were a total of 555,352 and 561,466 genome-wide markers in versions 1 and 3,
respectively. Based on the marker names, we found 545,080 markers in common to both
versions and 10,272 markers to be in version 1 but not in version 3. Of these discrepant
markers, 5,109 SNPs had been renamed since version 1, according to a batch query
we performed on dbSNP (www.ncbi.nlm.nih.gov/projects/SNP), and 5,023 of these
SNPs in version 1 were in fact in version 3. We recovered these SNPs in common by
renaming the older version 1 SNPs with the most current names as they appeared in
version 3, which brought the total number of markers in common to both versions 1
and 3 to 550,103. We note that we were unable to recover 16,386 markers that resided
in version 3 but not in version 1.
We studied the gene regions BRCA1 and PHB, both on chromosome 17 (we motivate
the study of these regions in Section 3.2.10). Therefore, we restricted the genome-wide
iControlDB data to chromosome 17. Ten of the SNPs on chromosome 17 (rs2469786,
rs1072101, rs2674954, rs11541311, rs2957407, rs3999623, rs4790958 rs1642220, rs2898645,
and rs692161) were recorded in version 1 on the opposing complementary strand as ver-
sion 3, so amongst the subjects in version 1 we recoded these SNPs in accordance with
version 3.
We further subsetted the chromosome 17 data to include control subjects who re-
ported to be Caucasian although a small proportion of individuals reported to be of
mixed Caucasian ancestry whom we excluded. The Caucasian data was used for sub-
sequent quality control procedures, phasing, and power analyses. In PLINK version
0.99s (Purcell, 2007; Purcell et al., 2007), we carried out the following quality control
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procedures. We computed the estimated proportion, pˆi, of alleles shared identity-by-
descent (IBD) for all pairwise comparisons of control subjects, in order to locate and
remove potentially related individuals such that the sample would consist of indepen-
dent controls. We also tested for HWE and calculated minor allele frequencies and
the rates of missing genotypes by SNP and subject. We then removed individuals and
SNPs that were missing more than 5% of their genotypes. SNPs with relatively low
MAFs were allowed to remain in the data set. For pairs of subjects who were related to
some degree, i.e. pˆi ≥ 0.2, we arbitrarily removed one of the related members. Lastly,
we made use of PLINK’s recoding facilities to output the resulting scrubbed genotype
data in fastPHASE format for which we inferred phase and reconstructed haplotypes
with fastPHASE version 1.2.3 (Scheet and Stephens, 2006).
3.2.10 Data Simulation to Assess the Power of the Competing
Tests
In order to evaluate the performance of the haplotype sharing measures and formal
tests, we generated simulated data sets from the pool of reconstructed iControlDB
control haplotypes, subsetted on 2 gene regions of particular interest to us, BRCA1
(breast cancer susceptibility gene 1, early onset) and PHB (prohibitin). Both genes
are larger than average spanning 81.16 and 10.82 kilobases, respectively, and are on
the q arm of chromosome 17 (17q21; BRCA1: base pair [bp] positions 38,449,840 to
38,530,994; PHB: bp positions 44,836,419 to 44,847,241; bp locations based on NCBI
B36 assembly / dbSNP b126). BRCA1 has been extensively researched with regard
to breast cancer onset in women (National Cancer Institute, 2009a; National Cancer
Institute, 2009b). PHB is thought to be a tumor suppressor and involved in sporadic
breast cancer (National Center for Biotechnology Information, Entrez Gene, 2009).
Aside from the biological relevance in studying BRCA1 and PHB, we were able to
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compare and contrast the power of the haplotype sharing measures, summary statistics,
clustering algorithm, and traditional approaches when applied to genomic segments of
relatively high and low LD as observed in BRCA1 and PHB, respectively.
We simulated phased SNP genotype data across N = 200 cases and N = 200 con-
trols (unrelated and independent) for a highly penetrant and rare disease by assuming a
disease prevalence (K) of 0.001, recessive genetic mode-of-inheritance risk model, geno-
type relative risk (GRR) of 750, and rare disease allele frequency (fD) of 0.0125 or 0.02,
depending on the pool of haplotypes carrying the disease allele, explained in greater
detail below. In order to simulate data sets with these assumed parameters, we sought
to explicitly define the genotype probabilities conditional on affection status, i.e. for the
cases Pr(dd|case), Pr(Dd|case), and Pr(DD |case), and for the controls Pr(dd|control),
Pr(Dd | control), and Pr(DD | control), where D represented the predisposing disease
allele and d the non-causal variant. With these conditional genotype probabilities, we
randomly determined the number of cases and controls with a specified genotype (dd,
Dd, or DD) and then for each case and control we randomly sampled without replace-
ment entire haplotypes from 2 distinct pools of haplotypes, according to the assigned
genotype. One pool consisted of 6,170 haplotypes that were phased and reconstructed
from the iControlDB Caucasian control subjects (please refer to Section 3.2.9) and hy-
pothetically carried the non-disease d allele (call it the “d haplotype pool”), whereas
the other pool comprised haplotypes hypothetically harboring the disease D allele (call
it the “D” haplotype pool). For example, if a case (or a control, for that matter) was
randomly assigned a Dd genotype, then we would randomly select without replacement
a haplotype from the D and d pools so as to construct the paternal and maternal chro-
mosomal segments. For homozygous cases and controls, i.e. subjects with either dd
or DD genotypes, we would randomly sample twice from the d or D haplotype pools,
respectively.
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For the set of power analyses based on the BRCA1 gene region, the haplotypes
in the d and D pools consisted of the SNPs present on the Illumina HumanHap550
marker platform at BRCA1. There were 12 such SNPs beginning at rs8176273 (bp
location 38,465,179) and ending at rs799923 (bp location 38,505,457). We selected an
additional 151 SNPs up and downstream of BRCA1, for a total of 314 SNPs spanning an
approximate 3 megabase region (rs3744786 to rs9891016 corresponding to bp positions
36,876,889 to 39,911,011). There were 6 markers covering PHB ranging from rs1049620
(bp location 44,836,513) to rs2277636 (bp location 44,847,176). Similar to BRCA1, we
chose an approximate 3 megabase segment centered about PHB, consisting of a total
of 486 SNPs (rs7220419 to rs9905480; bp locations 43,263,404 to 46,291,064) where 240
SNPs were located up and downstream of PHB.
The computational details are as follows. Assuming HWE, fD, and the non-disease
allele frequency (fd = 1− fD), we computed genotype probabilities as fdd = f 2d , fDd =
2 · fD · fd, and fDD = f 2D. The disease prevalence, K, can be written as
K = Pr(case | dd) · fdd + Pr(case |Dd) · fDd + Pr(case |DD) · fDD (3.18)
The GRR under a recessive genetic mode-of-inheritance risk model was defined to be
GRR =
Pr(case |DD)
Pr(case | dd) =
Pr(case |DD)
Pr(case |Dd) (3.19)
It followed from Equation 3.19 that
Pr(case | dd) = Pr(case |Dd) = Pr(case |DD)
GRR
(3.20)
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which we substituted into Equation 3.18 to yield
K =
Pr(case |DD)
GRR
· fdd + Pr(case |DD)
GRR
· fDd + Pr(case |DD) · fDD
= Pr(case |DD) ·
(
fdd
GRR
+
fDd
GRR
+ fDD
)
and rearranging terms gave us the penetrance of DD
Pen(DD) = Pr(case |DD) = K
fdd
GRR
+ fDd
GRR
+ fDD
(3.21)
As for the penetrances of dd and Dd, we substituted Equation 3.21 into Equation 3.20
Pen(dd) = Pen(Dd) =
K
fdd + fDd + fDD ·GRR (3.22)
where Pen(dd) and Pen(Dd) were Pr(case|dd) and Pr(case|Dd), respectively. Lastly, we
computed the genotype probabilities conditional on affection status using the following
general relationships for the cases and controls derived from Bayes’ theorem
Pr(genotype | case) = Pr(case | genotype) · fgenotype
K
Pr(genotype | control) = Pr(control | genotype) · fgenotype
1−K
where “genotype” was dd,Dd, orDD and Pr(control | genotype) = 1−Pr(case | genotype).
Specifically, the probabilities of the cases were
Pr(DD | case) = fDD
fdd+fDd
GRR
+ fDD
Pr(Dd | case) = fDd
fdd + fDd +GRR · fDD
Pr(dd | case) = fdd
fdd + fDd +GRR · fDD
(3.23)
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and for the controls were
Pr(DD | control) =
(
1− Kfdd+fDd
GRR
+fDD
)
· fDD
1−K
Pr(Dd | control) =
(
1− K
fdd+fDd+GRR·fDD
)
· fDd
1−K
Pr(Dd | control) =
(
1− K
fdd+fDd+GRR·fDD
)
· fdd
1−K
(3.24)
Therefore, the conditional genotype probabilities could be explicitly computed since
we assumed values for K and GRR and we calculated fdd, fDd, and fDD from the
assumed value of fD.
From the Equations in 3.21 and 3.22, the penetrances of our simulated data un-
der the assumed parameters (recessive genetic mode-of-inheritance risk model, K =
0.001, GRR = 750, and fD = 0.0125) were Pen(dd) = Pen(Dd) = 0.000895 and
Pen(DD) = 0.671. For the controls, Pr(control | dd) = Pr(control | Dd) = 0.999 and
Pr(control |DD) = 0.329. In other words, if an individual had 2 copies of the predis-
posing disease allele (DD), there was a firm chance of developing the disease. On the
other hand, if an individual did not have 2 copies of the disease allele (dd or Dd), with
a very high probability the individual would not contract the disease.
Moreover, our present investigation involved the unrelated case-control study de-
sign. Therefore, given our sample of N = 200 cases and N = 200 controls, their
genotype probabilities calculated from the set of Equations in 3.23 and 3.24 were
Pr(dd|case) = 0.873, Pr(Dd|case) = 0.022, and Pr(DD|case) = 0.105 amongst the cases
and Pr(dd |control) = 0.975, Pr(Dd |control) = 0.025, and Pr(DD |control) = 0.000051
amongst the controls. As an example, one of the realized simulated data sets con-
sisted of the following counts for the cases: 177 (dd), 3 (Dd), and 20 (DD) and for the
controls: 197 (dd), 3 (Dd), and 0 (DD).
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We further simulated sampling from a founder population in which random muta-
tions in the BRCA1 and PHB gene regions were induced and each haplotype carrying
the causal allele was followed throughout a number of generations and recombination
events. Specifically, for each simulated data set we generated a founder pool of haplo-
types that we designated as the “D haplotype pool” discussed above. We randomly se-
lected 1 or 5 loci within BRCA1 and PHB as the mutation site(s) and for each haplotype
we simulated recombination events across 20 or 100 generations under a Poisson process.
The recombination simulation was as follows. We randomly sampled a haplotype from
the 6,170 haplotypes in the “d haplotype pool” and randomly designated a location for
the mutation anywhere within the BRCA1 or PHB gene which did not necessarily have
to be at a locus that was genotyped. This mutation was followed after each meiosis.
We assumed that crossovers occurred randomly and independently over the entire chro-
mosome (i.e. no interference), which essentially was the Haldane mapping function. In
order to determine the number of crossover events for a given meiosis, we multiplied
the number of generations (20 or 100) by the recombination fraction, θ, and used this
expected number of crossovers as the λ input parameter of the Poisson distribution to
draw a random variate. We assessed θ for the designated regions centered about BRCA1
and PHB by first interpolating the sex-averaged map positions in centiMorgans (cM) of
the physical positions (in basepairs) that bounded the given gene region via the Rutgers
Map Interpolator web application (compgen.rutgers.edu/old/map-interpolator; Matise
et al., 2007). Due to the non-additivity of θ, we first calculated the difference of the
bounding map positions which gave us the number of cMs for the entire region. We
then converted this estimate of additive map distance, x, into the non-additive θ by
use of the Haldane map function (Haldane and Smith, 1947),
θ = 1
2
[1− exp(−2|x|)]
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Thus, the single Poisson input parameter (i.e. the expected number of crossovers across
20 or 100 generations) was computed as λ = θ · 20 or λ = θ · 100, in order to generate a
Poisson random variate that designated the number of crossovers for a given meiosis.
Subsequently, we randomly assigned the crossover sites according to the LD map
scaled in linkage disequilibrium units (LDUs). The LD maps for BRCA1 and PHB were
constructed with the program LDMAP (cedar.genetics.soton.ac.uk/public html/helpld.html;
Maniatis et al., 2002) and plotting the LDUs against the physical map in base pairs
revealed a pattern of plateaus and steps. The plateaus signified regions of low haplo-
type diversity or “LD blocks” whereas the steps reflected recombination hot-spots. We
separately read into the LDMAP program the entire set of 312 and 486 SNPs centered
about BRCA1 and PHB, respectively, across all 6,170 iControlDB haplotypes, in or-
der to generate the LD structure observed for this sample. We randomly specified the
crossover locations such that the size of the steps in the LD maps was proportional to
the likelihood of a recombination event. In other words, larger steps resulted in a higher
chance of a crossover. For each crossover, we randomly picked a haplotype from the d
haplotype pool and recorded the segment corresponding to the region on the disease
harboring haplotype that was recombined.
The founder pools containing 5 independently selected mutations were simply a
collection of 5 founder pools, each pool consisting of a distinct mutation.
3.2.11 Power Calculations to Evaluate the Performance of the
Haplotype Sharing Measures, Summary Statistics, Clus-
tering Algorithm, and Traditional Approaches
To calculate power of the haplotype sharing measures and accompanying summary
statistics, clustering algorithm, and traditional approaches, for each of the mutational
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models (i.e. 1 disease mutation inherited across 20 generations, 1 mutation / 100 gener-
ations, 5 mutations / 20 generations, and 5 mutations / 100 generations) we simulated
100 data sets using the BRCA1 and PHB gene region SNP sets discussed in Section
3.2.10. Then for each of the simulated data sets, we computed all single marker and
haplotype association tests as described in Sections 3.2.4, 3.2.6, 3.2.7, and 3.2.8, across
a selected subset of SNPs, designated as all of the SNPs in BRCA1 and PHB in addi-
tion to 5 SNPs up and downstream of these genes. For BRCA1, this subset started at
rs8076790 (bp location 38,408,126) and ended at rs11651341 (bp location 38,783,587) for
a total size of 375.46 kilobases on 22 SNPs (Table 3.1). For PHB, the segment analyzed
ranged from rs2584663 (bp location 44,823,146) to rs4794054 (bp location 44,887,097)
which was smaller than the BRCA1 region at 63.95 kilobases across a smaller set of 16
SNPs (Table 3.2).
The SNPs within the BRCA1 and PHB sets served as the analysis focal points for
the battery of association tests performed. At a given SNP, we carried out the allelic
test (Section 3.2.6) and for the haplotype χ2 test we positioned this SNP in the center
of windows that were 3, 7, and 11 SNPs wide (i.e. 1, 3, and 5 SNPs to each side of the
given SNP) and carried out the “Delete” and “Collapse” methods. We used these same
windows for the haplotype sharing measures based on fixed windows (Section 3.2.2), and
these scores were log10(CHSS
w2
w1
), Matchw2w1 , Length
w2
w1
, and Countw2w1 . This given SNP was
also the reference marker for the scores generated from the reference marker approach
(Section 3.2.1), which were log10(CHSS
r), Lengthr, and Countr. To evaluate the Length
reference marker and fixed window measures, we defined the physical positions of all of
the SNPs in the data sets per the NCBI B36 assembly which corresponded to dbSNP
b126. Subsequently, the clustering algorithm (Section 3.2.8) employed all of these
reference marker and fixed window scores at this SNP. The threshold scores (Section
3.2.3) were computed for all of the reference marker and fixed window scores and were
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based on 6 percentiles: 75%, 90%, 95%, 99%, 99.5%, and 99.9%. Lastly, for each
score we calculated 3 summary statistics (Section 3.2.4), SumCase, SumDiff, and M , and
estimated their statistical significance by setting the number of permutations, B, at
5,000 and then evaluating the permutation p-value in Equation 3.17. To compute M ,
we specified µ as 0.001 since we simulated the data sets under a disease prevalence K
of 0.001.
In the R×2 contingency tables of the clustering algorithm, we enforced cluster sizes
(i.e. row totals) to be at least 10 and we also compared the performance of the clustering
algorithm when there was no cluster size restriction. This row total criterion was
utilized in all 3 of the approaches of the R× 2 clustering algorithm (“No Regrouping”,
“Regrouping”, and “Small Cluster Row”). The same series of percentiles (75%, 90%,
95%, 99%, 99.5%, and 99.9%) utilized for the threshold scores was also employed in the
R× 2 and 2× 2 clustering algorithm. Furthermore, for the 2× 2 clustering algorithm,
both 1- and 2-sided tests were performed.
At each of the 22 and 16 SNPs in the BRCA1 and PHB sets, respectively, we
computed all of the above-mentioned test statistics and p-values across all 100 simulated
data sets. For a given test and SNP, we calculated the power to be the proportion of
times out of 100 that the test was significant at the 0.05 alpha level.
We adjusted the power estimates for multiple testing across the 22 and 16 SNPs by
way of Bonferroni and an empirical method. Specifically, for the Bonferroni adjustment
we determined the minimum p-value for a given test throughout all of the referent SNPs
and for a given simulated data set. We then assessed the Bonferroni adjusted power
by computing the proportion of times out of 100 the minimum p-value was significant
at the 0.0023 (= 0.05 / 22) or 0.0031 (= 0.05 / 16) alpha level for the BRCA1 or PHB
SNP sets, respectively. Additionally, we empirically controlled the overall type I error
by first simulating 2,500 data sets under the null model that no association existed
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between case-control status and the genotypes simulated at the putative disease locus.
Then at a particular test and simulated null data set, we found the minimum p-value
amongst the referent SNPs, resulting in an empirical null distribution of minimum
p-values based on 2,500 minimum p-values. From this null distribution, we located
the minimum p-value that demarcated the smallest 5% of the minimum p-values and
designated this as the empirically determined significance cutoff that controlled the
overall type I error rate at 5%. The location of this empirical threshold corresponded
to the 125-th smallest minimum p-values. We note that these multiple testing methods
corrected for the multiple tests conducted amongst the SNPs and did not adjust for
the array of various types of association tests we performed.
We investigated the power of removing rare SNPs as well as SNPs in strong LD
with each other. Specifically, one filter removed SNPs that had a MAF of 2% or lower
and another filter excluded SNPs with pairwise r2 of 1% or more. We calculated r2
in PLINK (Purcell, 2007; Purcell et al., 2007) as the squared correlation based on
genotypic allele counts. For each of the 100 BRCA1 and PHB simulated data sets, we
analyzed the set of SNPs in 4 different ways: 1) without any filters, which included all
SNPs; 2) 2% MAF filter applied; 3) 1% r2 filter applied; 4) both the 2% MAF and 1%
r2 filters applied. We used PLINK’s data management capabilities to exclude SNPs
that did not meet the 2% MAF and 1% r2 criteria.
We computed power in the smaller pruned BRCA1 and PHB data sets in the same
manner as that described for the full data sets. The referent SNPs in the filtered data
sets were the same 22 and 16 referent SNPs chosen previously from the full BRCA1
and PHB data sets, respectively, less any SNPs that were excluded due to the 2% MAF
and/or 1% r2 filter, depending on the exclusion scenario. Consequently, the Bonferroni
and empirical corrections were based on the smaller number of analyzed SNPs.
Hardy-Weinberg equilibrium (HWE) was assumed throughout the power analyses.
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3.2.12 Computational Aspects and Complexity
To offer the reader an appreciation of the magnitude of the tests performed for the power
calculations across the group of SNPs about BRCA1 and PHB and the computational
requirements this entailed both in collecting and summarizing the data, we begin by
describing the tests conducted at a particular SNP and a given simulated data set:
1. Allelic test
2. Haplotype χ2, Delete and Collapse methods, 3 windows each ⇒ 6 tests
3. Summing / Permutation tests
(a) 3 reference marker scores
(b) 4 fixed window scores, 3 windows each ⇒ 12 scores
(c) For each of the reference marker and fixed window scores, there was a non-
threshold score plus binary and ratio threshold scores with 6 percentiles each
⇒ 13 scores
(d) For each score, there were 3 summary measures ⇒ 15 (= 3 + 12) primary
scores × 13 sub-scores × 3 summary statistics = 585 total tests
4. R× 2 clustering algorithm
(a) 3 reference marker scores
(b) 3 fixed window scores, 3 windows each ⇒ 9 scores
(c) For each of the scores, we defined 6 percentiles to compute thresholds so as
to cluster the haplotypes
(d) For each percentile, there were 12 test types, i.e. no minimum cluster size /
cluster size of 10, No Regrouping / Regrouping / Small Cluster Row, and
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Keep / Delete⇒ 12 (= 3 + 9) scores × 6 percentiles × 12 test types = 864
total tests
5. 2× 2 clustering algorithm
(a) 3 reference marker scores
(b) 3 fixed window scores, 3 windows each ⇒ 9 scores
(c) For each of the scores, we defined 6 percentiles to compute thresholds so as
to cluster the haplotypes
(d) For each percentile, we conducted both 1- and 2-sided tests ⇒ 12 (= 3 + 9)
scores × 6 percentiles × 2 = 144 total tests
6. Grand total number of distinct tests per SNP = 1,600
Moreover, for the full data sets of BRCA1 and PHB we analyzed 22 and 16 SNPs,
respectively, so there were 35,200 (= 1,600 tests × 22 SNPs) and 25,600 (= 1,600 tests
× 16 SNPs) tests performed. We further applied the 3 MAF and LD exclusion criteria
as described in Section 3.2.11, resulting in the following number of tests conducted: 1)
2% MAF filter — there were 21 (BRCA1 set) and 15 (PHB set) SNPs for analysis,
contributing 33,600 and 24,000 tests; 2) 1% r2 filter — there were 2 referent SNPs for
each gene set, adding 3,200 tests each; 3) 2% MAF and 1% r2 filters — there was 1
referent SNP for each gene set, furnishing 1,600 tests each. Thus, for BRCA1 and PHB
we conducted 73,600 and 54,400 tests, respectively, for each of the 4 mutational models
(i.e. 1 disease mutation inherited across 20 generations, 1 mutation / 100 generations,
5 mutations / 20 generations, and 5 mutations / 100 generations), bringing the number
of tests to 294,400 and 217,600. Lastly, to compute the power we iterated through these
tests 100 times, for a grand total of 294,400,000 and 217,600,000 tests carried out which
included BRCA1 and PHB, all mutational models, and all SNP exclusion criteria.
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Data preprocessing, the haplotype pairing scores (Sections 3.2.1 and 3.2.2), thresh-
old scores (Section 3.2.3), summary statistics (Section 3.2.4), permutation tests (Section
3.2.5), allelic test (Section 3.2.6), haplotype χ2 test (Section 3.2.7), and clustering al-
gorithm (Section 3.2.8) were coded in C. We used a select set of subroutines from the
Numerical Recipes in C UNIX/Linux Version 2.10 (Press et al., 2002; software and
license obtained from www.nr.com), including “ran2” to generate uniform random de-
viates, “select” to return the k-th smallest value from a given array of values, “sort2”
to sort an array into ascending order using Quicksort while making the corresponding
rearrangements of another array, and “gammq” to compute p-values from the χ2 dis-
tribution. Appropriate changes were made to the source code of these subroutines so
as to conform to the architecture of our code. There were a total of 19,644 lines of
code spanning 384 single-sided printed pages (an uncompressed text file of almost 1
megabyte in size), which consisted of current and older versions of original subroutines,
the Numerical Recipes code, and detailed comments throughout.
We coded the simulation engines in both C and R, which generated the simulated
data sets as discussed in Section 3.2.10. The C code covered the probability sampling
of haplotypes and the R code constituted the construction of the founder pools.
In order to compute the power of the multitude of tests described above for the
BRCA1 and PHB gene sets, across all combinations of the 4 MAF/LD exclusion cri-
teria and 4 mutational models (Section 3.2.11), we had the computational burden of
processing 400 referent SNPs. For each of the simulated data sets, the 5,000 permu-
tations to estimate the statistical significance of the summary statistics (Section 3.2.4)
was incredibly time consuming, initially carried out serially on UNC’s Emerald, a 850-
processor Beowulf Linux cluster. In lieu of running these jobs for several months upon
end, in the C code we parallelized the permutation step by coding this with Message
Passing Interface (MPI) so as to take advantage of the parallel computing environment
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offered by UNC’s Topsail, a 4,160-processor Dell Linux cluster that was ranked by
TOP500 (www.top500.org) as the 87-th fastest publicly known supercomputer in the
world.
As an example, to analyze a particular SNP within the PHB gene set, on Topsail
it took 24 processors running in parallel almost 5 hours to complete 100 simulated
data sets. This was equivalent to over 4 and a half days of CPU time. On the other
hand, analyzing 2,500 null data sets to determine the null distribution of minimum
p-values for the empirically evaluated multiple test adjustments was more demanding.
For example, at a single SNP, 32 parallel processors ran for over 3 days, equivalent to
over 100 days of CPU time.
We wrote numerous Bash scripts that aided in automatically deploying the massive
number of jobs on Topsail as well as organizing the results, approximately 17 gigabytes
worth. In summarizing the results, we wrote R code that arranged the power estimates
in tables formatted in LATEX. Across BRCA1 and PHB, all mutational models, and all
SNP exclusion criteria, there were 1,632 one-sided landscape pages of results.
Finally, the LD displays in the Results (Section 3.3) were produced using Haploview
version 4.1 (Barrett et al., 2005).
3.3 Results
Upon subsetting the genome-wide SNP data from the consensus set of HumanHap550
version 1 and 3 platforms, there were 14,109 SNPs originating from chromosome 17.
We further restricted the subjects to Caucasian; there were a total of 3,172 Caucasians
(58.27% of the sample) of which there were 1,579 and 1,593 from versions 1 and 3,
respectively. We removed 87 (2.74% of the Caucasians) individuals who were likely re-
lated based on their computed pˆi, leaving 3,085 unrelated and independent Caucasians.
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None of these subjects were missing more than 5% of their genotypes and so none were
removed for low genotyping. However, 214 SNPs (1.52%) were missing genotypes at
a rate of more than 5%, thus we eliminated them from further analysis, resulting in
a total of 13,895 chromosome 17 SNPs. Lastly, although we computed the MAFs, we
allowed rare SNPs to remain in the data set.
Phasing of the genotypes in fastPHASE required almost 26 days (618 hours) using
one processor and a maximum of 296 and 313 megabytes of random access memory and
swap space, respectively, on UNC’s Emerald, a 850-processor Beowulf Linux cluster.
The 6,170 inferred and independent haplotypes (each of the 3,085 subjects contributed
2 haplotypes) served as the “d haplotype pool” from which we sampled to simulate the
data sets for the power analyses, as described in Section 3.2.10.
The SNP names, physical positions, description of locations, alleles, and computed
MAFs of the set of SNPs that we designated as the referent SNPs for the power analyses
are presented in Tables 3.1 and 3.2 for BRCA1 and PHB, respectively. In the BRCA1
set, there were 5 SNPs that were relatively rare as their MAFs were less than 10%
(rs775990, rs8176225, rs3737559, rs4793211, rs8078799) and rs8176225 was incredibly
uncommon with a MAF of 0.1%, located in the intron of BRCA1. On the other hand,
more than half of the SNPs’ MAFs were about 30%. In the PHB set, there were 3 SNPs
that had MAFs of less than 10% (rs8065814, rs8066722, rs2277636) in which rs2277636
was quite infrequent (MAF = 0.9%), positioned in the intron of PHB. Conversely, the
majority of SNPs had MAFs greater than 30%, of which a handful were above 40%.
Figures 3.1 and 3.2 provide a graphical display of the LD patterns observed in the
BRCA1 and PHB data sets, respectively, that covered an approximate 3 megabase seg-
ment roughly centered about the genes of interest. In the BRCA1 data set (Figure 3.1),
there were distinctive LD blocks of varying sizes throughout the region, and BRCA1
exhibited the largest conserved area. On the contrary, in the PHB data set (Figure
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TABLE 3.1: Characterization of the 22 SNPs chosen within (12 SNPs) and surrounding
the BRCA1 gene (5 SNPs up and downstream). These SNPs served as the referent
locations for the subsequent power analyses.
Nucleotide
Index dbSNP IDa Positionb Location Allelesc MAFd
1 rs8076790 38,408,126 RPL27, intron C / T 0.200
2 rs775990 38,412,059 IFI35 C / T 0.059
3 rs382571 38,425,007 VAT1, intron G / A 0.183
4 rs9911630 38,441,868 G / A 0.355
5 rs11657053 38,444,655 T / G 0.336
6 rs8176273 38,465,179 BRCA1, intron C / T 0.333
7 rs8176265 38,467,522 BRCA1, intron A / G 0.333
8 rs8176257 38,469,731 BRCA1, intron A / C 0.272
9 rs8176225 38,475,122 BRCA1, intron T / G 0.001
10 rs1799966 38,476,620 BRCA1, intron G / A 0.333
11 rs3737559 38,487,830 BRCA1, intron A / G 0.077
12 rs1060915 38,487,996 BRCA1, intron C / T 0.335
13 rs16942 38,497,526 BRCA1, intron G / A 0.335
14 rs799917 38,498,462 BRCA1, intron T / C 0.357
15 rs16940 38,498,763 BRCA1, intron C / T 0.333
16 rs1799949 38,498,992 BRCA1, intron T / C 0.269
17 rs799923 38,505,457 BRCA1, intron A / G 0.229
18 rs4793211 38,552,381 C / T 0.017
19 rs9646417 38,779,779 A / G 0.337
20 rs8078799 38,782,474 A / G 0.010
21 rs4793230 38,782,929 C / A 0.352
22 rs11651341 38,783,587 C / T 0.339
adbSNP: www.ncbi.nlm.nih.gov/projects/SNP
bNucleotide positions based on NCBI B36 assembly, dbSNP b126
cMinor / major allele
dMinor allele frequency
eNumber of non-missing alleles
RPL27: ribosomal protein L27
IFI35: interferon-induced protein 35
VAT1: vesicle amine transport protein 1 homolog (T. californica)
BRCA1: breast cancer susceptibility gene 1, early onset
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TABLE 3.2: Characterization of the 16 SNPs chosen within (6 SNPs) and surround-
ing the PHB gene (5 SNPs up and downstream). These SNPs served as the referent
locations for the subsequent power analyses.
Nucleotide
Index dbSNP IDa Positionb Location Allelesc MAFd
1 rs2584663 44,823,146 T / C 0.356
2 rs8065814 44,825,719 C / T 0.077
3 rs8066722 44,830,006 A / G 0.078
4 rs2197159 44,832,634 C / T 0.328
5 rs4987082 44,836,373 G / A 0.410
6 rs1049620 44,836,513 PHB, UTR A / G 0.197
7 rs2898883 44,837,952 PHB, intron A / G 0.305
8 rs2233669 44,839,002 PHB, intron G / A 0.435
9 rs935129 44,841,015 PHB, intron A / G 0.305
10 rs7502499 44,845,101 PHB, intron A / G 0.302
11 rs2277636 44,847,176 PHB, intron T / C 0.009
12 rs7222591 44,862,018 T / G 0.406
13 rs2119930 44,869,038 C / A 0.416
14 rs2584684 44,875,052 G / A 0.125
15 rs2584681 44,884,745 T / C 0.269
16 rs4794054 44,887,097 T / G 0.114
adbSNP: www.ncbi.nlm.nih.gov/projects/SNP
bNucleotide positions based on NCBI B36 assembly, dbSNP b126
cMinor / major allele
dMinor allele frequency
eNumber of non-missing alleles
PHB: prohibitin
UTR: untranslated region
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FIGURE 3.1: LD plot (r2) of the 3.03 megabase region consisting of the BRCA1 gene
approximately centered within flanking segments. There were a total of 314 SNPs, of
which 12 resided in BRCA1. White represents r2 = 0, shades of grey 0 < r2 < 1, and
black r2 = 1.
FIGURE 3.2: LD plot (r2) of the 3.03 megabase region consisting of the PHB gene
approximately centered within flanking segments. There were a total of 486 SNPs, of
which 6 resided in PHB. White represents r2 = 0, shades of grey 0 < r2 < 1, and black
r2 = 1.
3.2), the LD blocks were less apparent though indeed present, suggesting a greater
degree of diversity along this portion of the chromosome. PHB, located to the right
of a medium-sized LD block and approximately in the center of Figure 3.2, was barely
noticeable in addition to much weaker r2 values computed within the gene, compared
to BRCA1.
Figures 3.3 and 3.4 show a closer view of BRCA1 and PHB, respectively, that
emphasizes the difference between these genes as well as the areas directly up and
downstream of them. There were 12 SNPs residing in BRCA1 (SNPs 6 through 17 in
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Figure 3.3) that constituted a large number of high r2 values (black squares). The rarest
SNP, rs8176225, was not correlated to any of the SNPs in BRCA1 (r2 = 0 throughout,
white squares). The other uncommon SNP, rs3737559, though more prevalent than
rs8176225 exhibited weak correlations with all of the SNPs in BRCA1. Downstream of
BRCA1 (SNPs 18 through 22), r2 values remained strong with the exception of 2 less
common SNPs, rs4793211 and rs8078799. Upstream of BRCA1 (SNPs 1 through 5),
the correlations appeared to taper off.
In contrast to BRCA1, PHB contained half as many SNPs (SNPs 6 through 11 in
Figure 3.4), likely owing to its smaller physical size (BRCA1: 81.16 kilobases; PHB:
10.82 kilobases). There was only one high pairwise r2 value, whereas the other cor-
relations were largely moderate (shades of grey). The correlations became weaker
downstream of PHB (SNPs 12 through 16), while on the contrary the correlations were
moderate at best upstream of PHB (SNPs 1 through 5).
These contrasting gene regions of BRCA1 and PHB allowed us to compare the per-
formance of the haplotype analysis techniques between hypothetical disease harboring
chromosomal segments that differed in LD and physical size.
Table 3.3 contains the results of the power analysis conducted on the BRCA1 data
sets, in which single founder mutation events were simulated and followed through-
out 100 generations, for the log10(CHSS), Length, and Count reference marker scores
and accompanying summary statistics, SumCas, SumDiff, and M at each of the 22 se-
lected SNPs within and surrounding the BRCA1 gene. The Bonferroni and empirically
adjusted powers of the log10(CHSS) reference marker score as well as the powers com-
puted at each of the 22 SNPs were much greater than the Length and Count scores,
for which their powers were about the same after controlling for multiple tests. SumCas
and M had nearly the same power across all 22 referent SNPs and after adjustment,
while SumDiff was markedly consistently lower. Interestingly, for SumCas and M based
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FIGURE 3.3: LD plot (r2) of the BRCA1 gene surrounded by 5 SNPs up and down-
stream, for a total size of 375.5 kilobases and 22 referent SNPs. White represents
r2 = 0, shades of grey 0 < r2 < 1, and black r2 = 1.
on log10(CHSS), the powers at the SNPs within BRCA1 (SNPs 6 through 17) were
overall higher than at the 5 locations upstream (SNPs 1 through 5), in contrast to the
5 SNPs downstream (SNPs 18 through 22) for which the powers steadily climbed to a
maximum of 0.96.
Instead of one founder mutation for a given simulated data set, five founder muta-
tions were created and the disease allele frequency was set slightly higher at fD = 0.02
in lieu of fD = 0.0125 for the one mutation models. All of the other model parame-
ters remained the same (i.e. disease prevalence K = 0.001, recessive genetic mode-of-
inheritance risk model, and genotype relative risk GRR = 750). Table 3.4 contains
the five mutation model results. All of the same patterns and features discussed for
Table 3.3 also held for Table 3.4. Specifying the same model parameters for the five
mutation model as for the one mutation model returned overall lower powers (data not
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FIGURE 3.4: LD plot (r2) of the PHB gene surrounded by 5 SNPs up and downstream,
for a total size of 64.0 kilobases and 16 referent SNPs. White represents r2 = 0, shades
of grey 0 < r2 < 1, and black r2 = 1.
shown), suggesting that the log10(CHSS), Length, and Count reference marker scores
and accompanying summary statistics, SumCas, SumDiff, and M were not as powerful
in detecting disease associations when multiple independent mutations were present in
a given founder pool.
For the remaining analyses (Tables 3.5 through 3.12) based on causal mutations in
BRCA1, we simulated a single founder mutation event for each simulated data set.
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The power of the binary and ratio threshold scores, computed from the log10(CHSS)
reference marker measures, and SumCas, SumDiff, and M are shown in Table 3.5. For
both the binary and ratio threshold scores, as the percentiles increased from 75% to
99.9%, the powers increased as well. The binary scores outperformed the ratio scores;
the binary scores achieved a power of 1.00 at a 99% threshold, empirically adjusted,
whereas the maximum empirically adjusted power from the ratio scores was 0.92 for
a stringent 99.9% threshold. As the threshold percentiles increased, the differences in
power between the SumCas/M and SumDiff summary statistics became greater (SumDiff
having lower powers) and then gradually became less for the higher percentiles (99%,
99.5%, and 99.9%), with the SumCas and M having equivalent powers. For the binary
scores, we did not observe large differences in power depending on the location of the
reference marker (e.g. within BRCA1 versus outside), with the exception of the first 5
SNPs (SNPs 1 through 5) when a 95% threshold was used. On the other hand, for the
ratio scores, beginning at about the 99% threshold, the earlier SNPs (SNPs 1 through
5) tended to have lower power compared to the powers for SNPs within BRCA1 and
powers at the posterior SNPs (SNPs 18 through 22) were higher than the powers for
SNPs within BRCA1, as we saw before in Tables 3.3 and 3.4.
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We determined the power of employing windows of fixed lengths in comparison to
the reference marker approach, as discussed in Section 3.2.2. Table 3.6 presents the
power of the log10(CHSS), Length, Count, and Match scores for fixed windows of sizes 3,
7, and 11 SNPs and accompanying summary statistics. None of the measures achieved
the same or greater amount of power than their reference marker counterparts (i.e. the
log10(CHSS), Length, and Count measures) that were demonstrated in Table 3.3. In
fact, the highest empirically adjusted power attained by the window based scores was
0.50 by the log10(CHSS) and Sum
Cas/M , which was 0.41 lower than its reference marker
analog at 0.91, also the highest power amongst all of the reference marker scores. The
powers of the Length and Count fixed window scores were also well below their reference
marker versions. The Match score almost performed as well as the log10(CHSS), its
maximum occurring with the empirically adjusted power of SumDiff at 0.44. Across all
of the measures, the smaller sized window of length 3 resulted in higher powers after
controlling for multiple testing. Lastly, it did not appear that SumDiff was significantly
less powerful than SumCas and M , as we observed previously for the reference marker
scores (Tables 3.3, 3.4, and 3.5).
117
T
A
B
L
E
3.
6:
P
ow
er
of
th
e
lo
g
1
0
(C
H
S
S
),
L
en
gt
h
,
C
ou
n
t,
an
d
M
at
ch
sc
or
es
fo
r
fi
x
ed
w
in
d
ow
s
of
si
ze
s
3,
7,
an
d
11
S
N
P
s
an
d
ac
co
m
p
an
y
in
g
su
m
m
ar
y
st
at
is
ti
cs
,
S
u
m
C
a
s ,
S
u
m
D
iff
,
an
d
M
at
ea
ch
of
th
e
22
se
le
ct
ed
S
N
P
s
w
it
h
in
an
d
su
rr
ou
n
d
in
g
th
e
B
R
C
A
1
ge
n
e.
B
on
fe
rr
on
i
(B
on
f.
)
an
d
em
p
ir
ic
al
ly
(E
m
p
.)
ad
ju
st
ed
p
ow
er
s
ar
e
in
cl
u
d
ed
,
th
at
ac
co
u
n
te
d
fo
r
th
e
m
u
lt
ip
le
te
st
in
g
ac
ro
ss
S
N
P
s.
O
n
e
fo
u
n
d
er
m
u
ta
ti
on
ca
rr
ie
d
th
ro
u
gh
ou
t
10
0
ge
n
er
at
io
n
s
w
as
si
m
u
la
te
d
.
W
in
d
o
w
S
u
m
m
a
ry
M
a
rk
e
r
P
o
si
ti
o
n
s
S
iz
e
S
ta
ti
st
ic
1
2
3
4
5
6
7
8
9
1
0
1
1
1
2
1
3
1
4
1
5
1
6
1
7
1
8
1
9
2
0
2
1
2
2
B
o
n
f.
E
m
p
.
lo
g
1
0
(C
H
S
S
)
3
S
u
m
C
a
s
0
.2
2
0
.2
0
0
.1
9
0
.1
8
0
.2
0
0
.1
9
0
.2
1
0
.2
0
0
.1
9
0
.1
7
0
.1
7
0
.1
7
0
.1
9
0
.2
0
0
.2
0
0
.1
7
0
.2
2
0
.2
0
0
.2
0
0
.1
7
0
.1
6
0
.1
7
0
.2
7
0
.5
0
S
u
m
D
if
f
0
.2
0
0
.1
9
0
.1
6
0
.1
7
0
.2
0
0
.1
9
0
.2
0
0
.1
8
0
.1
7
0
.1
6
0
.1
6
0
.1
6
0
.1
9
0
.2
1
0
.1
9
0
.1
5
0
.1
3
0
.1
3
0
.1
9
0
.1
7
0
.1
6
0
.1
7
0
.2
2
0
.4
6
M
0
.2
2
0
.2
0
0
.1
9
0
.1
8
0
.2
0
0
.1
9
0
.2
1
0
.2
0
0
.1
9
0
.1
7
0
.1
7
0
.1
7
0
.2
0
0
.2
1
0
.2
0
0
.1
7
0
.2
2
0
.2
0
0
.2
0
0
.1
7
0
.1
6
0
.1
7
0
.2
8
0
.5
0
7
S
u
m
C
a
s
0
.2
5
0
.2
4
0
.2
3
0
.2
1
0
.1
8
0
.1
9
0
.1
9
0
.2
0
0
.2
0
0
.1
9
0
.1
9
0
.1
9
0
.1
8
0
.1
8
0
.1
7
0
.1
6
0
.1
7
0
.1
7
0
.1
5
0
.1
7
0
.1
8
0
.1
6
0
.1
2
0
.2
6
S
u
m
D
if
f
0
.2
4
0
.2
0
0
.2
1
0
.1
9
0
.1
6
0
.1
7
0
.1
9
0
.1
8
0
.1
8
0
.1
8
0
.1
8
0
.1
7
0
.1
6
0
.1
8
0
.1
6
0
.1
5
0
.1
6
0
.1
6
0
.1
5
0
.1
5
0
.1
8
0
.1
6
0
.1
2
0
.2
6
M
0
.2
5
0
.2
4
0
.2
3
0
.2
1
0
.1
8
0
.1
9
0
.2
0
0
.2
0
0
.2
0
0
.1
9
0
.1
9
0
.1
9
0
.1
8
0
.1
8
0
.1
7
0
.1
6
0
.1
7
0
.1
7
0
.1
5
0
.1
7
0
.1
8
0
.1
6
0
.1
2
0
.2
6
1
1
S
u
m
C
a
s
0
.2
3
0
.2
2
0
.2
0
0
.2
1
0
.1
9
0
.1
7
0
.1
7
0
.1
9
0
.1
8
0
.1
9
0
.2
0
0
.1
9
0
.1
9
0
.1
8
0
.1
8
0
.1
8
0
.1
5
0
.1
5
0
.1
6
0
.1
6
0
.1
6
0
.1
6
0
.1
0
0
.2
3
S
u
m
D
if
f
0
.2
2
0
.2
1
0
.1
8
0
.1
7
0
.1
8
0
.1
5
0
.1
4
0
.1
8
0
.1
9
0
.2
0
0
.1
8
0
.1
8
0
.1
8
0
.1
6
0
.1
6
0
.1
6
0
.1
6
0
.1
5
0
.1
7
0
.1
5
0
.1
5
0
.1
6
0
.0
8
0
.2
2
M
0
.2
3
0
.2
2
0
.2
0
0
.2
1
0
.1
9
0
.1
7
0
.1
7
0
.1
9
0
.1
8
0
.1
9
0
.2
0
0
.1
9
0
.1
9
0
.1
8
0
.1
8
0
.1
8
0
.1
5
0
.1
5
0
.1
6
0
.1
6
0
.1
6
0
.1
6
0
.1
0
0
.2
3
L
e
n
g
th
3
S
u
m
C
a
s
0
.1
9
0
.1
5
0
.1
2
0
.1
4
0
.2
1
0
.2
2
0
.1
6
0
.1
9
0
.1
9
0
.1
7
0
.1
7
0
.2
0
0
.2
1
0
.1
4
0
.1
4
0
.2
1
0
.1
5
0
.1
8
0
.1
7
0
.1
7
0
.1
9
0
.1
8
0
.1
4
0
.3
7
S
u
m
D
if
f
0
.1
7
0
.1
5
0
.1
2
0
.1
4
0
.2
1
0
.2
2
0
.1
5
0
.1
9
0
.1
9
0
.1
8
0
.1
9
0
.2
0
0
.2
0
0
.1
4
0
.1
3
0
.2
1
0
.1
4
0
.1
9
0
.1
5
0
.1
7
0
.2
0
0
.1
8
0
.1
3
0
.3
7
M
0
.1
9
0
.1
5
0
.1
2
0
.1
4
0
.2
1
0
.2
2
0
.1
6
0
.1
9
0
.1
9
0
.1
7
0
.1
7
0
.2
0
0
.2
1
0
.1
4
0
.1
4
0
.2
1
0
.1
5
0
.1
8
0
.1
7
0
.1
7
0
.1
9
0
.1
8
0
.1
4
0
.3
7
7
S
u
m
C
a
s
0
.1
4
0
.1
5
0
.1
5
0
.1
7
0
.1
7
0
.1
7
0
.2
2
0
.1
9
0
.1
8
0
.1
8
0
.1
8
0
.1
8
0
.1
8
0
.2
2
0
.1
7
0
.1
9
0
.1
8
0
.1
8
0
.2
0
0
.1
9
0
.1
8
0
.1
7
0
.0
6
0
.3
1
S
u
m
D
if
f
0
.1
3
0
.1
4
0
.1
5
0
.1
6
0
.1
6
0
.1
7
0
.2
2
0
.1
9
0
.1
8
0
.1
8
0
.1
7
0
.1
8
0
.1
9
0
.2
3
0
.1
9
0
.1
9
0
.1
9
0
.1
9
0
.1
8
0
.1
9
0
.1
6
0
.1
6
0
.0
7
0
.3
1
M
0
.1
4
0
.1
5
0
.1
5
0
.1
7
0
.1
7
0
.1
7
0
.2
2
0
.1
9
0
.1
8
0
.1
8
0
.1
8
0
.1
8
0
.1
8
0
.2
2
0
.1
7
0
.1
9
0
.1
8
0
.1
8
0
.2
0
0
.1
9
0
.1
8
0
.1
7
0
.0
6
0
.3
1
1
1
S
u
m
C
a
s
0
.1
5
0
.1
4
0
.1
4
0
.1
7
0
.1
7
0
.1
7
0
.1
7
0
.1
8
0
.1
9
0
.1
7
0
.1
8
0
.2
2
0
.2
0
0
.2
3
0
.2
1
0
.2
0
0
.2
1
0
.1
8
0
.2
1
0
.2
0
0
.2
1
0
.2
3
0
.0
6
0
.2
1
S
u
m
D
if
f
0
.1
3
0
.1
4
0
.1
4
0
.1
6
0
.1
7
0
.1
7
0
.1
7
0
.1
7
0
.1
8
0
.1
6
0
.1
8
0
.2
1
0
.1
9
0
.2
1
0
.2
0
0
.1
9
0
.1
9
0
.1
9
0
.1
8
0
.1
9
0
.1
9
0
.1
9
0
.0
6
0
.2
1
M
0
.1
5
0
.1
4
0
.1
4
0
.1
7
0
.1
7
0
.1
7
0
.1
7
0
.1
8
0
.1
9
0
.1
7
0
.1
8
0
.2
2
0
.2
0
0
.2
3
0
.2
1
0
.2
0
0
.2
1
0
.1
8
0
.2
1
0
.2
0
0
.2
1
0
.2
3
0
.0
6
0
.2
1
C
o
u
n
t
3
S
u
m
C
a
s
0
.1
6
0
.1
5
0
.1
3
0
.1
4
0
.1
8
0
.1
8
0
.2
0
0
.1
9
0
.1
9
0
.1
1
0
.1
4
0
.1
4
0
.1
8
0
.1
8
0
.2
0
0
.2
1
0
.2
2
0
.2
1
0
.1
3
0
.1
8
0
.1
8
0
.1
8
0
.1
4
0
.2
6
S
u
m
D
if
f
0
.1
5
0
.1
5
0
.1
3
0
.1
4
0
.1
7
0
.1
8
0
.2
0
0
.1
9
0
.1
9
0
.1
0
0
.1
2
0
.1
4
0
.1
8
0
.1
8
0
.2
0
0
.1
9
0
.2
2
0
.2
1
0
.1
3
0
.1
9
0
.1
8
0
.1
8
0
.1
6
0
.2
7
M
0
.1
6
0
.1
5
0
.1
3
0
.1
4
0
.1
8
0
.1
8
0
.2
0
0
.1
9
0
.1
8
0
.1
1
0
.1
4
0
.1
4
0
.1
8
0
.1
8
0
.2
0
0
.2
1
0
.2
2
0
.2
1
0
.1
3
0
.1
9
0
.1
8
0
.1
8
0
.1
4
0
.2
6
7
S
u
m
C
a
s
0
.1
7
0
.1
5
0
.1
4
0
.1
4
0
.1
5
0
.1
8
0
.1
9
0
.1
8
0
.1
8
0
.1
7
0
.1
6
0
.1
8
0
.1
9
0
.2
2
0
.2
3
0
.2
2
0
.2
3
0
.2
3
0
.2
3
0
.2
5
0
.1
7
0
.2
1
0
.0
7
0
.1
3
S
u
m
D
if
f
0
.1
7
0
.1
4
0
.1
4
0
.1
3
0
.1
5
0
.1
6
0
.1
9
0
.1
7
0
.1
8
0
.1
7
0
.1
6
0
.1
6
0
.1
8
0
.2
1
0
.2
2
0
.2
2
0
.2
1
0
.2
1
0
.2
2
0
.2
3
0
.1
6
0
.2
1
0
.0
7
0
.1
4
M
0
.1
7
0
.1
5
0
.1
4
0
.1
4
0
.1
5
0
.1
8
0
.1
9
0
.1
8
0
.1
8
0
.1
7
0
.1
6
0
.1
8
0
.1
9
0
.2
2
0
.2
3
0
.2
2
0
.2
3
0
.2
3
0
.2
3
0
.2
5
0
.1
7
0
.2
1
0
.0
7
0
.1
4
1
1
S
u
m
C
a
s
0
.1
6
0
.1
5
0
.1
6
0
.1
4
0
.1
6
0
.1
3
0
.1
6
0
.1
9
0
.1
9
0
.1
8
0
.1
8
0
.1
9
0
.1
9
0
.1
9
0
.2
1
0
.1
9
0
.2
1
0
.2
3
0
.2
2
0
.2
3
0
.2
3
0
.2
3
0
.0
5
0
.1
0
S
u
m
D
if
f
0
.1
5
0
.1
5
0
.1
5
0
.1
4
0
.1
5
0
.1
3
0
.1
5
0
.1
8
0
.1
9
0
.1
8
0
.1
8
0
.2
0
0
.1
9
0
.1
8
0
.2
0
0
.1
9
0
.2
1
0
.2
1
0
.2
2
0
.2
3
0
.2
2
0
.2
1
0
.0
5
0
.1
3
M
0
.1
6
0
.1
5
0
.1
6
0
.1
4
0
.1
6
0
.1
3
0
.1
6
0
.1
9
0
.1
9
0
.1
8
0
.1
8
0
.1
9
0
.1
9
0
.1
9
0
.2
1
0
.1
9
0
.2
1
0
.2
3
0
.2
2
0
.2
3
0
.2
3
0
.2
3
0
.0
5
0
.0
9
M
a
tc
h
3
S
u
m
C
a
s
0
.1
7
0
.1
4
0
.1
6
0
.1
4
0
.1
7
0
.2
2
0
.1
5
0
.1
6
0
.1
4
0
.1
6
0
.1
8
0
.1
9
0
.1
6
0
.1
4
0
.1
4
0
.2
5
0
.2
1
0
.2
4
0
.1
7
0
.2
1
0
.2
1
0
.1
9
0
.1
6
0
.4
2
S
u
m
D
if
f
0
.1
7
0
.1
4
0
.1
5
0
.1
4
0
.1
7
0
.2
2
0
.1
6
0
.1
6
0
.1
4
0
.1
6
0
.1
9
0
.1
9
0
.1
6
0
.1
5
0
.1
4
0
.2
6
0
.2
2
0
.2
5
0
.1
6
0
.1
8
0
.2
0
0
.2
0
0
.1
7
0
.4
4
M
0
.1
7
0
.1
4
0
.1
6
0
.1
4
0
.1
7
0
.2
2
0
.1
5
0
.1
6
0
.1
4
0
.1
6
0
.1
8
0
.1
9
0
.1
6
0
.1
4
0
.1
4
0
.2
5
0
.2
1
0
.2
4
0
.1
7
0
.2
0
0
.2
1
0
.1
9
0
.1
6
0
.4
2
7
S
u
m
C
a
s
0
.1
6
0
.1
5
0
.1
8
0
.1
9
0
.1
3
0
.1
4
0
.2
0
0
.1
8
0
.1
7
0
.1
6
0
.1
4
0
.1
5
0
.1
5
0
.2
6
0
.2
4
0
.3
2
0
.3
2
0
.3
2
0
.3
2
0
.2
9
0
.1
7
0
.1
6
0
.1
2
0
.3
9
S
u
m
D
if
f
0
.1
6
0
.1
5
0
.1
8
0
.1
9
0
.1
3
0
.1
3
0
.2
0
0
.1
7
0
.1
6
0
.1
5
0
.1
4
0
.1
6
0
.1
4
0
.2
2
0
.2
4
0
.2
8
0
.2
9
0
.3
0
0
.3
0
0
.2
8
0
.1
6
0
.1
6
0
.1
2
0
.4
1
M
0
.1
6
0
.1
5
0
.1
8
0
.1
9
0
.1
3
0
.1
4
0
.2
0
0
.1
8
0
.1
7
0
.1
6
0
.1
4
0
.1
5
0
.1
5
0
.2
6
0
.2
4
0
.3
2
0
.3
2
0
.3
2
0
.3
2
0
.2
9
0
.1
7
0
.1
6
0
.1
2
0
.3
9
1
1
S
u
m
C
a
s
0
.2
0
0
.1
6
0
.1
7
0
.1
8
0
.1
8
0
.2
0
0
.1
5
0
.1
6
0
.1
7
0
.1
7
0
.1
3
0
.2
9
0
.2
8
0
.2
9
0
.3
0
0
.2
9
0
.3
1
0
.3
1
0
.2
6
0
.2
5
0
.2
9
0
.2
6
0
.1
3
0
.3
6
S
u
m
D
if
f
0
.1
9
0
.1
6
0
.1
7
0
.1
7
0
.1
8
0
.2
0
0
.1
5
0
.1
6
0
.1
7
0
.1
6
0
.1
3
0
.2
3
0
.2
3
0
.2
7
0
.2
6
0
.2
7
0
.2
9
0
.2
9
0
.2
5
0
.2
4
0
.2
8
0
.2
2
0
.1
1
0
.3
4
M
0
.2
0
0
.1
6
0
.1
7
0
.1
8
0
.1
8
0
.2
0
0
.1
5
0
.1
6
0
.1
7
0
.1
7
0
.1
3
0
.2
9
0
.2
8
0
.2
9
0
.2
9
0
.2
9
0
.3
1
0
.3
1
0
.2
6
0
.2
5
0
.2
9
0
.2
6
0
.1
3
0
.3
6
118
We assessed the impact of removing rare SNPs and SNPs that were in relatively high
LD with each other, as described in Section 3.2.10. Applying the 2% MAF criterion,
19 SNPs were extracted, leaving 295, a 6.1% reduction. Of the 22 selected SNPs within
and surrounding the BRCA1 gene in the unpruned data sets, SNP 9 (rs8176225) was
removed due to its MAF of 0.001, resulting in 21 referent SNPs for analysis, and the
power results are presented in Table 3.7 for the log10(CHSS) reference marker score
and summary statistics. The effect of removing rare SNPs from the data sets was
substantial, power decreased by 0.23 and 0.36 for the SumCas/M and SumDiff summary
statistics, as compared to the unpruned analysis in Table 3.3, resulting in the empirically
adjusted powers of 0.68 and 0.45 for SumCas/M and SumDiff, respectively, which was
previously 0.91 and 0.81.
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TABLE 3.8: Power of the log10(CHSS) reference marker score and accompanying sum-
mary statistics, SumCas, SumDiff, and M after the 1% LD filter was imposed on the
entire set of 314 SNPs in the simulated data sets. A total of 277 SNPs were excluded,
reducing the number of SNPs to 37. Of the 22 selected SNPs within and surrounding
the BRCA1 gene in the unpruned data sets, 20 were removed resulting in only 2 referent
SNPs left for analysis. Bonferroni (Bonf.) and empirically (Emp.) adjusted powers are
included, that accounted for the multiple testing across SNPs. One founder mutation
carried throughout 100 generations was simulated.
Summary Marker
Statistic Positions
3 9 Bonf. Emp.
SumCas 0.21 0.24 0.18 0.21
SumDiff 0.15 0.18 0.14 0.17
M 0.21 0.25 0.18 0.21
We imposed the 1% LD filter on the full data set; 88.2% of the SNPs (N = 277)
were pruned for which 37 of the SNPs remained in total and only 2 referent SNPs were
left for analysis (Table 3.8). This had an even greater impact on power than the 2%
MAF filter as the empirically adjusted powers of SumCas/M and SumDiff were 0.21 and
0.17, respectively.
In the last SNP exclusion scenario, we enforced both the 2% MAF and 1% LD
criteria. A total of 285 SNPs were excluded (90.8% of the SNPs), leaving 29 SNPs in
the entire data set and one SNP for analysis (Table 3.9). The same powers at SNP 3
were computed compared to when only the 1% LD filter was utilized (Table 3.8), 0.21
and 0.15 for SumCas/M and SumDiff, respectively.
The power of the allelic and haplotype χ2 tests for fixed windows of sizes 3, 7,
and 11 are shown in Table 3.10. Based on the Bonferroni and empirically adjusted
powers, the allelic and haplotype χ2 tests were about comparable, regardless of window
size for the haplotype χ2 test. However, in comparison to the reference marker scores
(log10(CHSS), Length, and Count) using Sum
Cas/M (Table 3.3) and both the binary
and ratio threshold scores of log10(CHSS) (Table 3.5), both the unadjusted and adjusted
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TABLE 3.9: Power of the log10(CHSS) reference marker score and accompanying sum-
mary statistics, SumCas, SumDiff, andM after both the 2% MAF and 1% LD filters were
imposed on the entire set of 314 SNPs in the simulated data sets. A total of 285 SNPs
were excluded, reducing the number of SNPs to 29. Of the 22 selected SNPs within
and surrounding the BRCA1 gene in the unpruned data sets, 21 were removed resulting
in only 1 referent SNP left for analysis. One founder mutation carried throughout 100
generations was simulated.
Summary Marker
Statistic Position
3
SumCas 0.21
SumDiff 0.15
M 0.21
powers of the allelic and haplotype χ2 tests were considerably lower. On the other
hand, the window based scores (Table 3.6) overall had lower powers than the allelic
and haplotype χ2 tests.
The power of our novel, quick, and efficient R×2 clustering algorithm and grouping
techniques (No Regrouping, Regrouping, and Small Cluster Row) is presented in Table
3.11. For lower threshold values of 75%, 90%, and 99%, the powers calculated at
each SNP and after multiple testing adjustments were unsatisfactory, ranging from
an empirically adjusted power of 0.41 (90% threshold and Small Cluster Row/Keep)
to 0.66 (99% threshold and Regrouping/Delete). In this threshold range from 75% to
99%, the Regrouping technique was consistently higher than the other 2 approaches (No
Regrouping and Small Cluster Row) and as a matter of fact, its power remained stable
at about 0.65, whereas the powers of the other 2 approaches steadily climbed. However,
at the 99.5% threshold, all of the grouping techniques’ powers jumped to above 0.80.
At the higher 2 thresholds of 99.5% and 99.9%, the No Regrouping approach was the
most powerful and not the Regrouping method that was the most powerful before. The
empirically adjusted power of No Regrouping/Keep was 0.93 at the 99.5% threshold and
then was 0.99 at the most stringent 99.9% threshold. In these higher thresholds, keeping
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the “other” group of haplotypes in the R × 2 tables seemed to be more powerful than
deleting this group of the analysis entirely. On the contrary, for the prior thresholds
from 75% to 99%, the Keep and Delete methods were similar.
In comparison to the permutation based approach of SumCase/M using the log10(CHSS)
reference marker (Table 3.3) and threshold scores (Table 3.5), the R×2 clustering algo-
rithm at the highest 99.9% threshold performed better than the reference marker and
ratio scores and was comparable to the binary scores. We note that the powers of the
R × 2 clustering algorithm reached above 0.90 at the 99.5% threshold though for the
binary scores, higher powers were attained at the lower 99% threshold.
Finally, constructing 2× 2 tables with the clustering algorithm did not prove to be
a beneficial or competing approach (Table 3.12). The greatest power calculated was
0.74 at the 99.9% threshold and for the 1-sided test. At the lower thresholds from 75%
to 99.5%, the empirical powers ranged from 0 to 0.21.
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The same analytical approaches that were carried out for BRCA1 were also con-
ducted for PHB and are included in Tables 3.13 through 3.22. Table 3.13 presents the
power of the log10(CHSS), Length, and Count reference marker scores and accompa-
nying summary statistics for the PHB simulated data sets. Overall, the powers were
greater in the PHB than the BRCA1 simulated data sets. The majority of the empiri-
cally adjusted powers were above 0.87. Conversely, the Length reference marker score
performed the best as its empirically adjusted powers for SumCas/M almost reached
1.00, whereas log10(CHSS) had the highest powers for BRCA1. Also, the powers of the
Count reference marker score were considerably better at 0.90 (empirically adjusted)
for SumCas/M . The empirically adjusted powers of the log10(CHSS) reference marker
score improved slightly by 0.03 (SumCas/M = 0.94 and SumDiff = 0.87). Similar to
our observation with BRCA1, the permutation based SumDiff was consistently not as
powerful as SumCas and M . For the data sets that incorporated 5 independent founder
mutations carried throughout 100 generations (Table 3.14), the empirically adjusted
powers of the log10(CHSS) and Length reference marker scores for Sum
Cas/M were
fairly similar. This was not the case with BRCA1 as the same patterns of results were
seen with the 5 mutation models as with the 1 mutation models.
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Table 3.15 shows the power of the binary and ratio threshold scores based on the
log10(CHSS) reference marker scores. As with BRCA1 (Table 3.5), the binary scores
resulted in greater powers than the ratio scores for the more stringent thresholds in
the PHB simulated data sets. However, for PHB the maximal powers of the binary
scores occurred as of the 99.5% threshold in contrast to BRCA1 in which powers peaked
earlier at the 99% threshold.
Table 3.16 contains the results of the window based scores, analogous to the BRCA1
results in Table 3.6. All of the observations described previously for BRCA1 also held
for the PHB analysis, with the exception that the empirically adjusted powers of the
Length and Match scores were almost equivalent for the smaller window sizes of 3 and
7 and these scores were also the most powerful. On the other hand, for the BRCA1
simulated data sets, the log10(CHSS) had the greatest power.
Table 3.17 exhibits the power of the log10(CHSS) reference marker score and ac-
companying summary statistics after the 2% MAF filter was imposed on the entire set
of 486 SNPs in the PHB simulated data sets. In contrast to the BRCA1 results (Table
3.7), there was not a substantial decrease in power after removing rare variants for
SumCas and M as their power remained stable at 0.91 (without removing rare SNPs
their power was 0.94). Though for SumDiff its power decreased considerably from 0.87
(Table 3.13) to 0.67.
In the second and third SNP exclusion scenario in which the 1% LD and 2%
MAF/1% LD filters were applied (Tables 3.18 and 3.19), both the unadjusted and
adjusted powers were approximately equivalent to those of the BRCA1 simulated and
pruned data sets.
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TABLE 3.17: Power of the log10(CHSS) reference marker score and accompanying
summary statistics, SumCas, SumDiff, and M after the 2% MAF filter was imposed
on the entire set of 486 SNPs in the simulated data sets. A total of 12 SNPs were
excluded, reducing the number of SNPs to 474. Of the 16 selected SNPs within and
surrounding the PHB gene in the unpruned data sets, SNP 11 (rs2277636) was removed
due to its MAF of 0.009, resulting in 15 referent SNPs for analysis. Bonferroni (Bonf.)
and empirically (Emp.) adjusted powers are included, that accounted for the multiple
testing across SNPs. One founder mutation carried throughout 100 generations was
simulated.
Summary Marker Positions
Statistic 1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 Bonf. Emp.
SumCas 0.86 0.82 0.81 0.87 0.89 0.81 0.90 0.92 0.90 0.88 0.89 0.88 0.79 0.80 0.77 0.79 0.91
SumDiff 0.63 0.62 0.62 0.59 0.66 0.64 0.63 0.68 0.75 0.68 0.70 0.68 0.61 0.59 0.58 0.55 0.67
M 0.86 0.82 0.81 0.87 0.89 0.81 0.90 0.92 0.90 0.88 0.89 0.88 0.79 0.80 0.78 0.79 0.91
The allelic and haplotype χ2 tests were also carried out for PHB (Table 3.20).
The allelic test performed similarly for both gene regions; the empirically adjusted
powers were 0.59 and 0.55 for PHB and BRCA1 (Table 3.10), respectively. However,
for the haplotype χ2 test computed using a window consisting of 3 adjacent SNPs,
the empirically adjusted powers were almost the same for PHB and BRCA1 (0.62 and
0.58, respectively) and then for the PHB simulated data sets the empirically adjusted
powers steadily climbed from 0.69 (window size 7) to 0.76 (window size 11), while on the
contrary for the BRCA1 simulated data sets the empirically adjusted powers remained
under 0.60.
The R × 2 clustering algorithm was also applied to the PHB simulated data sets
and the results are in Table 3.21. Similar to the BRCA1 analysis, the powers using
the range of thresholds from 75% to 99% revealed inadequate powers as the maximum
empirically adjusted power computed was 0.76 for No Regrouping and Keep/Delete at
the 99% threshold. The empirically adjusted powers then improved significantly as of
the 99.5% threshold. The majority of the empirically adjusted powers were above 0.90,
the maximum empirically adjusted power occurring at the 99.9% threshold for the No
Regrouping/Keep approach. Similarly to BRCA1, the No Regrouping technique was
amongst the most powerful for the highest 2 thresholds of 99.5% and 99.9%. However,
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TABLE 3.18: Power of the log10(CHSS) reference marker score and accompanying
summary statistics, SumCas, SumDiff, and M after the 1% LD filter was imposed on the
entire set of 486 SNPs in the simulated data sets. A total of 430 SNPs were excluded,
reducing the number of SNPs to 56. Of the 16 selected SNPs within and surrounding
the PHB gene in the unpruned data sets, 14 were removed resulting in only 2 referent
SNPs left for analysis. Bonferroni (Bonf.) and empirically (Emp.) adjusted powers are
included, that accounted for the multiple testing across SNPs. One founder mutation
carried throughout 100 generations was simulated.
Summary Marker
Statistic Positions
11 15 Bonf. Emp.
SumCas 0.17 0.20 0.17 0.20
SumDiff 0.11 0.13 0.11 0.16
M 0.17 0.20 0.17 0.21
TABLE 3.19: Power of the log10(CHSS) reference marker score and accompanying
summary statistics, SumCas, SumDiff, and M after both the 2% MAF and 1% LD
filters were imposed on the entire set of 486 SNPs in the simulated data sets. A
total of 438 SNPs were excluded, reducing the number of SNPs to 48. Of the 16
selected SNPs within and surrounding the PHB gene in the unpruned data sets, 15
were removed resulting in only 1 referent SNP left for analysis. One founder mutation
carried throughout 100 generations was simulated.
Summary Marker
Statistic Position
15
SumCas 0.23
SumDiff 0.16
M 0.23
TABLE 3.20: Power of the allelic and haplotype χ2 tests for fixed windows of sizes 3,
7, and 11 at each of the 16 selected SNPs within and surrounding the PHB gene. Bon-
ferroni (Bonf.) and empirically (Emp.) adjusted powers are included, that accounted
for the multiple testing across SNPs. One founder mutation carried throughout 100
generations was simulated.
Marker Positions
Method 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Bonf. Emp.
Allelic Test 0.23 0.14 0.14 0.21 0.28 0.17 0.33 0.33 0.28 0.36 0.03 0.32 0.32 0.15 0.28 0.11 0.48 0.59
Haplotype χ2 Test
3 0.34 0.27 0.30 0.47 0.38 0.42 0.45 0.49 0.53 0.44 0.31 0.20 0.03 0.00 0.36 0.40 0.53 0.62
7 0.54 0.51 0.49 0.54 0.47 0.53 0.50 0.55 0.49 0.46 0.50 0.54 0.53 0.55 0.59 0.59 0.63 0.69
11 0.56 0.55 0.56 0.57 0.56 0.55 0.50 0.50 0.55 0.61 0.61 0.66 0.70 0.69 0.60 0.67 0.66 0.76
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the Small Cluster Row had similar empirically adjusted powers as the No Regrouping
technique, which we did not observe with the BRCA1 analysis. In addition, for the
thresholds between 75% and 95%, there was not a clear distinction amongst the three
competing grouping approaches, whereas for BRCA1 the Regrouping technique was
consistently higher at these threshold levels. Lastly, keeping and deleting the “other”
group of haplotypes in the R×2 tables had similar powers throughout the entire range
of thresholds.
Finally, in Table 3.22 the powers of the 2× 2 clustering algorithm are presented for
the PHB simulated data sets. The empirically adjusted powers were quite similar to
those of the BRCA1 analysis in Table 3.12, revealing poor power for this method in
that none of the empirically adjusted powers reached 0.70, even for the higher 99.9%
threshold.
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3.4 Discussion
We have demonstrated the utility of the log10(CHSS) reference marker score, recod-
ing the log10(CHSS) as a threshold score, and the R × 2 clustering algorithm. These
approaches were powerful when analyzing data sets of unrelated cases and controls sim-
ulated under a rare and highly penetrant recessive mode-of-inheritance disease model
for which the disease harboring haplotypes arose from founder populations. We hy-
pothesized that generating haplotype sharing scores for all
(
4N
2
)
pairs of haplotypes
from these simulated unrelated cases and controls would result in a powerful approach
since the genetic area flanking the founder mutation within the gene of interest would
be highly conserved amongst the cases throughout the recombination events across
100 generations. The simulated rare, highly penetrant, and recessive disease model
distributed the disease harboring haplotypes, that arose from the simulated founder
pools, primarily amongst the cases. Therefore, the haplotype sharing measures were
powered to detect excess sharing in the cases as compared to the controls who mainly
carried the control haplotypes sampled from the general population.
In addition, we observed that the log10(CHSS) reference marker score outperformed
the Length and Count in the BRCA1 analysis (Table 3.3), whereas all three scores
were sufficiently powered in the PHB analysis (Table 3.13). BRCA1 is a more con-
served region than the PHB gene. Therefore, we would expect that haplotype sharing
amongst the pairs of case haplotypes would be somewhat comparable to the amount
of sharing amongst the pairs of control haplotypes since the highly conserved region
within BRCA1 would exhibit a similar haplotype architecture in both the case and
control haplotypes. The result of this was that the Length and Count measures did
not adequately distinguish excess sharing amongst the cases versus the controls. On
the other hand, the PHB gene is much less conserved than BRCA1, thus the case hap-
lotypes that originated from a single mutated founder haplotype would share many
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more alleles than pairs of control haplotypes that likely did not resemble each other
because they arose from a sample of haplotypes that had different haplotype signatures
in this less conserved gene region. That said, we would expect the Length and Count to
sufficiently distinguish excess haplotype sharing amongst the cases than the controls,
which we observed as the Length and Count reference marker scores had robust powers
in the PHB analysis, as well as log10(CHSS).
Furthermore, log10(CHSS) did not suffer a loss in power as the Length and Count
did for the BRCA1 analysis, due to the rare SNPs contributing substantial weight to
the computed log10(CHSS) scores in contrast to the Length and Count that were not
designed to emphasize rare variants. This was clearly evident when we removed the rare
SNPs by applying the 2% MAF criterion to the BRCA1 simulated data sets, causing
the power of the log10(CHSS) to drop significantly as shown in Table 3.7.
We confirmed Lange and Boehnke’s (2004) claim that SumDiff is not as powerful as
SumCas. They showed this in the parent-parent-affected offspring trio design whilst we
have shown this in the unrelated case-control study design. Analogous to Lange and
Boehnke’s postulate, under the alternative hypothesis, the within group similarity for
the groups of case and control haplotypes is high while the between group similarity is
low. Thus, when subtracting off the sum of the control scores, the computed difference
is small which does not reveal this grouping effect.
We found that the Mantel statistic (Mantel, 1967), M , advocated by Beckmann
et al. (2005) had similar power to SumCas. This was not surprising since by defini-
tion for the rare disease that we simulated with disease prevalence K = 0.001, the
weights applied to the entire set of
(
4N
2
)
pairs of haplotype scores were 0.998 (close to
one) if both haplotypes were from cases, 10−6 (close to zero) if both haplotypes were
from controls, and -0.000999 if the haplotypes were from discordant affected individuals
(Section 3.2.4). Essentially, the approximate zero weight for the pairs of control haplo-
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types removed their corresponding scores from the sum and the scores from discordant
individuals were given very little weight, which minimally decreased the overall sum.
Thus, the values of M were close to the values of SumCas.
The binary threshold scores recoded from the log10(CHSS) reference marker scores
was an incredibly powerful approach when the thresholds were set at a sufficiently high
enough percentile. The binary score discretely separated the pairs of haplotypes that
had relatively high scores from those that did not. These scores of greater magnitude
were likely due to excess sharing amongst a small set of case haplotypes that comprised
rare SNPs that matched. Therefore, upon shuﬄing the affection status labels in the
permutation testing, the likelihood that all of these case haplotypes would have been
assigned case labels was small relative to the assignment of some mixture of case/case,
case/control, or control/control labels, which would not result in a summary statistic
as high or greater than that observed.
Although the threshold ratio scores had excellent power at the highest 99.9% thresh-
old, in general it did not perform as well as the binary scores. For scores that did not
meet the given threshold, they were divided by the threshold in order to produce a
distribution of ratios between zero and one. Scores that met or exceeded the threshold
were simply assigned a value of one. In other words, scores were separated into groups
of relatively high and low haplotype sharing, much like the binary score. However,
upon permuting the affection status labels in order to assess statistical significance, the
results suggest that the ratios would by chance, more often than not, inflate the per-
muted summary test statistic, thus weakening the power of the ratio score. In contrast,
the binary score did not allow the smaller scores to augment the summary statistic
since the smaller scores were assigned a value of zero.
Restricting the haplotype scoring to fixed windows of a specified number of adja-
cent SNPs proved to be an inadequate approach. For pairs of haplotypes that matched
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for longer stretches of alleles than the window’s coverage, the magnitude of the com-
puted score was limited, therefore restricting the size of the score and subsequently the
power of the summary statistic. In other words, the window based scores did not suf-
ficiently distinguish between haplotype pairs that matched for great lengths and pairs
that matched to a lesser degree. Although defining windows lends itself well to the
theoretical tractability of the test statistics, we do not recommend the window based
approach in haplotype sharing.
For the log10(CHSS) reference marker score, we showed that removing rare SNPs
could adversely affect power. Though we did not demonstrate this, the Length and
Count reference marker scores also suffered substantial losses in power regardless of
the LD structure, physical size, and number of rare alleles in the gene region analyzed
(i.e. losses were observed in both the BRCA1 and PHB analyses). Excluding the rare
SNPs likely results in pairs of haplotypes that originally shared a great deal of alleles to
not match as much, for which the altered case/case and control/control pairings would
have the greatest effect on reducing power.
Pruning SNPs based on pairwise r2 was also not desirable. The motivation for doing
so would be to reduce the number of referent SNPs to analyze, thus alleviating the
multiple testing burden. However, despite the multiple testing burden being minimal
to none, the calculated power was extremely low.
We have proposed a fast and efficient algorithm that clusters similar haplotypes
based on applying thresholds to the log10(CHSS) reference marker score. This method
of constructing R × 2 contingency tables was adequately powerful as of the 99.5%
threshold and reached almost 1.00 for the 99.9% threshold. At these higher thresh-
olds, the clustering algorithm was powered to detect discrete clusters of haplotypes
in the simulated study subjects and differentiate between the specific sharing in the
cases and controls. The motivation behind the clustering algorithm was similar to
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the threshold scores that essentially separated the score data into groups of high and
low sharing. The clustering algorithm further developed this idea of dichotomizing
the data, whereby allowing the haplotype pairs with excess sharing to additionally be
categorized into separate classes. In essence, more information was extracted from the
score data by using the clustering algorithm than with the threshold score coupled with
the summary statistic which required computationally intensive permutation testing to
assess statistical significance. In contrast, the clustering algorithm was rapid since the
test statistic of the R × 2 table was Pearson’s χ2 statistic for which statistical signifi-
cance was determined with the χ2 distribution. For genome-wide data, the clustering
algorithm would clearly be the analytical tool of choice because of the minimal com-
putational resources required and the minimal time needed to carry out, in addition to
its equivalent power to the slower permutation based threshold score.
We posited that the 2 × 2 tables would be more powerful than the R × 2 tables
using the clustering algorithm, since the 2×2 tables would decrease the dimensionality
of the R×2 tables. However, the lesser degrees of freedom did not overcome the loss of
information resulting from grouping all haplotypes with excess sharing into one cluster.
Therefore, we would recommend the use of the R× 2 tables in the clustering algorithm
and not the 2× 2 tables.
There were several limitations of this investigation. First, we assumed that the
data was phased for which we initially phased the genotype data using fastPHASE. If
phasing must be computationally inferred, errors in the estimation of haplotypes clearly
could cause the results to be misleading if associations were observed. Furthermore, if
haplotype sharing techniques would be applied on a genome-wide scale, genotype data
that must be phased would be an immense computational endeavor. Future work to
incorporate phasing of genotype data is undoubtedly needed.
Second, our results were limited to the unrelated case-control study design, though
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analogous examinations on the power for other study designs could be conducted. In
fact, much of the initial C code for the simulation engine and haplotype analysis was
designed for the parent-parent-affected offspring trio design.
Third, we have presented the usefulness of haplotype sharing under the alternative
hypothesis of a rare, highly penetrant, and recessive disease in which the disease har-
boring haplotypes emerged from founder populations. This is a very specific disease
scenario amongst a spectrum of disease possibilities such as any combination of 1) the
disease prevalence, e.g. from rare to common; 2) varying degrees of penetrance; 3) the
genetic mode-of-inheritance risk models, e.g. multiplicative, dominant, over-dominant;
4) the presence or absence of a founder effect. In the initial stages of this investigation,
we simulated a multiplicative genetic mode-of-inheritance risk model, no founder effect,
and both common and rare causal SNPs sampled from the 6,170 phased iControlDB
Caucasian haplotypes. The R × 2 and 2 × 2 clustering algorithm nor the reference
marker, window based, nor threshold scores exceeded the power of the allelic or haplo-
type χ2 tests. Therefore, the haplotype sharing techniques that we have shown to have
adequate power in this report would perform well under this particular disease setting
(i.e. rare, highly penetrant, and recessive).
Lastly, we did not research the option of allowing for up to one mismatch on either
side of the reference marker, as Lange and Boehnke (2004) did. Thus, future investiga-
tions could address the issues of genotyping error, recombination events, and mutations
for haplotypes that are similar yet not completely identical though they may share a
common ancestor.
In this report, we conducted a comprehensive investigation of haplotype sharing
methods that have been proposed by other authors. It is our understanding of the
current literature that to date there does not exist such a study. In addition, we
elaborated on methods initially introduced by Lange and Boehnke (2004), such as the
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use of thresholds with reference marker scores and the log10(CHSS) reference marker
score, and we proposed a quick, efficient, and powerful algorithm that clusters like
haplotypes. We found that the log10 version of the CHSS outperformed the other
reference marker scores, dichotomizing the haplotype sharing scores with a threshold
based on percentiles increased power, using fixed windows was detrimental to power,
removing rare SNPs and SNPs in high LD with each other was not recommendable,
and our novel clustering algorithm had competitive power and was significantly faster
than permutation testing, which is desirable for genome-wide scans.
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CHAPTER 4
GENE AND PATHWAY-BASED
P-VALUES
4.1 Introduction
A commonly used approach in candidate gene association studies is to individually test
each SNP within the candidate gene and focus attention on the most significant SNP
or SNPs while ignoring those SNPs that did not reach statistical significance. However,
this “most-significant SNP” approach can pose several problems. First, depending on
the number of interrogated SNPs and hence the burden of multiple hypothesis testing,
genetic variants that confer small disease risks could be missed. The “most-significant
SNP” approach is not conducive to the phenomenon that multiple loci within a gene
or multiple genes within a pathway often jointly function together in the etiology of
common diseases (Peng et al., 2009). Second, due to locus heterogeneity (i.e. alleles
at different loci that cause diseases in different populations), replicating a significant
finding at a single marker can be a difficult task (Sladek et al., 2007). Replicating a
significant association at the gene level may be easier than at the SNP level since a
gene, particularly a pathway, comprises an interplay of components that act together
to perform specific biological tasks (Peng et al., 2009). Third, often the location of the
specific causal variant is unknown and therefore we rely on indirect association with
a SNP that is in high linkage disequilibrium (LD) with the actual susceptibility locus.
Thus, a given single SNP may poorly predict the unobserved causal variant. Whereas
a joint analysis of SNPs within a gene could be more powerful since information is
combined across a collective number of SNPs.
Several methods have been suggested in order to jointly analyze SNPs within a gene
or region, such as Fisher’s method (Fisher, 1932), Hotelling’s T 2 test (i.e. the standard
multivariate test) (Xiong et al., 2002; Chapman et al., 2003; Fan and Knapp, 2003),
a weighted Fourier transform (Wang and Elston, 2007), and conventional haplotype
analysis (Schaid et al., 2002). Furthermore, in attempts to combine the information
amongst the set of single SNP tests conducted, often the maximum value (i.e. mini-
mum p-value) serves as the test statistic, for which the null distribution is unknown and
its corresponding p-value is empirically evaluated through permutations of the disease
status across all individuals (Chapman and Whittaker, 2008) or a conservative Bonfer-
roni correction is applied. In gene expression microarray experiments, it is generally
acceptable practice to represent the expression value of a gene by the maximum or
median value of all its transcripts and/or probe sets, since a typical gene has only a few
transcripts, and their expression levels are generally correlated (Wang et al., 2007). On
the other hand, in a gene association study, a few or several hundred common SNPs
on a chip may represent a typical gene, yet only one or a few of them contribute to
disease susceptibility or are in LD with causal variants (Wang et al., 2007). Therefore,
it is not immediately clear if taking the maximum test statistic proves to be a fair
representation of the gene’s impact on disease risk. This may be particularly true as
focus shifts to rare variants.
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Fisher’s method for combining p-values is the following statistic,
TFisher = −2 ·
n∑
j=1
log(pj) (4.1)
where pj is the p-value corresponding to the single locus test at locus j and n is the
number of loci. Fisher showed that under the global null hypothesis, TFisher follows a χ
2
distribution with 2n degrees of freedom granted that the tests are mutually independent.
However, the single locus tests at nearby loci are likely to be correlated and therefore
the limiting distribution of TFisher is unknown and statistical significance is estimated
via permutation tests.
Assuming a single underlying causal locus and a genotype-based model, Chapman
et al. (2003) showed that the appropriate multivariate score test statistic is
THotelling = U
TV −1U (4.2)
where U =
∑N
i=1(Yi − Y¯ )Xi = XT (Y − Y¯ ), N is the number of genotyped individuals,
Y = (Y1, . . . , YN)
T is an N × 1 vector of phenotypic values, X = (X1, . . . , XN)T is a
N × n matrix of genotype data for which each of N subjects contributes n genotypes
across the genotyped loci (i.e. a n× 1 vector of genotypes, Xi), and V is the estimated
null variance-covariance matrix of U . Under the null hypothesis of no association
between the putative causal locus and the phenotype, THotelling has an asymptotic χ
2
distribution with n degrees of freedom.
Multiple linear/logistic regression is also an alternative to testing multiple variant
sites simultaneously. Such an approach could have substantial advantages over single
SNP analyses (Balding, 2006). For example, covariates such as gender, age, environ-
mental exposures, or SNP interactions can be included in the model. On the other
hand, multiple regression-like analysis methods are appropriate only if the predictor
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variables (e.g. the multiple marker loci) are not in strong LD, since an underlying as-
sumption is that the predictor variables are independent. For example, if there are
SNPs that are in LD with multiple functionally relevant variants, then standard regres-
sion analyses that do not control for the multicollinearity (i.e. the LD) would result in
misleading results (Draper and Smith, 1981). Furthermore, in the presence of mod-
erate to strong multicollinearity among the predictor variables, fitting the regression
model could be computationally problematic when singular matrices must be inverted
(Draper and Smith, 1981). Additionally, when the number of predictor variables far
exceeds the number of subjects, such as in the case of genetic association studies for
which thousands of SNPs may be genotyped, the least squares solution to estimation
either can not be obtained or is highly problematic.
To circumvent the above-mentioned issues in multiple regression analysis of genetic
association studies, Malo et al. (2008) propose the use of ridge regression. Ridge
regression can deal with a large number of predictor variables compared to the number
of subjects as well as predictors that are highly correlated. Ridge regression allows
the inclusion of all SNPs in the model, rather than selecting a “representative” subset
of SNPs as potential phenotype predictors. Since the 1970s, ridge regression has been
available as a statistical tool to deal with multicollinearity, and small sample size and/or
a large number of explanatory variables (Gruber, 1998; Hastie et al., 2001). Ridge
regression places constraints on the size of the parameter estimates in attempts to
control the large variances. In other words, these constraints effectively “shrink” the
contribution of the redundant variables (e.g. the SNPs that are in strong LD with
each other) toward zero. The ridge estimates of the usual linear regression model,
Y = Xβ + ε is
βˆRidge = (XTX + kI)−1XTY (4.3)
where X is an n×p matrix of genotypes (p is the number of SNPs or markers genotyped
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on a set of n subjects), Y is an n-dimensional vector containing phenotype values for
each individual, and the ridge parameter k > 0 represents the degree of shrinkage
(Malo et al., 2008). The term kI aids in reducing multicollinearity and preventing the
matrix XTX from being singular even if X is not full rank. None of the regression
coefficients are allowed to become very large, therefore it guards against over fitting
and high variances usually associated with correlated coefficients. In contrast, the
standard parameter estimates obtained by minimizing the residual sum of squares,
RSS = (Y −Xβ)T (Y −Xβ), is
βˆMLR = argmin(RSS) = (XTX)−1XTY (4.4)
Wu et al. (2009) suggest the use of lasso penalized logistic regression for genome-
wide association analysis. The lasso penalty is another effective device for continuous
model selection, particularly when the number of predictors p far exceeds the number of
observations n (Tibshirani, 1996). Let yi be the response for case i, xij the j-th predictor
for case i, βj the regression coefficient corresponding to the j-th predictor and µ the
intercept. Also let θ = (µ, β1, . . . , βp)
T and xi = (xi1, . . . , xip)
T . The objective function
in ordinary linear regression is f(θ) =
∑n
i=1(yi− µ− xTi β)2, whereas in lasso penalized
regression, the following modified objective function is minimized
g(θ) = f(θ) + λ
p∑
j=1
|βj| (4.5)
where the tuning constant λ controls the strength of the penalty, which shrinks each
βj toward the origin and enforces sparse solutions (Wu et al., 2009).
As an alternative to penalized regression for model selection in order to jointly assess
statistical significance for a set of SNPs within a gene of interest, the authors of PLINK
(Purcell, 2007; Purcell et al., 2007) implement an algorithm based on pruning SNPs
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in LD with each other as measured by r2. Under the section “Association / Set-based
tests”, the authors describe the algorithm in the following manner:
1. For each set, for each SNP determine which other SNPs are in LD, above a certain
threshold R.
2. Perform standard single SNP analysis (which might be basic case/control associ-
ation, family-based TDT or quantitative trait analysis).
3. For each set, select up to N “independent” SNPs (as defined in step 1) with
p-values below P . The best SNP is selected first; subsequent SNPs are selected
in order of decreasing statistical significance, after removing SNPs in LD with
previously selected SNPs.
4. From these subsets of SNPs, the statistic for each set is calculated as the mean
of these single SNP statistics.
5. Permute the dataset a large number of times, keeping LD between SNPs constant
(i.e. permute phenotype labels).
6. For each permuted dataset, repeat steps 2 to 4 above.
7. Empirical p-value for set (EMP1) is the number of times the permuted set-statistic
exceeds the original one for that set.
There are potential problems with this strategy of pruning SNPs based on the r2
measure of LD. If many SNPs are correlated, the chosen SNP may not actually be
the functional SNP. Furthermore, it is possible that more than one SNP is functional
amongst those that are in moderate LD, such that choosing one to represent a cluster of
correlated SNPs would not reflect the fact that more than one position in the sequence
is phenotypically relevant (Malo et al., 2008). Perhaps of greater concern is the forced
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evaluation of a single test statistic defined by the mean of all individual SNP test
statistics for individual “independent” (independence defined based on a user-defined
ad hoc threshold) SNPs that reach a user-defined threshold of statistical significance. In
this manner, it is plausible that a highly significant SNP will be combined with several
marginally significant results and the resulting test statistic would likely reflect a far
less significant finding than if the most significant SNP was the only SNP considered.
Furthermore, the iterative inclusion of individual SNP test statistics to the running
sum (from all other previously included SNPs) test statistic representing the combined
effect of the most significant SNPs ignores the impact of modest linkage disequilibrium
between the SNPs on the individual SNP test statistics.
Li and Leal (2008) propose two strategies for combining information across multiple
marker loci in the presence of rare variants. Li and Leal discuss their methods in light
of the next generation sequencing efforts that would inevitably lead to the identification
of rare variants, which will comprise both nonfunctional and functional rare variants in
disease etiology. They argue that an effective first approach is to identify the genes that
are involved in disease onset, although understanding the effects of specific rare variants
is ultimately important. The details of their proposed methods are the following.
Assume there are N cases and N controls that are genotyped across M SNPs. For
Li and Leal’s “Collapsing Method”, they set an indicator variable X for the j-th case
individual to 1 if rare variants are present within the M SNPs and 0 otherwise. They
define Yj similarly for the control individuals. The authors claim that due to the rarity
of variants, the probability of carrying more than one variant for an individual is low.
Thus, collapsing the genotypes across all variants could enrich the association signals,
granted that nonfunctional variants are not intermingled with functional ones. Li and
Leal test whether the proportion of individuals with rare variants in the cases (φA) and
controls (φA¯) differ, i.e. H0 : φA = φA¯, by way of Pearson’s χ
2 statistic.
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Moreover, Li and Leal (2008) propose the “CMC Method” that combines collapsing
and multivariate tests. Based on some predefined criteria such as marker allele frequen-
cies, the M markers are divided into k subgroups (g1, . . . , gk) for which each group gj
contains nj (j = 1, . . . , k) SNP members. For each group gj, the Collapsing Method as
described above is carried out such that each subject has k indicator variables X that
specify the presence or absence of at least one rare variant within the group gj. Note
that no collapsing is performed for groups with a single member. Lastly, Hotelling’s T 2
test is utilized on the resulting data structure to jointly assess the statistical significance
of the gene.
Li et al. (2009) introduce yet another gene-based association test (ATOM: a multi-
marker Association Test by combining Optimally weighted Markers) that incorporates
marker weights that are proportional to the amount of information it captures about
the unknown trait locus. In particular, Li et al. define a score for an individual i
Si =
1
m
m∑
j=1
wjgij (4.6)
where m is the number of markers under study, wj weights the genotype at marker j,
and gij is the genotype at marker j for subject i for which gij ∈ {0, 1, 2} counts the
number of alleles 1j (markers are diallelic with alleles 1j and 0j). The genotype weights
are defined as
wj =
∆j
pjqj
(4.7)
where pj and qj are the allele frequencies at marker j and ∆j is the LD coefficient
between the quantitative trait locus (QTL) and marker j (typically referred to as D
and computed as ∆j = pT1j−pTpj where pT is the allele frequency of T at the diallelic
QTL and pT1j is the joint probability of alleles T and 1j at the QTL and marker j,
respectively. ∆j measures the difference between the observed joint frequency of T
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and 1j and the expected co-occurrence of T and 1j assuming independent loci). The
authors motivate wj by proving that the beta coefficients in the linear regression models
that regress the QTL genotypes on the phenotype and the marker genotypes on the
phenotype follow the relationship
β = βT
∆
pApa
(4.8)
where β and βT are the regression coefficients of the genotypes for the marker and QTL,
respectively, pA and pa are the allele frequencies at a given marker for alleles A and a,
respectively, and ∆ is the LD coefficient between the QTL and marker. Thus, the slopes
at the marker and QTL differ by a factor ∆/(pApa), the weighting function. In general,
the stronger the LD is between the trait and marker loci, the greater the magnitude
will be for the weight wj. Therefore, the score Si defined in Equation 4.6 effectively
allocates weights to markers according to their levels of LD with the trait locus (Li
et al., 2009). The association information contained in all m markers is captured in
one score for an individual i and the dimension is reduced from m to 1.
Since the location of the QTL is unknown, the weights must be estimated. Li
et al. (2009) propose gathering information on the LD structure of the candidate
gene by using a reference dataset such as the genotypes contained in the International
HapMap Project (www.hapmap.org), other publicly available dense SNP datasets, or
resequencing data from a subset of the study sample. In particular, employing the
reference sample containing M markers as well as the study sample consisting of m
markers (for whichM > m in most scenarios) at each marker k in the reference dataset
(1 ≤ k ≤M) would yield a score Si,k for every individual i
Si,k =
1
m
m∑
j=1
wkj gij (4.9)
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where wkj = ∆
k
j/pjqj is the LD coefficient between markers k and j and pj and qj are
the allele frequencies at marker j. Upon computing these score estimates for all of
the subjects in the study sample, each subject will have M scores. Li et al. (2009)
then conduct principal components analysis (PCA) in order to reduce the dimension-
ality of the dataset while retaining as much as possible the variation contained therein.
The PCA transforms the original set of M correlated scores {S1,k, . . . , Sn,k}Mk=1 across
n individuals into a set of m uncorrelated principal components. Once the principal
components are computed, a series of linear (for a quantitative phenotype) or logistic
(for a binary trait) regression models are constructed in which the predictive set of
principal components for a given model is selected based on a designated proportion
of the variance explained by the principal components. For each model, a joint test
involving all the regression coefficients is conducted. The authors choose the maxi-
mum statistic, TATOM, as the test statistic and estimate its statistical significance via
permutation tests.
Li et al. (2009) suggest that their method is different from traditional PCA-based
approaches that operate directly on the marker genotypes observed in the study sample.
In contrast, their method operates on the set of scores {S1,k, . . . , Sn,k}Mk=1 for all M
markers in the reference dataset. With traditional PCA approaches, the regression
coefficients are determined solely by the correlation structure among the genotyped
markers. Whereas with Li et al.’s strategy, additional LD information for that region
is integrated into their defined weights wkj .
We propose a method based on forward variable selection in regression that pro-
vides a joint test of the statistical significance of a gene. We compared our method
with existing and conventional methods such as computing the minimum p-value while
assessing statistical significance via permutation testing and PLINK’s Set-Based As-
sociation Test that calculates the average test statistic for a set of single SNPs and
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the overall p-value is also determined via permutation testing. We evaluated all meth-
ods under various alternative hypotheses, simulating candidate gene studies as well as
studies involving a candidate list of genes. Each method excelled in certain circum-
stances, for example, when simulating candidate gene studies, the minimum p-value
based approaches appeared to be more powerful under alternative models for which a
single QTL was responsible for the genetic variation. Both PLINK and our method
were most powerful in detecting more than one QTL, and our method performed the
best when pairwise SNP x SNP interactions were modeled. Lastly, for the simulations
comprising multiple candidate genes, our approach and Fisher’s Method had consistent
and greater power than the other techniques.
We note that although an aspect of our simulation study consisted of analyzing a set
of various candidate genes, one could plausibly apply the foregoing analytical methods
to a putative biological pathway comprising several genes.
4.2 Methods
4.2.1 Minimum P-Value Across All SNPs
We employed the approach of computing the minimum p-value across all of the single
SNP tests, as discussed in the Introduction (Section 4.1). We estimated the statistical
significance of this minimum p-value by permuting a large number of times the column
vector of quantitative phenotypes in a given simulated data set (while preserving the
LD structure of the SNPs across the sample of simulated subjects), and for each per-
mutation computing the minimum p-value from the single SNP tests. The permutation
adjusted minimum p-value was then taken to be the proportion of times the permuted
minimum p-values were less than or equal (i.e. as extreme or more extreme) than the
observed minimum p-value.
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For a data set containing SNPs within a specific gene region, this method offered a
way to test the significance of the gene. Furthermore, for data sets comprising multiple
genes within a biological pathway, the resulting p-value was an estimate of the statistical
significance of the pathway.
4.2.2 Minimum P-Value by Gene, Bonferroni Adjusted
Across NGenes genes within a given data set, we calculated the minimum p-value
amongst the single SNP tests within a particular gene, resulting in NGenes gene-specific
minimum p-values. We then estimated the statistical significance of these minimum
p-values via permutation testing as described above in Section 4.2.1. To adjust for
multiple hypothesis testing, we then applied the Bonferroni correction to the minimum
of the permutation adjusted minimum gene-specific p-values. Namely, we multiplied
the overall minimum p-value by NGenes and simply took the p-value to be one if this
product exceeded one.
We note that for data sets comprising a single gene, this method was equivalent to
taking the minimum p-value across all single SNP tests discussed in Section 4.2.1.
4.2.3 Minimum P-Value by Gene, Fisher’s Method
As an alternative to the Bonferroni adjustment detailed above in Section 4.2.2, we car-
ried out Fisher’s method for combining p-values, described in the Introduction (Section
4.1) and contained in Equation 4.1. We note that for single gene data sets, this was not
equivalent to computing the minimum p-value amongst all single SNP tests (Section
4.2.1) since TFisher was ultimately based on a χ
2 distribution with 2NGenes degrees of
freedom.
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4.2.4 PLINK’s Set-Based Association Test
We performed PLINK’s set-based association test, explicitly described in the Introduc-
tion (Section 4.1). For data sets consisting of a single gene or entire biological pathway,
we defined the set to be the gene or pathway. We used the most current version (1.06)
of PLINK available at the time of implementation (Purcell, 2007; Purcell et al., 2007).
4.2.5 Joint Test Based on Forward SNP Selection
We propose a method based on forward variable selection in regression that provides a
joint test of the statistical significance of a gene or pathway. We assume that we have
n subjects that are genotyped on p SNPs within a candidate gene or pathway and that
have been measured for a quantitative phenotype. Specifically, the algorithm to build
the multi-SNP linear regression model is the following, for j = 1, . . . , p SNPs:
1. Begin forward selection (i.e. when j = 1) by carrying out single SNP linear
regression models across all p SNPs. After the first iteration (i.e. for j > 1),
adjust for the selected SNPs (i.e. SNP1, . . . , SNPj−1) in the model.
2. While adjusting for the selected set of SNPs (SNP1, . . . , SNPj−1), construct p−
(j−1) linear regression models across the remaining p−(j−1) SNPs that have not
yet been selected to represent the candidate gene or pathway. Do not consider
any SNPs that are in “high” LD with any of the SNPs already entered in the
SNP covariate set, based on a user-defined r2 threshold (i.e. prune any SNPs
with pairwise r2 values above a given r2 threshold). Note, for j = 1 we simply
select the SNP with the smallest p-value.
3. For each of the p−(j−1) models, conduct a joint test of all the SNPs, i.e.H0 : β1 =
· · · = βj = 0 and find the most significant p-value. If this minimum joint p-value is
smaller than the j−1-th joint p-value, then add this SNP to the SNP covariate set,
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provided that the p-value corresponding to the test on the individual parameter is
less than a user-defined p-value threshold. If the individual p-value does not meet
this p-value threshold, then consider the next “most significant” joint (that also
improves upon the prior joint p-value) and corresponding individual p-values, and
so forth. As a final filter, the SNP covariate set may not exceed a user-defined
number of members. The j-th SNP corresponding to this joint test is selected
as a predictor from the candidate gene or pathway in explaining the phenotypic
variation. Record the p-value for this joint test under the j-th iteration.
4. Repeat steps 1 through 3 for each iteration of j until no more SNPs can be
added in the multi-SNP linear regression model, based on the predefined stopping
criterion defined in the prior step. When the forward selection procedure ceases,
there will be p∗ SNP predictors in the model that contains the largest number of
variables.
5. The minimum p-value amongst the p∗ joint p-values will be the last joint p-value
recorded, as defined by the nature of the algorithm. This set of p∗min SNPs is
chosen to act as a proxy for the candidate gene or pathway. Estimate the p-value
of this test statistic via permutation testing. This joint p-value represents the
statistical significance of the candidate gene or pathway.
Alternative Stopping Criterion
We allowed for a more relaxed criterion in building the SNP covariate set. If the
current joint p-value being evaluated did not improve upon the prior joint p-value,
then we admitted this SNP in the set (granted that its individual p-value met the
threshold and the maximum number of SNP members in the set was not yet satisfied)
and continued building the set under the usual guidelines as specified above. We ceased
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to expand the SNP set when we encountered a joint p-value that was not smaller than
the overall minimum joint p-value.
Inclusion of Pairwise SNP x SNP Interactions
We designed the option to include pairwise SNP x SNP interactions. As we constructed
the SNP covariate set, we sequentially added all possible pairwise SNP x SNP inter-
actions in the linear model containing the current state of the SNP set (as well as all
other previously entered interactions). We decided to keep the interaction term if the
joint p-value that assessed all terms in the model was more significant.
A Note on the Thresholds: r2, Individual P-Value, and Max Number of
SNP Members
We analogously implemented the r2, individual p-value, and maximum number of SNP
members thresholds described in the Introduction in reference to PLINK’s set-based
association test (Section 4.1) so as to allow a fair and direct comparison of PLINK’s
approach and our competing method. The essential difference between the two tech-
niques was that PLINK assessed overall statistical significance by averaging the single
SNP test statistics contained in the set, whereas the p-value in our proposed method
was based on the joint test of the parameters in a general linear model.
Setting the maximum number of members in a set to one and not imposing a p-
value filter (i.e. setting the p-value threshold to one) resulted in a test based on the
“best” single SNP for PLINK’s set-based test and our forward selection procedure. On
the other hand, by not constraining the number of SNPs in the set and by turning the
p-value and r2 filters off (i.e. p-value threshold = 1 and r2 threshold = 1), PLINK’s test
included all test statistics across all of the SNPs in the data set. For our method, it was
not feasible to construct a regression model with a considerable number of parameters.
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4.2.6 Simulations: FTO as a Candidate Gene
To evaluate the power of the proposed methods, we simulated genotype-phenotype
data for a candidate gene in the following manner. We designated FTO (official full
name: fat mass and obesity associated; residing on chromosome 16; 410.5 kilobases in
length; spanning base pair positions 52,295,376 to 52,705,882) as the candidate gene
and subsetted the corresponding genotypes in 3,172 Caucasian subjects from Illumina’s
iControlDB who were genotyped on Illumina’s HumanHap550 platform. These subjects
served as the sampling pool from which we generated simulated data sets. There were a
total of 97 representative SNPs in FTO on this genotype panel. For the purposes of the
simulation, we required all of the subjects to have been successfully genotyped at all
97 SNP loci. Thus, we removed 510 subjects who were missing at least one genotype,
leaving a total of 2,662 subjects in the genotype sampling pool.
Based on a review of the literature, we chose SNP rs8050136 within FTO to act as
a “causal” locus. This SNP has been previously reported in investigations on obesity
(Scott et al., 2007; Scuteri et al., 2007; Grant et al., 2008; Thorleifsson et al., 2009;
Pecioska et al., 2010) and is a perfect proxy to rs9939609, for which we discerned
using the web-based tool from the Broad Institute, SNAP (SNP Annotation and Proxy
Search; Johnson et al., 2008; http://www.broadinstitute.org/mpg/snap/), based on the
CEU data in HapMap. The SNP rs9939609 is located within FTO and has been widely
published (Frayling et al., 2007; Scuteri et al., 2007; Wellcome Trust Case Control
Consortium, 2007).
To simulate the data for the power analyses, we randomly picked 3,000 subjects
(with replacement) from the iControlDB sampling pool described above. We assumed
that the quantitative phenotype was normally distributed and for each of the 3,000
simulated Caucasian subjects we generated the quantitative phenotype by drawing a
normal random variate based on the genotypes observed at the rs8050136 “suscepti-
160
bility” locus for that subject. Specifically, we assumed that rs8050136 explained 0.5%
of the phenotypic variation (i.e. we set the coefficient of determination of the simple
linear regression model, R2, to 0.005) and then solved for the slope parameter using
the relationship
β1 =
√
σ2Y
σ2X
·R2 (4.10)
where σ2Y and σ
2
X were the variance of the quantitative phenotype and genotypes (at
rs8050136, in our example), respectively. We defined the variance of the phenotype
to be σ2Y = 1 and its mean to be E(Y ) = 0, i.e. the phenotype followed a standard
normal distribution. Assuming an additive genetic model coding for the bi-allelic SNP,
the expectation and variance of the genotypes were
E(X) = µX = 0 · fdd + 1 · fDd + 2 · fDD (4.11)
V (X) = σ2X = (0− µX)2 · fdd + (1− µX)2 · fDd + (2− µX)2 · fDD (4.12)
whereX = 0, 1, 2 under the additive coding for genotypes dd, Dd, andDD, respectively,
and fdd, fDd, and fDD were the probabilities of observing said genotypes. We assumed
Hardy-Weinberg Equilibrium such that fdd = f
2
d , fDd = 2fDfd, and fDD = f
2
D, where
fd and fD were the frequencies of the non-risk and risk alleles, respectively. Finally,
since the mean of the quantitative phenotype was zero, then the intercept was
E(Y | µX) = 0 = β0 + β1 · µX
β0 = −β1 · µX
(4.13)
where β1 and µX were defined in Equations 4.10 and 4.11, respectively.
Therefore, utilizing the relationships specified above in Equations 4.10 through 4.13,
for rs8050136, fD = 0.3989 in the iControlDB genotype sampling pool, σ
2
Y = 1, and
R2 = 0.005, the intercept and slope were computed to be −0.08146 and 0.1021, respec-
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tively.
Using this information, upon constructing the data set for the simulations, the
quantitative phenotype for each of the 3,000 randomly sampled vectors of genotypes was
generated by randomly sampling from the normal distribution with mean β0+β1X and
standard deviation of one, where X(= 0, 1, 2) was the observed genotype at rs8050136.
Single SNP Simulation Models for SNPs in Low to Modest LD with rs8050136
In addition to the data sets described above for which rs8050136 was the causal locus,
we also generated an additional two sets of data sets using alternative causal loci. In
the first and second sets, we chose SNPs in low and modest LD with rs8050136 (MAF =
0.3989), rs16953002 had a pairwise D′ = 0.056 (MAF = 0.1741) and rs10521307 had a
pairwise D′ = 0.311 (MAF = 0.2977). We subsequently generated the two sets of data
sets with rs16953002 and rs10521307 as the causal loci, in the same manner described
above for rs8050136. The corresponding intercept and slope for the rs16953002 models
were −0.04591 and 0.1319, and for rs10521307 were −0.06511 and 0.1094.
Two SNP Simulation Models for SNPs in Low to Modest LD with rs8050136
We simulated two other sets of data sets for which two SNP loci were responsible for
the genetic variation observed in the quantitative trait. The first SNP was the original
rs8050136 SNP and the second SNP was either rs16953002 (low LD with rs8050136)
or rs10521307 (modest LD with rs8050136). The effect sizes (i.e. slope parameters)
were defined as above for the single SNP data sets, such that the two causal SNPs
explained a cumulative proportion of 1% of the total phenotypic variation. In contrast
to that described above for the single SNP data sets, to generate the quantitative
trait we randomly sampled from a normal distribution with mean β0 + β1X1 + β2X2
and standard deviation of one, where X1 was the sampled genotype (0, 1, or 2) at
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rs8050136 and X2 was the sampled genotype at either rs16953002 or rs10521307.
Simulation Models Including Pairwise SNP x SNP Interactions with rs8050136
Building upon the two SNP models described above, we added pairwise SNP x SNP
interactions with rs8050136. To accomplish this, we simply incorporated an interaction
parameter when randomly sampling from the normal distribution with mean β0+β1X1+
β2X2 + β3X1X2 and standard deviation of one. X1X2 was the product of the observed
sampled genotypes, e.g. X1X2 could have the values of 0, 1, 2, or 4.
The specification of the interaction parameter was more involved than for the simple
linear regression models. We assumed that the total phenotypic variation could be
decomposed into both genetic and environmental components,
σ2T = σ
2
G + σ
2
E (4.14)
For example, by assuming that the quantitative trait arose from a normal distribution
with standard deviation of one, then σ2T = 1. In addition, for these interaction models,
we assumed that the total genetic variation was fixed at 1%, i.e. σ2G = 0.01. Since
we further assumed the mean of the phenotype to be zero (E(Y ) = 0), then from the
definition of variance,
σ2T = E(Y
2)− [E(Y )]2
= E(Y 2)
(4.15)
Therefore, the genetic variation for a two SNP model including interactions (first SNP:
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minor/major alleles a/A; second SNP: minor/major alleles b/B) was
σ2G = faafbb(β0 + 2β1 + 2β2 + 4β3)
2
+ faafBb(β0 + 2β1 + β2 + 2β3)
2
+ faafBB(β0 + 2β1)
2
+ fAafbb(β0 + β1 + 2β2 + 2β3)
2
+ fAafBb(β0 + β1 + β2 + β3)
2
+ fAafBB(β0 + β1)
2
+ fAAfbb(β0 + 2β2)
2
+ fAAfBb(β0 + β2)
2
+ fAAfBB(β0)
2
(4.16)
where faa, fAa, and fAA and fbb, fBb, and fBB were the probabilities of observing
the genotypes for SNPs one and two. We note that we assumed the two SNPs to be
completely independent. Similarly, for E(Y ) = 0
E(Y ) = 0 = faafbb(β0 + 2β1 + 2β2 + 4β3)
+ faafBb(β0 + 2β1 + β2 + 2β3)
+ faafBB(β0 + 2β1)
+ fAafbb(β0 + β1 + 2β2 + 2β3)
+ fAafBb(β0 + β1 + β2 + β3)
+ fAafBB(β0 + β1)
+ fAAfbb(β0 + 2β2)
+ fAAfBb(β0 + β2)
+ fAAfBB(β0)
(4.17)
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We had two equations (Equations 4.16 and 4.17) and two unknowns (β0 and β3) for
which β1, β2, and the genotype probabilities were completely specified. We solved for
β0 in Equation 4.17 and substituted β0 into Equation 4.16. This resulted in a quadratic
equation which we solved algebraically using the quadratic formula. Thus, given the
two SNPs’ allele frequencies, effect sizes, and genetic variation, we were able to solve
for the interaction parameter and intercept of the multiple linear regression model.
Namely, for the simulated data sets modeling rs8050136, rs16953002 (low LD with
rs8050136), and their pairwise interaction, the interaction parameters were 0.05659 and
−0.2331 with corresponding intercepts −0.1058 and −0.02533. For the simulated data
sets modeling rs8050136, rs10521307 (modest LD with rs8050136), and their interaction,
the interaction parameters were 0.04185 and −0.1876 with corresponding intercepts
−0.1235 and −0.01451.
Simulation Parameters and r2, P-Value, and Max Number of SNPs in Set
Filters
For the power analyses, we simulated 100 data sets for each simulation scenario in
which each data set contained 3,000 subjects. Whereas for the type I error analysis,
we simulated 500 data sets. For each data set, we permuted the phenotype 500 times
in carrying out the permutation-based tests.
For PLINK’s set-based association test and our forward selection procedure, we set
the r2 pruning thresholds to 1 (i.e. effectively no filter), 0.8, 0.5, and 0.1, the p-value
thresholds to 1 (i.e. effectively no filter), 0.05, and 0.0025. The 0.0025 p-value threshold
was chosen because based on prior power calculations, this cutoff was predicted to give
us 80% power to detect a variant that explained 0.5% of the variation in 3,000 subjects.
Lastly, the number of SNPs in the set was not allowed to exceed 5 or 10.
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4.2.7 Simulations: Body Mass Index Related List of Candi-
date Genes
We assessed the power of the competing approaches in analyzing a list of candidate
genes, in contrast to one specific candidate gene as described in Section 4.2.6. We
continued under the hypothetical scenario of studying obesity as a quantitative trait
such as body mass index (BMI). Willer et al. (2009) reported the association of SNPs
within or near eight genes (NEGR1, TMEM18, GNDPA2, MTCH2, SH2B1, FTO,
MC4R, and KCTD15). We note that the FTO gene (the gene we used to simulate the
candidate gene studies) was also listed amongst these genes.
We prepared the pool of genotypes across the candidate genes in the following
way. Within the iControlDB Caucasian sample (N = 3,172) and for each gene, we
subsetted the SNPs located within 50 kilobase pairs upstream or downstream of the
gene, including the SNPs in the gene itself, resulting in eight pools of gene-specific
genotypes. Then, for each genotype pool we removed any subject that was missing at
least one genotype at any of the loci. We were left with 1,663, 2,881, 3,135, 3,150, 3,036,
2,497, 2,993, and 2,677 vectors of genotypes for the NEGR1, TMEM18, GNDPA2,
MTCH2, SH2B1, FTO, MC4R, and KCTD15 gene pools. The number of SNPs and
other characteristics of these genes are reported in the Results (Section 4.3).
The flanking SNPs for each gene defined the boundaries for the minimum p-value
gene-based methods described in Sections 4.2.2 and 4.2.3.
To generate the simulated data sets for the subsequent power analysis, we designated
five “causal” SNPs and proceeded in the same fashion as that described for the two
SNP candidate gene models (Section 4.2.6). The only difference being that instead
of randomly sampling with replacement from one pool of genotypes, we selected from
eight pools of gene-specific genotypes. The random selection of vectors of genotypes
for one pool was independent of the random selection for another pool. In essence, we
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assumed the genes were not in LD and so we did not attempt to preserve the observed
LD structure across the genes.
We simulated data under two alternative models. For both models, we assigned
two SNPs in FTO (rs8050136 and rs10521307, in moderate LD with the former) and
one SNP near MC4R (rs10871777) as QTLs. We selected the two SNPs in FTO based
on one of the two SNP causal models from the FTO candidate gene simulation study.
In addition, we chose these two genes and SNPs because Willer et al. (2009) strongly
confirmed their associations with BMI. We note that Willer et al. (2009) reported the
variant rs17782313, though this SNP was not on the Illumina HumanHap550 panel.
We therefore employed SNAP (Johnson et al., 2008) and located rs10871777, a perfect
proxy (r2 = 1 and D′ = 1) for rs17782313 that was on the array and is 666 base
pairs away. We allowed the primary FTO SNP (rs8050136) and the MC4R SNP to
explain 0.35% of the phenotypic variation, whereas the other FTO SNP (rs10521307)
explained slightly less (R2 = 0.25%). This corresponded to slope parameters of 0.08543,
0.07732, and 0.09836, respectively. Also, for both alternative models we simulated 3,000
subjects as we did prior for the FTO candidate gene models (Section 4.2.6), and an
overall phenotypic mean and standard deviation of 0 and 1, respectively. We did not
model any pairwise SNP interactions.
Under the first model, we chose two other SNPs (beyond the three described above)
in MTCH2 (rs10838738) and SH2B1 (rs7498665), two genes for which there were few
representative SNPs (nine and five) on the Illumina HumanHap550 genotyping plat-
form. In contrast, under the second model, instead of the MTCH2 and SH2B1 causal
SNPs, we selected a SNP from NEGR1 (rs2568958) and TMEM18 (rs4854344), two
genes that contributed a fair number of SNPs to the analysis (144 and 34). Similar to
the MC4R SNP, we identified proxies for the NEGR1 and TMEM18 SNPs as described
in Willer et al. (2009), specifically, Willer et al. documented associations for rs2815752
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(in NEGR1) and rs6548238 (in TMEM18), although these SNPs were not on the Illu-
mina HumanHap550 array. We pursued the second model in order to assess the impact
on power when the QTLs were embedded in a larger set of SNPs. We posited that the
minimum p-value gene-based methods (for which the analyst must define the gene re-
gions) would suffer in power compared to PLINK’s or our step-wise method. For these
secondary SNPs, we set R2 to 0.25%, marginally less than the FTO and MC4R primary
SNPs (R2 = 0.35%). The corresponding slope parameters of the MTCH2 and SH2B1
SNPs for the first model were 0.07460 and 0.07353, and under the second model the
effect sizes of the NEGR1 and TMEM18 SNPs were 0.07501 and 0.09115, respectively.
Lastly, the vast majority of genes contained merely one or two SNPs on the Human-
Hap550 panel, thus we found it reasonable to include a 100 kilobase pair window about
the genes of interest, so as offer a fair assessment of power for the gene-based minimum
p-value methods with PLINK and our step-wise forward SNP selection procedure.
4.2.8 Computational Details
All code was written in R (R Development Core Team, 2006) and all power analyses
were carried out on UNC’s Topsail, a 4,160-processor Dell Linux cluster (2.3 GHz
Intel EM64T processors and 12 GB of memory). Due to the computationally intensive
permutation testing, we implemented parallel code in R using the library “snowfall”,
designating at least 8 CPUs for every simulated data set.
The LD displays were produced using Haploview version 4.1 (Barrett et al., 2005).
4.3 Results
Figure 4.1 contains the LD plot (D′) of the FTO gene region in the iControlDB sam-
ple of Caucasians (N = 2,662 subjects with no missing genotypes at any SNP loci).
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There were 97 representative SNPs on the Illumina HumanHap550 genotype platform.
The primary causal SNP (rs8050136) was located at position number 12, amongst a
relatively medium-sized LD block. The second disease bearing SNP was rs16953002,
which was SNP number 87, positioned on the extreme downstream end of the FTO
gene region. This SNP was in “low” LD with rs8050136 (D′ = 0.056) and was seated
in between relatively large (upstream) and small (downstream) LD blocks. The third
quantitative trait locus selected was rs10521307 (position number 25) and was in “mod-
est” LD with rs8050136 (D′ = 0.311).
FIGURE 4.1: LD plot (D′) of the FTO gene (residing on chromosome 16; 97 repre-
sentative SNPs on the Illumina HumanHap550 genotype platform; 395.96 kilobases in
length; spanning base pair positions 52,306,470 to 52,702,426) in the iControlDB sam-
ple of Caucasians (N = 2,662 subjects with no missing genotypes at any SNP loci).
White represents D′ < 1 and LOD < 2, shades of pink/red D′ < 1 and LOD ≥ 2, blue
D′ = 1 and LOD < 2, and bright red D′ = 1 and LOD ≥ 2.
Table 4.1 presents a brief characterization of the eight genes in the candidate gene
list power analyses. The largest genes were NEGR1 and FTO and hence these genes
correspondingly offered the most SNPs on the Illumina HumanHap550 array. On the
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TABLE 4.1: Characterization of the eight genes selected for the candidate gene list
analytical approach.
Number of SNPsa
Size Gene 50 kbp “Risk” SNPsc
Gene Chr (kbp) Only Windowb Model 1 Model 2 MAF
1 NEGR1 1 879.7 135 144 rs2568958 0.3496
2 TMEM18 2 9.5 2 34 rs4854344 0.1836
3 GNPDA2 4 24.4 1 7
4 MTCH2 11 25.2 2 9 rs10838738 0.3410
5 SH2B1 16 10.2 1 5 rs7498665 0.3628
6 FTO 16 410.5 97 110 rs8050136 rs8050136 0.3958
rs10521307 rs10521307 0.2982
7 MC4R 18 1.4 1 15 rs10871777d rs10871777d 0.2371
8 KCTD15 19 17.4 1 24
Chr: Chromosome
kbp: kilobase pairs
MAF: Minor Allele Frequency
rs2568958 (in NEGR1), rs4854344 (in TMEM18), and rs10871777 (near MC4R)
were strong proxies to rs2815752, rs6548238, and rs17782313, SNPs that Willer et al.
(2009) previously reported to show significant evidence for association with BMI
aBased on the Illumina HumanHap550 genotyping platform
bWe included SNPs residing within a 50 kilobase pair window flanking the gene
cWe set R2 = 0.35% for rs8050136 (in FTO) and rs10871777 (near MC4R) and
R2 = 0.25% for the remainder of the SNPs in the model
d rs10871777 is located near MC4R, not within
other hand, the smallest gene (MC4R) was not represented on the array, as well as the
SNP rs17782313 that was reported to be associated with BMI (Willer et al., 2009).
The variants rs2815752 (in NEGR1) and rs6548238 (in TMEM18) were also not on the
chip, thus we chose strong proxies that were proximal to the reported causal SNPs. All
of the SNPs included in the alternative models were fairly common (MAF above 18%).
Figure 4.2 is an LD plot of the pairwise D′ across the eight candidate genes. The
magnitude of the gene sets reflects the observations pointed out in Table 4.1. The genes
with a smaller number of SNPs (GNPDA2, MTCH2, SH2B1, and MC4R) revealed an
overall stronger LD pattern compared to NEGR1 and FTO (genes that had more SNPs)
that consisted of small blocks of LD. None of the genes appeared to be in LD with each
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other, as we suspected and designed into our simulation scheme (Section 4.2.7).
FIGURE 4.2: LD plot (D′) of the eight candidate genes (NEGR1, TMEM18, GNDPA2,
MTCH2, SH2B1, FTO, MC4R, and KCTD15; residing on chromosomes 1, 2, 4, 11, 16,
18, and 19; 348 representative SNPs on the Illumina HumanHap550 genotype platform;
a total of 2.01 megabases in length) in the iControlDB sample of Caucasians (N = 3,172
subjects). Each gene is flanked by a set of SNPs spanning approximately 50 kilobase
pairs up and downstream of the gene of interest. White represents D′ < 1 and LOD <
2, shades of pink/red D′ < 1 and LOD ≥ 2, blue D′ = 1 and LOD < 2, and bright red
D′ = 1 and LOD ≥ 2.
Table 4.2 presents the power of three gene-based p-value methods in analyzing the
FTO gene: 1) the overall minimum p-value computed across all SNPs, permutation
adjusted; 2) a consensus p-value calculated under the Bonferroni correction using the
minimum p-values by gene, permutation adjusted; 3) the same gene p-values determined
in method 2, though employing Fisher’s Method to combine the p-values. The sections
of columns in the table contain the various modeling scenarios considered. Specifically,
these models were: 1) a single variant contributed to the phenotypic variation; 2) two
SNPs were causal; 3) two SNPs were causal in addition to their positive interactive
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effect; 4) two SNPs were causal in addition to their negative interactive effect.
The highest powers achieved for the three minimum p-value based methods was for
the two SNP model that included the primary SNP (rs8050136) and the SNP that was
in low LD with it (rs16953002), with all three powers at 0.90 (Table 4.2). This is likely
due to the possibility of having two chances of detecting a causal variant instead of one
chance, as in the case of the single SNP models. For the single SNP models, the powers
were about 0.80 for the SNP 1 QTL and 0.70 for the SNP 2 QTL.
In contrast, there were significantly lower powers (around 0.77; Table 4.2) under
the two SNP model containing SNP 1 and the SNP in modest LD with it (rs10521307).
These powers were in the neighborhood of the powers under the single SNP models for
SNP 1 (0.80) and SNP 3 (0.78).
Modeling interactive effects between the two SNPs resulted in similar powers for
the SNP in low LD and for the SNP in modest LD with SNP 1 (around 0.90 and 0.77,
respectively; Table 4.2) when specifying the positive interaction parameter. However,
upon setting the interaction parameter with the negative parameter, the powers of the
three methods dropped considerably (0.31 and 0.10 for the SNP 1/SNP 2 and SNP
1/SNP 3 models, respectively).
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Table 4.3 presents the power results of PLINK’s Set-Based Association Test (SBT)
and our proposed step-wise forward SNP selection procedure (“Step”) in analyzing
the FTO gene under the single and two SNP causal models. We note that although
we imposed the r2 threshold for values of 1, 0.8, 0.5, and 0.1, we did not include
these results in Tables 4.3 and 4.4 because it did not appear that this threshold type
impacted the power to any appreciable degree. With SNP 1 (rs8050136) as the sole
QTL, PLINK attained the highest power above all other methods (0.86). However, the
more stringent p-value threshold (0.0025), adversely affected PLINK’s power whereas it
substantially improved our step-wise method (power = 0.80), though it did not greatly
improve upon the three minimum p-value based methods. Under the SNP 2 single
QTL model (rs16953002, in low LD with SNP 1), PLINK and our method performed
almost equivalently, with the exception of p-value threshold 1 / max 10 and p-value
threshold 0.05 / max 5 in which our method performed about 10% in power better. At
the more stringent thresholds (p-value = 0.0025 and max = 5 or 10), both PLINK and
“Step” were detecting this SNP at about the same rate as the minimum p-value based
methods. Lastly, under the SNP 3 QTL model (rs10521307, in modest LD with SNP
1), both PLINK and Step had similar powers, with the exception of thresholds p-value
= 0.05 and max = 10, for which we had an improvement of power of 16%. Similar to
the SNP 2 QTL model, PLINK and Step almost reached the power of the minimum
p-value based methods (power = 0.78; Table 4.2).
As for the two SNP models, PLINK outperformed all of the methods, including the
minimum p-value based ones, at a power of 0.93 and 0.88 (Table 4.3; SNP 1/SNP 2 and
SNP 1/SNP 3, respectively) versus 0.90 and 0.77 for the minimum p-value methods
(Table 4.2; SNP 1/SNP 2 and SNP 1/SNP 3, respectively). However, as we observed
before under the single SNP model of SNP 1, at the more rigorous p-value threshold
of 0.0025, PLINK had the worse power amongst all methods (0.85 and 0.70). Under
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TABLE 4.3: Power of PLINK’s Set-Based Association Test (SBT) and our proposed
step-wise forward SNP selection procedure (“Step”) in analyzing the FTO gene, under
the single and two SNP causal models.
Single SNP Models Two SNP Models
(SNP 2) (SNP 3) SNP 1/ SNP 1/
Thresholds SNP 1 Low LD Mod. LD Low LD Mod. LD
P-Value Max SBT Step SBT Step SBT Step SBT Step SBT Step
1.0000 5 0.85 0.67 0.52 0.59 0.64 0.69 0.93 0.89 0.84 0.82
1.0000 10 0.86 0.59 0.42 0.53 0.59 0.62 0.91 0.83 0.88 0.82
0.0500 5 0.86 0.65 0.54 0.62 0.62 0.65 0.93 0.88 0.83 0.83
0.0500 10 0.84 0.60 0.52 0.56 0.46 0.62 0.88 0.87 0.79 0.81
0.0025 5 0.72 0.80 0.70 0.69 0.74 0.76 0.84 0.89 0.70 0.85
0.0025 10 0.72 0.80 0.68 0.69 0.77 0.76 0.85 0.89 0.70 0.85
SNP 1: rs8050136
SNP 2: rs16953002, which is in “low” LD with SNP 1 (D′ = 0.056)
SNP 3: rs10521307, which is in “modest” LD with SNP 1 (D′ = 0.311)
The power calculations were based on 100 simulated data sets
3,000 subjects were simulated for each data set
500 permutations were carried out for the permutation testing
The overall type I error was fixed at 0.05
For the single SNP models, R2 was set at 0.5%, corresponding to effect sizes of 0.1021,
0.1319, and 0.1094 for SNPs 1, 2, and 3, respectively
For the two SNP models, R2 for each SNP was set at 0.5%, therefore the effect sizes
as specified above were utilized
The quantitative trait was randomly generated from a standard normal distribution
(i.e. mean zero and standard deviation of one)
the two SNP model that included the SNP in moderate LD with SNP 1, there was a
much greater gain in power utilizing our step-wise approach as compared to PLINK’s
SBT (SBT = 0.70 and Step = 0.85). In fact, our step-wise approach at this p-value
threshold of 0.0025 had greater power than the minimum p-value approaches.
Table 4.4 contains the power of the SBT and Step in analyzing the FTO candidate
gene, under the two SNP causal models including interactions. For the models with
the SNP 1/SNP 2 positive interactions, both the SBT and Step (around 0.92) had
powers slightly better than the three minimum p-value based methods (0.90; Table
4.2). However, for the SNP 1/SNP 3 positive interactions, both SBT and Step were
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more powerful (0.87 and 0.83, respectively) than the minimum p-value methods (0.77).
In some threshold instances, the SBT did better than Step and vice versa. Lastly, under
the negative interaction models, Step was the most powerful amongst all methods (0.38
for the SNP 1/SNP 2 scenario versus 0.31 for the min p-value methods; 0.23 for the SNP
1/SNP 3 scenario versus 0.10 for the min p-value methods). Furthermore, Step seemed
to consistently outperform SBT when modeling negative interactions. We note that
although Step was most powerful, these powers were relatively low and surprisingly not
an overall powerful method in discerning amongst the significant genetic parameters,
at least for the negative interaction models.
Table 4.5 contains the results of the candidate gene list approach in which we
analyzed “super” data sets (under two alternative models) comprising eight candidate
gene regions. The minimum p-value based approaches assessed at the gene level suffered
a substantial drop in power (less so for Fisher’s Method) under the alternative model
that housed the secondary QTLs in gene regions (NEGR1 and TMEM18) comprising
a larger set of SNPs (Model 2) compared to Model 1 that modeled secondary QTLs
in gene regions (MTCH2 and SH2B1) with less SNPs. Interestingly, computing the
minimum p-value across all available SNPs in the data set increased in power for Model
2. It is notable that Fisher’s Method under Model 1 performed the best (power =
0.99), which was somewhat not surprising since the gene regions bearing the simulated
QTLs exhibited little to no LD (Figure 4.2), and Fisher’s Method strictly assumes
mutually independent tests. The Bonferroni correction also had decent power (0.93),
though following Fisher’s Method in robustness was our step-wise procedure at 0.96.
Power marginally dropped upon imposing a stricter p-value threshold of 0.0025, which
was the opposite trend of what we observed for the candidate FTO gene alternative
models. PLINK showed adequate power when no p-value filter was implemented (0.86),
however, its power fell dramatically for the more stringent p-value threshold (0.67).
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TABLE 4.4: Power of PLINK’s Set-Based Association Test (SBT) and our proposed
step-wise forward SNP selection procedure (“Step”) in analyzing the FTO gene, under
the two SNP causal models including interactions.
Two SNP Models
+ Interactions − Interactions
SNP 1/ SNP 1/ SNP 1/ SNP 1/
Thresholds Low LD Mod. LD Low LD Mod. LD
P-Value Max SBT Step SBT Step SBT Step SBT Step
1.0000 5 0.91 0.91 0.87 0.82 0.28 0.35 0.080 0.20
1.0000 10 0.88 0.76 0.83 0.60 0.23 0.38 0.092 0.23
0.0500 5 0.90 0.89 0.82 0.78 0.25 0.28 0.080 0.14
0.0500 10 0.83 0.86 0.73 0.73 0.22 0.24 0.103 0.16
0.0025 5 0.88 0.92 0.70 0.83 0.30 0.31 0.080 0.11
0.0025 10 0.87 0.92 0.70 0.83 0.31 0.31 0.080 0.11
SNP 1: rs8050136
SNP 2: rs16953002, in “low” LD with SNP 1 (D′ = 0.056)
SNP 3: rs10521307, in “modest” LD with SNP 1 (D′ = 0.311)
Interactions: included in the model were pairwise SNP x SNP interac-
tions involving the two SNPs
+/− Interactions: the regression parameter of the interaction term
changed the phenotypic mean in the positive/negative direction for every
positive unit change in the interaction predictor
The power calculations were based on 100 simulated data sets
3,000 subjects were simulated for each data set
500 permutations were carried out for the permutation testing
The overall type I error was fixed at 0.05
The R2 for each SNP was set at 0.25%, corresponding to effect sizes of
0.07220, 0.09324, and 0.07732 for SNPs 1, 2, and 3
The interaction parameters explained 0.5% of the total phenotypic vari-
ation (i.e. R2 = 0.5%), corresponding to positive interaction parameters
of 0.05659 and 0.04185 and negative parameters of −0.2331 and −0.1876
(SNP 1 x SNP 2 and SNP 1 x SNP 3)
The quantitative trait was randomly generated from a standard normal
distribution (i.e. mean zero and standard deviation of one)
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Power remained roughly the same under Model 2 for the SBT and Step. We note
that the Step attained the highest power amongst all methods under Model 2 (0.96).
Overall, our step-wise method achieved substantially greater power than PLINK.
4.4 Discussion
We have reported results on some available methods for analyzing candidate gene or
a set of candidate genes. In contrast to tests of association that are conducted at the
SNP level, the approaches we have explored offer a consensus estimate of significance
for the entire set of SNPs comprising the gene or genes. With regard to analyzing a
data set consisting of multiple candidate genes, although we framed our power analyses
about a list of obesity-related genes, one could plausibly apply the foregoing analytical
methods to a putative biological pathway comprising various genes.
We assessed the power of three methods based on the minimum p-value for a given
candidate gene or genes: 1) the overall minimum p-value computed across all SNPs,
permutation adjusted; 2) a consensus p-value calculated under the Bonferroni correction
using the minimum p-values by gene, permutation adjusted; 3) the same gene p-values
determined in method 2, though employing Fisher’s Method to combine the p-values.
In the candidate gene approach, for the simulated data sets in which we modeled
an underlying single quantitative trait locus, these minimum p-value based methods
had decent power for the SNP 1 (rs8050136) and SNP 3 (rs10521307) models (power =
∼0.80; Table 4.2) though not for the SNP 2 (rs16953002) model. Consequently, SNPs
1 and 3 had much more abundant minor allele frequencies than SNP 2 (SNP 1 MAF
= 0.3989 and SNP 3 MAF = 0.2977 in comparison to SNP 2 MAF = 0.1741). Perhaps
due to the less frequent presence of SNP 2’s quantitative trait variant, the overall
phenotypic distribution was weighted heavier with trait values from homozygotes for
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TABLE 4.5: Power of the minimum p-value based methods (Overall, Bonferroni, and
Fisher’s Method), PLINK’s Set-Based Association Test (SBT), and our proposed step-
wise forward SNP selection procedure (“Step”) in analyzing the eight obesity-related
candidate genes in a single analysis, under two alternative modeling scenarios.
Method Model 1a Model 2b
Overall Min P-Value 0.80 0.87
Bonferroni (Gene) 0.93 0.78
Fisher’s Method (Gene) 0.99 0.93
Thresholds Model 1a Model 2b
P-Value Max SBT Step SBT Step
1.0000 5 0.86 0.96 0.87 0.96
1.0000 10 0.81 0.94 0.87 0.96
0.0500 5 0.88 0.96 0.88 0.96
0.0500 10 0.83 0.93 0.89 0.94
0.0025 5 0.72 0.90 0.72 0.90
0.0025 10 0.67 0.90 0.60 0.90
aModel 1: two QTLs in FTO (rs8050136:
R2 = 0.35%/slope = 0.08543; rs10521307:
R2 = 0.25%/slope = 0.07732), one near MC4R
(rs10871777: R2 = 0.35%/slope = 0.09836), and one
each in MTCH2 (rs10838738: R2 = 0.25%/slope =
0.07460) and SH2B1 (rs7498665: R2 = 0.25%/slope
= 0.07353)
bModel 2: the same SNPs and effect sizes in FTO
and near MC4R (noted above), and one QTL each
in NEGR1 (rs2568958: R2 = 0.25%/slope = 0.07501)
and TMEM18 (rs4854344: R2 = 0.25%/slope =
0.09115)
The power calculations were based on 100 simulated
data sets
3,000 subjects were simulated for each data set
500 permutations were carried out for the permuta-
tion testing
The overall type I error was fixed at 0.05
For the minimum p-value gene-based approaches
(Bonferroni and Fisher’s Method), the gene bound-
aries were defined as the SNPs that flanked the region
comprising the gene plus 50 kilobase pairs up and
downstream of the gene
The quantitative trait was randomly generated from
a standard normal distribution (i.e. mean zero and
standard deviation of one)
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the major allele. Hence, there was not such a clear distinction amongst this homozygous
distribution and the distributions arising from the heterozygotes and the homozygotes
for the minor allele.
As for the two SNP model results, we observed excellent power (0.90; Table 4.2)
when modeling SNP 1 and SNP 2 (the SNP in low LD with SNP 1) though we observed
a 12% decline in power for the SNP 1/SNP 3 models. This result can be explained
in the following way. We calculated the D′ between the SNPs as 0.311 whereas the
r2 was fairly low (0.02823). In addition, the minor allele frequencies of the two SNPs
were different (SNP 1, rs8050136: MAF = 0.3989; SNP 3, rs10521307: MAF = 0.2977),
therefore given the mathematical nature of D′ and r2, it is not surprising that their
values were discordant since D′ is affected by allele frequencies. These D′ and r2 results
imply no (or minimal) historical recombination events such that the representative pool
of haplotypes consisted of three possible haplotypes rather than all four. Taken together
with the power results, this suggests an overabundance of the haplotype bearing both
risk variants. Thus, including an additional causal SNP in simulating the quantitative
trait did not improve our chances in detecting these QTLs.
With respect to the two SNP models including interactions, overall the minimum
gene p-value based methods performed poorly, with the exception of the powers esti-
mated under the SNP 1/ SNP 2 (SNP in low LD with SNP 1) interaction models. This
was expected since taking the minimum gene p-value completely ignored the effects of
interaction on the quantitative trait.
Under the single and two SNP alternative models without interactions, PLINK
performed fairly well in comparison to our step-wise procedure. Taken together with our
observation that pruning SNPs in high LD with the significant SNPs did not positively
nor adversely affect power, PLINK’s approach of averaging the test statistics did not
push the averaged test statistic toward non-significance but rather this provided more
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power. This was counter-intuitive to us as we expected the average test statistic to be
less in magnitude than the overall minimum p-value across all SNPs.
On the contrary, under the single and two SNP alternative models without interac-
tions, our step-wise approach in many instances had significantly greater power than
PLINK when restricting individual p-values to be less than 0.0025. However, under
these alternative models and individual p-value restriction, we were not able to ex-
ceed the power attained by PLINK. A possible explanation for this drop in power with
PLINK’s method in these instances is the following. Upon removing SNPs that did
not meet the 0.0025 p-value threshold, the SNP or SNPs that drove the signal in the
averaged test statistic had corresponding p-values above 0.0025. Thus, in assessing
statistical significance of the observed average test statistic via permutation testing, it
was quite probable to calculate an average test statistic that was as extreme or more
extreme than the observed. On the other hand, for the instances in which power in-
creased under the 0.0025 p-value filter, the SNP or SNPs largely responsible for the
signal were likely retained after applying the filter.
As for the candidate gene list analyses, the minimum p-value approaches showed
acceptable power, though there were clearly gains in power in using our step-wise
method. Compared to the Bonferroni adjustment, Fisher’s method was more powerful
under both alternative model scenarios. Clearly, there was less of a penalty (or per-
haps no penalty at all) for multiple testing in combining the gene-specific permutation
adjusted minimum p-values using Fisher’s Method than Bonferroni. Regarding the
almost perfect power of Fisher’s Method under Model 1 (0.99), there were probably
strong associations at each gene, coupled with the small penalty for combining the p-
values and that each permutation test was for all practical purposes independent (due
to the minimal LD amongst the gene regions shown in Figure 4.2). The significant
decrease in power observed under Model 2 for the minimum p-value based methods at
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the gene level (not so much for Fisher’s Method) was likely due to the fact that two of
the QTL signals (in NEGR1 and TMEM18) were embedded amongst a greater number
of SNPs in contrary to MTCH2 and SH2B1 (Model 1). Fundamentally, under Model 2
there was more noise introduced that the methods had to tease out.
PLINK’s approach of averaging the test statistics did not prove to be much bet-
ter than the minimum p-value based methods, for the candidate gene list analyses.
Though the advantage to PLINK’s technique is that the analyst is not required to a
priori specify each gene region. This offers a more unbiased approach in computing
a consensus p-value for a candidate gene list of biological pathway. This was also a
desirable feature for our step-wise method.
In terms of the candidate gene list analyses, our step-wise forward SNP selection
procedure built on a linear regression modeling framework proved to be a more powerful
approach than PLINK. A possible explanation is the following. Under both modeling
scenarios, two SNPs contributed more to the phenotypic variation than the other set of
three SNPs (R2 = 0.35% for the primary two QTLs and R2 = 0.25% for the secondary
three QTLs). Since PLINK averages the test statistics in order to offer a proxy p-
value, the stronger associations from the primary QTLs were likely dampened by the
associations from the secondary QTLs, upon computing the average. On the contrary,
our step-wise method jointly tested the association at the various loci and was not
greatly disadvantaged by a mixture of strong and weaker QTLs.
Although we discussed (Section 4.2) and implemented an alternative stopping cri-
terion for our step-wise forward SNP selection technique (which was less stringent in
including a putative SNP in the SNP covariate set), we did not present these results
because the powers estimated were strikingly similar to the more rigorous approach
of ceasing to build the SNP covariate set at the first joint p-value that did not im-
prove upon the prior. In addition, during exploratory analyses we also implemented
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a third stopping criterion in which we mimicked PLINK’s set-based test criteria. In
other words, as long as a SNP fulfilled the r2 and individual p-value filters and the set
size did not exceed the maximum specified, the SNP in question was entered into the
set. The power results based on this third stopping criterion also were quite similar to
the first rule presented in the Tables, therefore we did not consider this rule in further
analyses.
Furthermore, pruning SNPs in “high” LD with significant SNPs also did not appear
to affect the powers of PLINK’s test nor ours, and so we presented the results for
which no LD pruning filter was turned on. This result suggests that SNPs in LD with
significant SNPs (as determined by PLINK’s SBT or our step-wise procedures) did not
add noise nor did they necessarily positively contribute in detecting a true association
with the quantitative trait.
In summary, we have presented results of methods that offer a consensus p-value
for analyzing data from a candidate gene study, or a study involving a list of candidate
genes or biological pathway. Each method bears advantages and disadvantages, and
under certain scenarios some methods performed better than others. There was no
single method that proved to be the best across all modeling and study design scenarios.
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CHAPTER 5
NATURAL EXTENSIONS TO
THE CURRENT
INVESTIGATIONS
5.1 Using Public Control Genotype Data to Increase
Power and Decrease Cost of Case-Control Ge-
netic Association Studies
There has been an increased use of imputing unobserved SNPs across commercial geno-
typing platforms, which has the advantage of enabling researchers to more exhaustively
test for association on a denser set of SNPs, by capitalizing on the available LD in-
formation contained across the genotyped loci. In terms of our proposed two-stage
replication-based design, further investigations could assess the impacts on power and
type I error of imputing untyped SNPs in the genome-wide association phase of the
study (i.e. stage one). Because the study cases and public controls were genotyped
at different points in time and also perhaps on different platforms, the question arises
on how best to deal with possible batch effects in terms of imputing SNPs. A clear
advantage of imputing SNPs in stage one is that the study cases and public controls
need not be initially genotyped on the same platform. However, to what extent is the
type I error affected by this and how much gain in power would imputation offer?
In addition, rare SNPs would presumably be imputed with a greater degree of
uncertainty as compared to common SNPs. One could investigate overall power as a
function of this uncertainty, over a range of minor allele frequencies (e.g. from incredibly
rare such as < 1% to more common such as 30%).
Granted that an imputed SNP in stage one is selected for follow-up in stage two,
how does this also influence power of our proposed two-stage design? For example, as
the proportion of true findings at imputed loci increases, what is the trend in power?
As a last point regarding imputation, how do we best handle SNPs with low to
high quality scores? As an extreme scenario, how powerful is our two-stage design for
low quality SNPs that truly are disease causing agents? Could we devise an analytical
approach that would account for such poor quality SNPs or even improve upon their
reliability somehow?
Finally, it would be fascinating to design and implement a study in practice that
utilizes our proposed two-stage replication-based study design. Such empirical results
could offer invaluable insight to the utility of our design in a practical setting, as
compared to our hypothesized alternative disease models.
5.2 Haplotype Sharing Methods in Association Stud-
ies
In comparing our haplotype sharing methods with currently available techniques, we
assumed that phase was known. This may or may not be a reasonable assumption
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in certain settings, thus some possibilities could be to explore alternatives to this as-
sumption. For example, we could develop sharing statistics in which phase is unknown,
therefore we utilize comparisons in genotypes rather than haplotypes. The sharing
measures would have to incorporate the phase ambiguity such as the use of penalties
or determining weights for the most probable pairs of alleles within genotypes, built
upon the extent of sharing observed throughout the sample.
If we impose phase as a preliminary pre-processing step, then we could examine
alternative ways to phase the genotype data, other than fastPHASE, the method
we employed for our study. For example, several programs utilize the expectation-
maximization (EM) algorithm in estimating haplotype signatures, such as PLINK,
Haploview, and haplo.stats. In addition, SimWalk2 uses a type of simulated annealing
approach to phase haplotypes. Would the haplotype measures assessed in our study
perform the same, better, or worse if we employed other methods to infer haplotype
phase?
5.3 Gene and Pathway-Based P-Values
An alternative to the proposed step-wise forward SNP selection method (Section 4.2)
would be a haplotype-based approach instead of a genotype-based approach to facilitate
the simultaneous analysis of multiple SNPs within a candidate gene. For example, one
could carry out a conventional haplotype χ2 test on the observed set of unique haplotype
signatures by categorizing the haplotypes on case-control status, as described in Section
3.2.7. In this way, all unique haplotype signatures would be assumed to be ancestrally
distinct, although consequently the formal test could have many degrees of freedom.
Optionally, the analyst could a priori classify the observed unique haplotype signatures
into groups if the plausibility exists that subgroups of the haplotypes originated from
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the same lineage or could allow the data to cluster individual haplotypes into different
“risk groups”. This would invariably decrease the degrees of freedom of the test and
increase power to detect an association, though allowing the data to generate haplotype
groupings would require a permutation test to account for the data driven nature of
the clustering.
We note that the aforementioned haplotype-based approach readily facilitate the
inclusion of a priori hypotheses (for example, the combining of putatively functional
alleles or genotypes based on public data bases) that, if properly applied, can increase
power. The potential advantage of such an approach should be its flexibility in allowing
the data to determine the optimal SNPs/haplotypes to include in the final test statistics,
though this greater flexibility could actually result in decreased power if good a priori
information is available and not incorporated or if results can in large be explained by
a single SNP.
In our current investigation, we explored a limited example of alternative models
that included SNP x SNP interactions, as well as one example of a list of candidate
genes. We could further our work by simulating larger or smaller lists of genes as well
as a putative biological pathway instead of a simple list of genes taken from a prior
study. Lastly, due to the computationally intensive nature of our step-wise forward
SNP selection procedure in which we employed parallel computing on high-end super-
computers, we could develop ways that are less computational such that our method
could be employed on a genome-wide scale.
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